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ABSTRACT 
 
Asthma and allergies affect a large number of people, with over 300 million people 
worldwide suffering from asthma alone. Although, on the „macroscopic‟ level, it is 
known how allergens trigger allergic reactions, it is not known how an allergen‟s „micro‟ 
structure causes such a profound allergic response in sensitised individuals. A review of 
inter-species carbohydrate motifs revealed a striking similarity between carbohydrate 
moieties (N-glycans) present on antigens derived from species known to give an allergic 
T helper (Th) 2 response in humans (such as pollen, schistosomes, and food allergens). 
Preliminary studies on mixtures of allergen extracts have suggested that these 
carbohydrate motifs (glycoproteins) bias the immune response to an allergic (Th2) 
response.  
 
This project presents work conducted towards the synthesis of three fragments of a larger 
N-glycan found on allergens. The synthesis of these N-glycans will allow the first 
detailed study regarding the relationship between N-glycan structure and Th2 bias to be 
performed and thereby aid in our understanding of the molecular triggers of asthma. 
Ultimately, this could lead to the elucidation of the mechanisms of the allergic Th2 
immune response. 
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Abbreviations used 
Ac  Acetyl   
APC  Antigen presenting cell 
AR  Analytical reagent 
Arom.  Aromatic 
ATR  Attenuated total reflection 
Bn  Benzyl 
Bu  Butyl 
COSY  Correlation spectroscopy 
CSA  Camphorsulfonic acid 
DALYs Disability adjusted life years 
DBU  1,8-Diazabicyclo[5.4.0]undec-7-ene 
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DMF  Dimethylformamide 
ELISA  Enzyme-linked immunosorbent assays 
ESI  Electrospray ionisation 
Fuc  Fucose 
GATA  GATA-binding protein 
GFP  Green fluorescent protein 
Glc  Glucose 
GlcNAc N-Acetyl glucosamine 
HBTU  O-(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate 
HMBC Heteronuclear multiple bond coherence 
HMDS  Hexamethyldisilazide 
HOBt  Hydroxylbenzotriazole 
HRMS  High resolution mass spectrometry 
HSQC  Heteronuclear single quantum coherence 
Hz  Hertz 
IFN  Interferon 
IgE  Immunoglobulin E 
IL  Interleukin 
IR  Infrared 
KLH  Keyhole limpet hemocyanin 
LPS  Lipopolysaccharide 
Man  Mannose 
MeOTf Methyl trifluoromethanesulfonate 
MHC  Major histocompatibility complex 
Mp  Melting point 
MP  p-Methoxyphenyl 
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MS  Molecular sieves 
NIS  N-Iodosuccinimide 
NKT  Natural killer T 
OVA  Ovalbumin 
PA  Pro analysis 
PCR  Polymerase chain reaction 
Ph  Phenyl 
Phth  Phthaloyl 
Rf  Retardation factor 
RT  Room temperature 
SPPS  Solid-phase peptide synthesis 
STAT  Signal transducer and activator of transcription 
TBAI  Tetrabutylammonium iodide 
TBDMS tert-Butyldimethylsilyl 
TBDMSCl tert-Butyldimethylsilyl chloride 
TCR  T cell receptor 
TDS  Thexyldimethylsilyl 
TES-H  Triethylsilane 
TfN3  Trifluoromethanesulfonic azide 
TFA  Trifluoroacetic acid 
TFAA  Trifluoroacetic anhydride 
TfO2  Trifluoromethanesulfonic anhydride 
TfOH  Trifluoromethanesulfonic acid 
Th  T helper 
THF  Tetrahydrofuran 
TLC  Thin-layer chromatography 
TLR  Toll-like receptor 
TMS  Trimethylsilyl 
TMSOTf Trimethylsilyl trifluoromethanesulfonate 
Tol  Toluene 
Troc  2,2,2-Trichloroethoxycarbonyl 
TSLP  Thymic stromal lymphopoietin 
p-TsOH para-Toluenesulfonic acid 
WHO World Health Organisation 
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Terms used 
 
Allergen An antigen that causes a Th2 immune response resulting in IgE 
production. 
Antigen A molecule recognized by the immune system. 
B cell A type of lymphocyte – their principal function is to make antibodies 
against antigens.  
Basophil A type of granulocyte – recruited to the site of allergic inflammation. 
C-type lectin A calcium dependant carbohydrate binding receptor.  
Chemokine A type of cytokine that guides the migration of cells. 
Cytokine  Proteins responsible for cellular signalling. 
DALYs Disability adjusted life years: The sum of years of potential life lost due to 
premature mortality and the years of productive life lost due to disability. 
Dendritic cell An immune cell that takes up and processes antigens for presentation to 
other cells. 
Epithelial cell Cells that line the cavities and surfaces of structures throughout the body. 
Eosinophil A type of granulocyte – responsible for killing antibody-coated parasites. 
Eosinophilia The state of high levels of eosinophils in the target location. 
GATA3 A human protein – it is a transcriptional activator which binds to the 
enhancer of the T-cell receptor genes. 
Glycoproteins A protein with oligosaccharides covalently bound to the peptide side 
chains. 
Granulocyte A class of white blood cell characterised by the presence of granules in 
their cytoplasm.  
Lymphocyte A class of white blood cell in the vertebrate immune system. 
Mast cell A type of granulocyte – releases granules containing histamine, heparin 
and other active agents. 
Macrophage A type of white blood cell – their main role is to phagocytose (engulf and 
digest) cellular debris and pathogens. 
 vii 
STAT5 and 6 Human genes – The STAT family members are phosphorylated by the 
receptor associated kinases in response to cytokines and growth factors. 
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INTRODUCTION 
 
1.1 Asthma Overview 
Asthma and allergies are important worldwide health issues and have been for some time. 
The Austrian scientist and paediatrician Clemens von Pirquet first defined the term 
“allergy” in 1906 to describe the “hypersensitive reactions” that were triggered and 
observed in particular individuals when exposed to certain substances.
1
 The term allergy 
is now more specifically defined as “disease following a response by the immune system 
to an otherwise innocuous antigen”.2 Today, more than 25% of the Western population is 
affected by allergies and The World Health Organisation (WHO) estimates that there are 
300 million asthma sufferers worldwide.
3-5
 Asthma is also the most common chronic 
disease among children. 
 
Asthma is a chronic respiratory disease which results in a local immune response within 
the lung that is characterised by airway inflammation and airway hyperresponsiveness 
(increased narrowing of the airways), with the individual affected suffering from 
recurrent attacks of wheezing, coughing, breathlessness and tightness in the chest.
6
 
Though the symptoms and severity differ between individuals, asthma prevents many 
sufferers from being able to live a normal life. In 2001, the disability adjusted life years 
(DALYs) lost worldwide due to asthma was estimated at 15 million years each year.
7
 The 
DALY ranking for asthma is similar to that for diabetes, cirrhosis of the liver, and 
schizophrenia. 
 
Asthma is most prevalent in Western countries such as the United Kingdom, the United 
States of America, Australia, and New Zealand (Figure 1), however, 80% of deaths 
(255,000 deaths worldwide in 2005)
4
 occur in low to low-middle income countries.
4
 
Asthma is of particular significance to New Zealand, as New Zealand has the second 
highest rate of asthma worldwide with over 600,000 people suffering from asthmatic 
symptoms (approximately 16% of adults and 25% of children).
8
 In addition, 
hospitalisation rates for asthma have more than doubled in the last 30 years and asthma is 
  2 
now the most common cause of admission to hospital for New Zealand children.
8
 The 
annual cost to New Zealand due to asthma is estimated to be greater than $825 million, 
with medical costs accounting for $125 million, while the other $700 million is 
associated with days absent from work, loss of healthy life due to disability, and 
premature death.
8
 In the United States medical costs associated with asthma are estimated 
to be $8.1 billion annually.
9
 
 
 
Figure 1: World map of the prevalence of asthma.
7
  Based on data collected by the World Health 
Organisation in 2001. 
 
 
 
1.2 Types of Asthma 
Asthma is an extremely complex disease with several different forms or phenotypes 
involving multiple cell types and several molecular and cellular pathways.
6
 These 
phenotypes include allergic asthma, severe steroid-resistant asthma, and asthma that is 
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induced by exposure to air pollution, cigarette smoke, diesel exhaust particles, obesity, 
aspirin, exercise, and even cold temperatures.
6
 An individual‟s asthmatic response need 
not be limited to one particular phenotype and is often the result of several different 
triggers and asthmatic pathways acting in synergy. That said, 70-80% of asthma, 
including the reported incidences in New Zealand, is related to allergic asthma which is 
typically caused by allergens that are inhaled.
8,10
 The source of allergens is broad and can 
include dust mites, pollen and plant material, food, and animal material (e.g. hair, saliva, 
urine, and dander-dead skin flakes).
4,8
 Although asthmatic allergens are defined on a 
macroscopic level, little is known about what it is that is responsible for inducing their 
sensitivity on a microscopic or “molecular” level. Most of the asthma research and 
treatment focus over the past 25 years has concerned allergic asthma. 
 
Allergic asthma gives rise to an immune response called the T helper (Th) 2 immune 
response, which is associated with the adaptive immune system. This is in contrast to the 
non-allergen induced immune response (i.e. asthma caused by air pollution, obesity, 
aspirin, exercise etc). Non-allergen induced asthma does not require a Th2 immune 
response to induce airway inflammation and airway hyper-reactivity, and is instead 
induced by various alternative cellular pathways including natural killer T (NKT) cells 
and Th17 cells.
6
 The remainder of this introduction will focus on and explain what is 
understood about allergic (or Th2 “driven”) asthma. 
 
Parasitic helminths (worms) are known to cause a Th2 immune response in humans,
11-13
 
and accordingly, are often used for in vivo mouse assays to study and model the Th2 
immune response.
14-16
 One such “Th2-model” uses the infective third stage (L3) larvae of 
the nematode (roundworm) Nippostrongylus brasiliensis, which are non-pathogenic to 
humans.
14,15
 The similarities between helminth-induced and allergic asthmatic Th2 
immune responses has led to the hypothesis that for individuals who are genetically 
predisposed to developing asthma, the immune system is tricked into sensitization by 
exposure to otherwise innocuous environmental allergens, which in turn results in an 
asthma attack. In contrast, in the case of parasitic infection, a Th2 immune response is 
desirable as it results in clearance of the parasite. 
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The prevalence of asthma and allergy has significantly increased in western countries 
since 1960.
6,17,18
 This rate of increase is too fast to be attributed to genetic changes alone, 
although it is agreed that the propensity to develop asthma and allergies is related to 
genetics. Similarly, this increase is unlikely to be due to better diagnosis as the symptoms 
of asthma and allergy are easily identified and have been recognised since the early 
1900‟s.17 Although the exact causes still remain unclear, broadly speaking, it has been 
suggested that the increase in the prevalence of asthma and allergy is due to the increased 
hygiene standards, increased use of antibiotics, and environmental changes associated 
with a “western lifestyle”.17,19 This belief is known as the “hygiene hypothesis”. 
 
According to the hygiene hypothesis, a lack of exposure to infectious agents, endotoxins, 
parasites, and other pathogenic and non-pathogenic microorganisms during early 
childhood leads to an increased susceptibility to allergies and asthma.
2,20
 There are two 
thoughts as to why this is. Initially it was believed that the underdevelopment of the Th1 
immune response, which is associated with bacterial and viral infections, promotes an 
immune system with an overactive Th2 immune response bias.
2
 However, this does not 
explain the inverse correlation seen between parasitic helminth infection and the 
development of allergy, as helminth infection results in a Th2 immune response and 
would therefore not aid in the development of the Th1 response. In view of this, the latest 
hypothesis is that exposure to infection early in life aids in the development of regulatory 
T cells, which in turn downregulate both Th1 and Th2 immune responses via the 
production of cytokine interleukin 10 (IL10).
2
 This latest proposition also helps to 
explain the increase of Th1-derived autoimmune diseases in Western countries.
2
 Parasites 
have developed mechanisms to induce IL10 production which enables them to remain in 
the host by downregulating the Th2 immune response
20,21
 and this may explain why 
individuals with parasite infections are less susceptible to developing allergies and 
asthma. In allergic and asthmatic immune responses such downregulatory mechanisms 
are not triggered or are overwhelmed by inflammatory factors thus leading to airway 
inflammation that is characteristic of an asthma attack.
20
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1.3 Generation of the Allergic T Helper 2 Immune Response  
Humans are exposed to allergens on a regular basis. Such environmental allergens are 
inhaled and come into contact with the mucosal surfaces and epithelial cells in the lungs. 
The mucosal layer and intercellular tight junctions between epithelial cells present in the 
respiratory tract provide a defence by limiting the access of allergens to the immune 
system.
10
  However, these barriers are not entirely impenetrable. In non-asthmatics, 
inhaled allergens that come in contact with the immune system induce tolerance and do 
not result in an inflammatory immune response. For people who suffer from allergic 
asthma, however, allergens interact with the immune system resulting in the Th2 immune 
response. The Th2 immune response leads to the secretion of a variety of cytokines, 
chemokines, and the recruitment of multiple cell types, which results in the airway 
remodelling (structural changes of the airway wall) and airway hyperresponsiveness 
(narrowing of the airways due to inflammation) associated with an asthma attack.
10
 
Asthma is a chronic disease resulting in “chronic inflammation” and it is this repetitive 
exposure to allergens that results in the continual presence of higher than normal levels of 
innate and adaptive immune cells.
20
 This alteration in cell number and type results in 
structural changes to the airways (airway remodelling)
20
  and also mean that the epithelial 
barrier is no longer as effective at preventing allergens from reaching the immune system, 
which in turn increases the individual‟s chance of an asthma attack.10   
 
 
1.3.1 Initiation of the Th2 Immune Response 
On a cellular level, the Th2 immune response is associated with the differentiation of 
naive CD4
+
 T cells (a type of lymphocyte) into Th2 cells via the action of several 
simultaneous cellular and signalling processes (Figure 2). Briefly, a T helper cell is a 
subgroup of lymphocytes that plays an important role in establishing and maximising the 
capabilities of the immune system.
2
 Mature T cells express the surface protein CD4 and 
are referred to as (naive) CD4
+
 T cells. In the generation of the Th2 immune response, it 
is generally understood that dendritic cells (DCs) take up antigens that have passed 
through the epithelial barrier then migrate to the lymph node where they act as antigen 
presenting cells (APCs) by presenting the antigen to naive CD4
+
 T cells.
2,22
 The antigen 
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is presented by the major histocompatibility complex (MHC) class II receptor of the DC 
and recognised by the T cell receptor (TCR) of the CD4
+
 T cell. For Th2 differentiation 
antigen presentation must occur in the presence of the cytokine IL4 and other co-
stimulatory factors.
2,23
 Although IL4 is required for Th2 differentiation,
23
 the cellular and 
signalling pathways responsible for the production of this initial IL4 are, surprisingly, 
still not well understood.
24
  
 
 
Figure 2: Allergens that pass though the epithelial cells are taken up and processed by DCs. The 
DCs then migrate to the lymph node where they present the allergen to naive CD4
+
 T 
cells. If this presentation occurs in the presence of IL4 and other co-stimulatory factors 
the naive CD4
+
 T cells differentiate to Th2 cells resulting in the allergic Th2 immune 
response. Adapted from Galli et al.
20
 
 
When considering the Th2 immune response in more detail, it is known that for Th2 
differentiation to occur in naive CD4
+
 T cells, allergen presentation must occur 
simultaneously with the expression of GATA-binding protein 3 (GATA3) and the 
activation of signal transducer and activator of transcription 5 (STAT5), both of which 
bind to important parts of the Th2 cytokine locus within the CD4
+
 T cell (Figure 3).
20,25
 
GATA3 is expressed upon the activation of STAT6, which is induced via IL4 binding to 
the IL4 receptor (IL4R) on naive CD4
+
 T cells.
25
 It has long been thought that the binding 
of IL4 resulting in STAT6 activation was the only way in which GATA3 expression 
could occur. However, recent work has illustrated that IL4 is not necessary to induce a 
Th2 immune response, although it is necessary for the resulting Th2 immune response 
once naive CD4
+
 T cells have been differentiated to the Th2 phenotype.
26
 In this study, in 
  7 
vivo GATA3 expression was IL4 independent. It has also been shown that GATA3 
expression can be induced in an IL4 independent manner by low signal strength TCR 
activation (i.e. allergen presentation by MHC class II complexes to the TCRs of CD4
+
 T 
cells). However, if high levels of allergen were used, GATA3 expression was not 
observed resulting in failure of Th2 differentiaiton.
27
 STAT5 activation occurs via IL2, 
IL7, and/or thymic stromal lymphopoietin (TSLP) binding to naive CD4
+
 T cells through 
their associated receptors.
25
  The sources of IL4, IL2, IL7, and TSLP are not well 
understood, however adaptive immune responses are often caused as a result of 
recognition of infectious agents by the innate immune system.
24
  
 
 
Figure 3: Th2 differentiation of naive CD4
+
 T cells requires binding of both GATA-binding protein 
3 (GATA3) and signal transducer and activator of transcription 5 (STAT5) to the Th2 
cytokine locus in the nucleus of the naive CD4
+
 T cell. GATA3 expression can occur via 
either IL4 induced STAT6 production or via low signal strength T cell receptor (TCR) 
activation. STAT5 can be activated by IL2, IL7, or thymic stromal lymphopoietin 
(TSLP). Adapted from Paul and Zhu.
25
  
 
Allergen presentation was long believed to occur via MHC class II presentation on DCs; 
however, recently, there has been strong evidence to suggest that MHC class II allergen 
presentation by basophils can induce a Th2 response. 
28-30
 The idea of basophil allergen 
presentation also supports the theory that the expression of GATA3 occurs as the result of 
IL4 IL2 IL7 TSLP 
Allergen 
MHC 
class II 
IL4R IL2R IL7R TSLPR TCR 
Th2 
Immune 
Response 
  8 
low strength TCR signalling for basophils express lower levels of MHC class II than 
DCs.
25
  These and other studies have also shown that upon allergen challenge, basophils 
can produce the IL4 and TSLP required for Th2 differentiation.
24
 It is quite possible that 
DCs and basophils both play a role in antigen presentation and that both mechanisms act 
in parallel. For example it has been proposed that TSLP produced by basophils could 
suppress IL12 production from DCs (a Th1 associated cytokine required for Th1 
differentiation), thus biasing antigen presentation by DCs away from Th1 and towards 
Th2.
25
 That said, there is still much to be understood about how the immune system 
activates naive CD4
+
 T cells in order to generate a Th2 immune response. 
 
 
1.3.2 Perpetuation of the Th2 Immune Response in Allergic Asthma 
Once Th2 cell activation has been initiated, a number of cellular and signalling processes 
occur, many of which act in a self-perpetuating manner to amplify and maintain the Th2 
immune response and thus give rise to the symptoms of asthma.
2
 Th2 cells induce their 
characteristic immune response via the production of various cytokines, including IL4, 
IL5, IL9, IL13, IL21, and IL25, and through their migration to specific tissue sites 
resulting in the recruitment and activation of cell types responsible for inflammation and 
airway hyperresponsiveness (Figure 4). Through the release of IL4 and IL13, Th2 cells 
promote B cell class switching to immunoglobulin E (IgE) resulting in the production of 
IgE.
6,25
 IgE was the fifth and final class of human antibody discovered and is responsible 
for transferring sensitivity to allergens.
5
 The IgE produced by B cells binds to the high 
affinity IgE receptor, FcεRI, on the surface of basophils and mast cells. Cross-linking of 
these IgE-FcεRI complexes by allergens triggers a complex process resulting in mast-
cell/basophil degranulation and the release of cytokines (IL4, IL5, and IL13), 
chemokines, histamine, heparin, serotonin, and proteases causing smooth muscle 
constriction (narrowing of the airways), vascular permeability, recruitment of 
inflammatory cells, and increased mucous secretion (further obstructing airways).
5,20,25
 
Cross-linking of the IgE-FcεRI complex also results in the increased expression of FcεRI 
leading to a powerful amplification mechanism.
25
 Asthmatic individuals have higher 
levels of IgE expression than non-asthmatics. As both IgE and mast cells are found in the 
  9 
mucosal tissue, they are often one of the first defence mechanisms against allergens and 
accordingly lead to the recurrent Th2 responses observed in asthmatic individuals.
5
 
 
 
Figure 4: Th2 cells control the allergic Th2 immune response via the production of cytokines in the 
lymph nodes and periphery. IL4 and IL13 promote B cell class switching resulting in the 
production of IgE. The produced IgE binds to the high affinity IgE receptor FcεRI on 
both mast cells and basophils which are recruited via IL9, IL4 and IL13. Cross-linking of 
IgE bound to either mast cells or basophils by an allergen causes degranulation resulting 
in the release of histamine, heparin and other soluble mediators, which act on smooth 
muscle cells, epithelial cells, and goblet cells. IL4 and IL13 also act on smooth muscle 
cells, epithelial cells, and goblet cells causing constriction and narrowing of the airways, 
mucous secretion and increased permeability of the epithelial barrier. IL4 and IL13 in 
combination with IL21 result in macrophage activation. IL5 triggers eosinophilia and 
IL25 results in increased production of Th2-type cytokines by non-B non-T cells. 
Adapted from Anthony et al.
31
  
 
Th2 cells also migrate to the lung tissue (from the lymph node where they are activated) 
and release IL5 resulting in the recruitment of eosinophils into the airways causing 
eosinophilia, one of the major characteristics of an asthma attack.
10,25
 Eosinophilia results 
in damage to airway epithelial cells (via the release of highly inflammatory granules), 
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stimulates mucous secretion, and induces airway hyperresponsiveness.
10
 Th2 cells in the 
lung also recruit and promote the growth of mast cells via IL9 production,
6,25,32
 and can 
also act directly on epithelial cells and smooth muscle cells (both via the generation of 
IL4 and IL13) which leads to mucous production, goblet cell metaplasia, and airway 
hyperresponsiveness.
25
 The Th2 cytokines IL4, IL13, and IL21 also activate  
macrophages, while IL25 acts on IL5 and IL13 producing non-B non-T cells further 
enhancing the generation of Th2-type cytokines.
25
  
 
 
1.3.3 Current Treatments for Asthma 
As the underlying cellular pathways involved in initiating the asthmatic Th2 immune 
response remain largely unknown, most of the available asthmatic medications are non-
specific and generally only control the symptoms of the Th2 response.
33
 These asthmatic 
medications are either anti-inflammatory or bronchodilator drugs, and help by relaxing 
the constricted muscle bands around the airways. Inhaled corticosteroids are a very 
effective anti-inflammatory drug and can be used for patients of all ages and disease 
severity.
4,33
 They can be used daily on a long term basis as the human body will not build 
up immunity towards the drugs, and when used in standard doses, show minor side 
effects.
33
 However, corticosteroids do not reduce or reverse airway remodelling and must 
be taken on a regular basis as inflammation recurs upon withdrawal of the treatment.
10
 In 
fact, it has been shown that lung function reduces more rapidly over time in asthmatic 
individuals than non-asthmatic individuals, illustrating the progressive nature of 
asthma.
10
 Bronchodilators can help relieve wheezing, coughing and tightness in the chest 
and, as they function instantaneously, they are taken when needed. However, like 
corticosteroids they do not treat the underlying cause of asthma. With the right treatment, 
most (but not all) patients can control their asthma using a combination of these two 
medications.
20
 The downside however, is that medication is needed on a daily basis and 
in individuals with more severe symptoms, it may be required multiple times a day.  
 
Other asthma treatments that have been developed recently include the IgE-specific 
antibody drug omalizumab. Omalizumab acts as a receptor antagonist to IgE and 
  11 
functions by binding to a site on IgE required for the binding of the high affinity IgE 
receptor, FcεRI, thus resulting in reduced mast cell and basophil degranulation.34 
Omalizumab is expensive and has only been approved for patients with moderate to 
severe persistent allergic asthma who do not respond to conventional treatment. Even 
then, the drug is not effective in all patients and if treatment is stopped, relapse is 
possible.
5,20
  It is, however, a step in the right direction for the treatment of asthma as it 
works by preventing part of the immune response rather than dampening the symptoms 
of the immune response. Recent results from trials of IL5 blocking antibodies have not 
been as promising as omalizumab. This suggests that blocking pathways earlier on in the 
immune response (e.g. IgE) may provide better therapies.
35
  
 
 
 
1.4 N-Glycans as Allergens 
To better understand the cause of allergic asthma and thus provide better, more specific 
therapies, the specific molecular triggers that cause the asthmatic (Th2) response need to 
be determined. In studies of allergens known to cause a Th2 response in humans, it was 
noticed that many of the glycoproteins isolated from these known allergens contained 
similar oligosaccharides. These conserved oligosaccharides were found on a wide range 
of allergens such as pollen,
36-39
 schistosomes,
40,41
 and food allergens,
42-44
 and contain a 
common pentasaccharide core [Man3(GlcNAc)2] with α-1,3-L-fucose and/or β-1,2-D-
xylose residues attached to the proximal GlcNAc and to the β-linked mannose, 
respectively (Figure 5).
36-40,43-45
 The oligosaccharide in turn, is N-linked to the protein via 
an amide linkage with the carboxamide side chains of asparagine residues. The 
asparagine residue is present in the tripeptide sequence, asparagine-X-serine/threonine, 
where X is any amino acid except proline.
36-40,43-45
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Figure 5: Common N-glycan structure, showing both the α-1,3-L-fucose and the β-1,2-D-xylose 
residues, found on allergens known to induce a Th2 immune response. 
 
The common pentasaccharide core of the oligosaccharide [Man3(GlcNAc)2] is present in 
N-glycans in humans and is capped with a combination of high mannose, lactosamine, 
and/or sialic acid residues attached to the two terminal mannose residues.
46-48
 The α-1,3-
L-fucose sugar, however, is not found on proximal GlcNAc residues in mammalian N-
glycans, though α-1,6-L-fucose proximal-linked residues are.40 Xylose residues are not 
present in mammalian N-glycans either, although both are common features of plant and 
invertebrate N-glycans.
36,38,42
 It is also interesting to note that viruses and bacteria, which 
elicit a Th1 rather than Th2 immune response, have different N-glycans and that these do 
contain α-1,3-L-fucose or β-1,2-D-xylose residues.49-51 
 
To illustrate that specific xylose- and/or fucose-containing glycoproteins elicit an allergic 
immune response, studies have been performed using glycoprotein allergens containing 
N-glycans with α-1,3-L-fucose and/or β-1,2-D-xylose residues isolated from natural 
sources. These studies illustrate that these glycoproteins cause an increase in the 
production of Th2 specific cytokines (such as IL4, IL5, IL10 and IL13).
37,40-42,52,53
 One 
study of N-glycan-containing peanut allergen extracts also postulated that the N-glycan 
caused Th2 cytokine production via its interaction with C-type lectins on DCs.
42
 
However, if true, it still remains to be understood how the allergen was processed and 
presented in order to induce the Th2 response. C-type lectins are most commonly 
associated with pathogen endocytosis and are not involved in antigen presentation.
41,54
 
Production of IgE
44,53,55
 and IgE binding
44,56-58
 in response to a number of glycoproteins 
from different classes of allergen (i.e. cross-reactivity between allergens) has also been 
observed with a variety of unrelated allergens containing α-1,3-L-fucose and/or β-1,2-D-
xylose residues on the core Man3(GlcNAc)2 motif. The cross-reactivity of unrelated 
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allergens, such as pollen (plant derived) and seafood or insect venom (invertebrate 
derived) can be explained by the conserved N-glycan structure.
36,59
 For example, when 
the carbohydrate residues of the glycoprotein allergens have been cleaved, IgE antibody 
binding is inhibited
60,61
 and there is a significant decrease in the production of Th2 
specific cytokines.
52
 These results suggest that the carbohydrate moiety of the 
glycoprotein allergen plays a vital role in producing the Th2 immune response. One study 
has also illustrated the possibility that the free carbohydrate moiety itself (i.e. not 
attached to a protein) may bind to the receptor(s) responsible for inducing the Th2 
response yet does not induce a Th2 response and rather, acts as a Th2 antagonist.
37
  
 
 
 
1.5 Project Aims 
This masters project focuses on synthesising truncations of the heptasaccharide N-
glycoprotein 1, in order to determine the specific molecular triggers that are responsible 
for causing the asthmatic (Th2) immune response.  
 
Although several studies suggest the importance of α-1,3-L-fucose and/or β-1,2-D-xylose 
residues on the conserved Man3(GlcNAc)2 core, due to the heterogeneity of the isolated 
glycoproteins tested thus far, it is difficult to assign, with certainty, a specific 
carbohydrate moiety as the cause of the Th2 response. In addition, a need for N-glycan 
allergens containing two or more glycosylated sites (multivalent) that bear the same 
carbohydrate moiety (homogeneous) has been expressed. It has been proposed that the 
specific sugar recognition patterns of anti-carbohydrate antibodies could have a 
significant impact on whether a specific carbohydrate moiety is able to result in IgE 
recognition and cross-linking.
44,59,62
 Multivalent N-glycans are needed because 
monovalent N-glycans (such as the previously tested pineapple bromelain antigen, which 
carries only one carbohydrate) are unable to cross-link IgE receptors and are therefore 
unable to result in mast cell and basophil degranulation.
44,62
 Chemical synthesis, 
however, enables the desired glycoprotein to be synthesised in sufficient quantity and 
purity to precisely determine the portion of the carbohydrate moiety responsible for 
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inducing the Th2 immune response. The carbohydrate portion of the glycoprotein can be 
synthesised and coupled to a protein or a fluorescent latex bead, or can be conjugated to a 
proteinaceous allergen, such as worm extract that has been stripped of its native 
carbohydrates. The use of the different protein or protein mimics, will establish whether 
the carbohydrate is, on its own, sufficient to cause a Th2 response and whether a specific 
carrier protein is needed. Furthermore, through synthesis, a library of homogeneous 
glycoproteins (truncated structures of the common heptasaccharide 1) can be assembled 
to determine the minimum structure required to induce a Th2 immune response. 
Understanding the structure-activity profile of N-glycans will provide insight into 
potential targets for receptor blocking drugs, and may lead to smaller, more easily 
synthesised structures for studying the Th2 immune response. 
 
 
 
1.6 N-Glycan Synthesis 
 
1.6.1 Overview of Syntheses of Similar N-Glycans 
To date, there has been no reported synthesis of the conserved heptasaccharide or any 
similar heptasaccharide glycoconjugate (e.g. 1). There are, however, a number of 
published syntheses of N-glycans that contain the Man3(GlcNAc)2 pentasaccharide core. 
As mentioned previously, this core pentasaccharide is present in N-linked glycoproteins 
that are biosynthesised by humans.
46-48
 Interest in the role that mammalian N-glycans 
play in biological systems
63-69
 has, in turn, resulted in the synthetic preparation of this 
Man3(GlcNAc)2 glycan. 
 
Both Ogawa and co-workers
70,71
 and Unverzagt and co-workers
72-74
 have published 
several syntheses of carbohydrates containing the pentasaccharide core. Both groups used 
similar protecting group strategies, with the N-acetate groups of the GlcNAc residues 
being protected as their N-phthalimido (N-Phth) derivatives and the reducing anomeric 
centre being protected as a β-azide, which can be reduced to give the desired β-amine 
required to form the N-linked glycopeptide (Scheme 1). That said, the disconnection 
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strategies employed by each group were slightly different. Both groups formed the core 
pentasaccharide 2 by bis-glycosylation of a suitably protected Man(GlcNAc)2 
trisaccharide (Scheme 1). Ogawa and co-workers used a mannose donor 3 with acetate 
protecting groups on the C-2 hydroxyl to install the two capping mannose residues. This 
gave the desired α-anomer selectively due to neighbouring group participation. Unverzagt 
and co-workers, en route to a larger carbohydrate motif, used a mannose donor 9 that was 
already glycosylated at the C-2 hydroxyl, meaning selectivity could not be controlled by 
neighbouring group participation. Here the α:β ratio of the coupling was not reported. 
The order of assembly of the Man(GlcNAc)2 trisaccharide 4 was different for each group. 
Ogawa and co-workers first formed the ManGlcNAc disaccharide 5, whereas Unverzagt 
and co-workers first coupled the two GlcNAc residues to give the (GlcNAc)2 
disaccharide 11. The other main difference was that Ogawa and co-workers chose to use 
mannose donor 7 to install the β-1,4-mannose linkage. The disadvantage of this strategy 
is that it resulted in the production of both α- and β-1,4-linked mannose in an almost 1:1 
ratio. Unverzagt and co-workers, however, chose to install the β-1,4-linked mannose 
using a glucose donor containing a 2-O-acetyl group to control β-selectivity via 
neighbouring group participation. This resulted in the β-anomer of 4 exclusively. 
Following this selective glycosylation, the stereochemistry of the C-2 hydroxyl was then 
inverted to give the desired mannose stereochemistry. This was achieved via the 
conversion of the C-2 hydroxyl, after acetate deprotection, to the corresponding triflate 
that was then heated, resulting in a manno-configurated imidocarbonate, hydrolysed to 
the carbonate, then subjected to methanolysis to give the C-2 hydroxyl with the desired 
mannose configuration. 
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Scheme 1: Strategies employed by Ogawa and co-workers (retrosynthesis A) and Unverzagt and co-
workers (retrosynthesis B) to synthesis carbohydrates containing the core Man3(GlcNAc)2 
pentasaccharide. P = protecting group, R = another sugar residue MP = p-methoxyphenyl. 
 
Danishefsky and co-workers have also produced a number of fully synthetic N-linked 
glycopeptides containing the core Man3(GlcNAc)2 pentasaccharide and have utilised 
several different assembly strategies to do so.
75-79
 For the installation of the β-1,4-linked 
mannose residue they have used mannose donors
77
 (α:β = 1:6), as well as glucose donors 
with neighbouring group participation
75,76
 (complete β-selectivity) and subsequent 
inversion of the C-2 hydroxyl (oxidation, reduction) to give the desired mannose 
stereochemistry. Danishefsky and co-workers also used two different protecting group 
strategies for the protection of the N-acetamide of the GlcNAc residues. Like Ogawa and 
Unverzagt, Danishefsky used N-phthalimido protected GlcNAc residues, which resulted 
  17 
in the selective formation of the desired β-1,4-linkage due to neighbouring group 
participation. However, they have also used sulfonamide protected GlcNAc residues. 
Unlike the use of the N-phthalimido protected GlcNAc donor, the use of the sulfonamide 
protected GlcNAc donor did not result in completely stereoselective glycosylation and 
instead gave a 1:6 α:β ratio when the two GlcNAc residues were coupled.75 Danishefsky 
and co-workers have most commonly employed 2-O-benzoate protection on the mannose 
donors to gain the desired α-linkage for the capping mannose residues via neighbouring 
group participation.
76,77
 They reported the formation of undesired orthoester in 
approximately 50% yield when 2-O-acetate protection was used.
75
 
 
Once the carbohydrate has been fully assembled the anomeric centre of the reducing end 
of the sugar must be converted to a β-amine, which is required for formation of the β-N-
linkage to the peptide (Scheme 2). There are two commonly employed routes for the 
formation of the required anomeric β-amine. The first employs β-azide protection of the 
anomeric centre whereby the azide can be subsequently reduced to the required β-amine. 
Danishefsky and co-workers used this method during their initial synthesis of the core 
Man3(GlcNAc)2 pentasaccharide. However, they reported that following reduction of the 
β-azide and subsequent acylation to the peptide they obtained the N-linked glycopeptide 
in approximately a 1:1 ratio of α:β anomers, indicating that the C-1 stereocentre had 
epimerised en route to the N-linked glycopeptide (Scheme 2).
75
 An alternative to azide 
reduction is the conversion of the anomeric hydroxyl of the reducing end GlcNAc residue 
to the corresponding β-amine (Scheme 2). This methodology has been used very 
successfully by Danishefsky and co-workers to selectively create β-N-linked 
glycopeptides of very complex oligosaccharides.
76,77
 For the conversion of the hydroxyl 
to the β-amine, Danishefsky and co-workers employed Kochetkov amination 
conditions.
80
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Scheme 2: Formation of the anomeric β-amine via either A: reduction of an azide or B: Kochetkov 
amination of a free sugar and subsequent acylation to form an N-linked glycopeptide. 
 
The carbohydrate moiety can be conjugated to the peptide in either a stepwise or 
convergent manner (Scheme 3). Stepwise synthesis involves coupling of the carbohydrate 
moiety to an individual amino acid residue to give a glycosylated amino acid building 
block that can then be used in stepwise solid-phase peptide synthesis (SPPS).
81
 SPPS is 
limited to producing peptides of <50 amino acid residues; however, the production of 
larger glycopeptides and glycoproteins has been achieved using native chemical ligation 
of glycopeptides.
82
 Stepwise synthesis has two main drawbacks. Firstly, some of the O-
glycosidic bonds present in complex oligosaccharides are not stable under the acidic 
conditions normally used in SPPS for resin cleavage or side-chain deprotection.
81,83
 
Secondly, introducing the sugar to the peptide via a glycosylated amino acid building 
block means that the sugar is incorporated as part of a linear synthetic strategy, thus 
reducing the efficiency of the synthesis with respect to the carbohydrate moiety. This is 
undesirable given the amount of effort required to synthesise complex oligosaccharides.
83
 
As we are planning to couple our carbohydrates directly to proteins, stepwise synthesis 
will not be further discussed. The other method, which we plan to use, is convergent 
synthesis in which the carbohydrate moiety is coupled to an already formed peptide. Here 
it needs to be noted that when a peptide is used instead of an amino acid, there is the 
possibility of a competing intramolecular side reaction to form the aspartimide (Scheme 
4). Cohen-Anisfeld and Lansbury,
83
 however, discovered that minimising the amount of 
base used in the reaction reduces the amount of aspartimide formation. It could also be 
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expected that coupling to a peptide would result in lower yields than coupling to a single 
amino acid residue. To circumvent this potential problem, it was found that using O-
(Benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate (HBTU) resulted 
in high yields and that using fully deprotected sugars instead of their O-acetate 
derivatives also increased yields. The procedure developed by Cohen-Anisfeld and 
Lansbury
83
 has been successfully used by several groups to produce complex 
glycopeptides.
76,77,84
  
 
 
Scheme 3: Different strategies for glycopeptide synthesis. Amino acid (AA). 
 
 
Scheme 4: Aspartimide formation from an activated aspartic acid residue during a convergent 
synthetic approach to glycopeptides. 
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1.6.2 Synthetic Targets for this Masters Project 
This masters project focuses on synthesising three glycoconjugates, that of the GlcNAc 
monosaccharide 14, the FucGlcNAc disaccharide 15, and the Man3 trisaccharide 16 
(Figure 6). All three structures are truncations of the heptasaccharide N-glycan 1.  
 
 
Figure 6: Synthetic targets for this masters project. 
 
The synthesis of monosaccharide glycoconjugate 14 involves conversion of the 
commercially available N-acetylglucosamine (GlcNAc) to the corresponding 
glycosylamine using Kochetkov amination
80
 and subsequent conjugation to either a 
protein or a fluorescent latex bead using Cohen-Anisfeld and Lansbury‟s coupling 
methodology.
76,83
 Two different proteins, keyhole limpet hemocyanin (KLH) or 
ovalbumin (OVA), will be used in order to assess the effect that the protein has on the 
Th2 bias. KLH has been chosen as it is a highly antigenic protein and it stimulates a 
strong CD4
+
 T cell response including detectable Th2 activity. OVA, on the other hand, 
has been chosen as it also stimulates a good CD4
+
 T cell response but does not bias 
towards a Th2 immune response. By comparing the Th2 activity of the KLH and OVA 
glycoconjugates, insight will be gained into the importance of the protein in the asthmatic 
Th2 response. The fluorescent latex bead conjugates can also be synthesised and tested in 
order to deduce whether a protein component is necessary for a Th2 response. 
 
Retrosynthetic analyses for the glycoconjugates 15 and 16 are shown in Scheme 5. Here, 
it should be noted that the syntheses of the glycoconjugates 15 and 16 were designed with 
the synthesis of the heptasaccharide 1 in mind.  
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Scheme 5: Retrosyntheses for the target glycoconjugates 15 and 16. 
 
The Man3 glycoconjugate 16 can be synthesised from the protected trisaccharide 17. This 
requires complete deprotection of the trisaccharide 17, followed by conversion of the 
resulting free glycan to the corresponding glycosylamine using Kochetkov amination
80
 
and subsequent conjugation to either a protein or a fluorescent latex bead using Cohen-
Anisfeld or Lansbury acylation.
76,83
 The protected trisaccharide 17 can itself be 
constructed via a trimethylsilyl trifluoromethanesulfonate (TMSOTf) mediated 
glycosylation reaction
85
 between mannose trichloroacetimidate donor 18 and the triol 
mannose acceptor 19. There is literature precedent for selective 3,6-bis-glycosylaion of 
mannose acceptors that are only protected at the anomeric centre,
86-90
 and the success of 
this reaction is probably based on steric factors. Both donor 18 and acceptor 19 are 
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readily prepared from the mannose orthoester 20, itself synthesised from D-mannose in 
four steps following literature procedures.
91,92
 The O-2-benzoyl protection of mannose 
donor 18 was chosen to give α-selectivity via neighbouring group participation, with 
benzoyl protection being chosen over acetate protection because 2-O-acetate protected 
mannose donors can lead to the formation of undesired orthoester.
86
 The mannose donor 
18 will also be used for installing the two mannose capping residues in the larger 
heptasaccharide glycoconjugate and accordingly, will be synthesised on a large scale. 
 
The disaccharide glycoconjugate 15 can be synthesised from the protected disaccharide 
21, using methodology similar to that mentioned above along with azide reduction and 
acetylation to give the required N-acetyl group. The protected disaccharide 21 can in turn 
be constructed from the two selectively protected building blocks 22 and 23 via Ogawa 
glycosylation with CuBr2/Bu4NBr.
93-95
 The desired α stereochemistry of the 1,3-linkage 
can be obtained via the anomeric effect. Benzyl protected thiofucose donors are 
commonly used for installation of α-fucose residues, with both thiophenyl96-98 and 
thioethyl
94-96,99
 donors having been used for this purpose. We chose to use a thioethyl 
group as glycosylation can be achieved using Ogawa conditions,
93
 which are milder than 
the triflic acid (TfOH) and N-iodosuccinimide (NIS)
96,98
 conditions used for thiophenyl 
activation. The ability to achieve coupling under milder conditions was desired as 
difficulties in installing the α-fucose residue have been reported in literature.72,100,101 This 
is often attributed to the increased acid lability of the resulting α-fucosyl linkage. The 
chosen thiofucose building block 22 can in turn be prepared from L-fucose in five steps 
following modified literature procedures.
102,103
 Glucosazide building block 23 can be 
prepared from D-glucosamine in six steps following modified literature procedures.
104-106
 
Here, the protecting group pattern and functionality of 23 was chosen such that 23 can be 
used for both GlcNAc residues in the core pentasaccharide [Man3(GlcNAc)2], creating a 
more convergent synthesis if one considers the preparation of the larger N-glycan. The N-
acetyl groups present in the glycoconjugate targets were masked as azides due to the 
Lewis basicity of N-acetyl groups which makes them incompatible with Lewis acid 
mediated glycosylation reactions required for imidate and thiol donors. Although the 
azido group is not able to induce the desired β-1,4-linkage between the two GlcNAc 
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residues via neighbouring group participation, the desired β-selectivity can be achieved 
via the use of acetonitrile as a participating solvent.
107,108
 The azide can be reduced and 
acetylated in the final stages of the synthesis to give the desired N-acetyl group. To 
illustrate the need for the orthogonality of the protecting group pattern on 23, one needs 
to first realise that coupling at either the 3-OH or 4-OH position of the glucosazide is 
required. Coupling at the 4 position is required for construction of the heptasaccharide 
and other structures containing the (GlcNAc)2 disaccharide, while selective 3-OH 
coupling is required for the construction of the introduction of the fucose residue.  
 
The formation of the β-1,4-linkage joining the two GlcNAc residues will also be 
investigated during this Masters project via the synthesis of the GlcNAc(Fuc)GlcNAc 
trisaccharide 24 (Scheme 6). Formation of this β-linkage is vital to the successful 
synthesis of the larger glycoconjugates and accordingly, needs to be thoroughly 
investigated. The trisaccharide 24 can be synthesised via the TMSOTf mediated coupling 
of the glucose azide donor 25 with FucGlc disaccharide acceptor 26 using acetonitrile to 
induce the desired β-selectivity.107,108 The FucGlc disaccharide acceptor 26 is also a key 
intermediate in the synthesis of the heptasaccharide 27 (Scheme 6) required for the 
synthesis of glyconconjugate 1. FucGlc disaccharide acceptor 26 can be synthesised via 
selective opening of the 4,6-benzylidene of the FucGlc disaccharide 21. The imidate 
donor 25, required for this model glycosylation, can be synthesised from the glucose 
azide building block 23, further illustrating the orthogonality of the protection strategy of 
23. 
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Scheme 6: Retrosynthesis of the Glc(Fuc)Glc trisaccharide 24. The synthetic methodology required 
for the formation of the β-1,4-linkage between the two GlcNAc residues can be 
established via the synthesis of trisaccharide 24 before it is required for the formation of 
the heptasaccharide 27. 
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1.7 Biological Testing 
Biological testing of the conjugated N-glycans will be conducted at the Malaghan 
Institute of Medical Research, Wellington, New Zealand. Though the testing itself is 
outside the scope of this project, brief mention of the assays that will be used is given 
below. 
 
Glycoconjugates 14, 15, and 16 will be tested for their ability to bias the Th response to a 
Th2 immune response using the recently developed IL4/green fluorescent protein (GFP) 
reporter mice.
15
 IL4/GFP reporter mice have a fluorescent reporter gene construct stably 
inserted into the IL4 gene locus and when a T cell differentiates to the Th2 phenotype, 
the IL4 gene locus becomes active and transcribes the fluorescent reporter construct. The 
advantage of using the IL4/GFP reporter system is that GFP is not secreted making it 
possible to detect the in vivo development of Th2 cells using flow cytometry without 
requiring in vitro restimulation. GFP also has a relatively long half life. These 
characteristics make GFP a sensitive reporter for the in vivo production of IL4.  
 
Testing of the synthesised N-glycan‟s ability to induce a Th2 immune response using the 
IL4/GFP reporter mice will involve the injection of solutions of the N-glycan into the 
dermal layer of a mouse ear and then collecting the ear draining lymph node after seven 
days. The absolute number of CD4
+
 GFP
+
 T cells in the ear draining lymph node is 
calculated using flow cytometry and expressed as the number of CD4
+
 GFP
+
 cells per ear 
draining lymph node.  
 
If the N-glycans stimulate the production of IL4 in the IL4/GFP assay, other assays will 
be conducted to determine whether the glycoproteins stimulate all aspects of a Th2 
immune response. Enzyme-Linked ImmunoSorbent Assays (ELISA) of mouse blood will 
be used for determination of IgE antibody production, quantitative polymerase chain 
reaction (PCR) analysis of lymph nodes will be used for the determination of other Th2 
cytokines (IL5 and IL13), and cytospin assays will be used for the determination of 
eosinophil and basophil infiltration of tissue sites injected with the glycoprotein. The 
fluorescent latex bead glycoconjugates, 14, 15, and 16, can be visually tracked by 
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fluorescent microscopy and will provide information on the types of antigen presenting 
cells (DCs, basophils, B cells, macrophages) involved with the initial recognition and 
cellular uptake of the N-glycans. 
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RESULTS AND DISCUSSION 
 
2.1 Synthesis of the Mannose Trisaccharide 
 
2.1.1 Synthesis of the Mannose Imidate Donor Building Block 
Mannose imidate 18 is the building block responsible for installing the terminal mannose 
capping residues of the Man3(GlcNAc)2 pentasaccharide core (Scheme 7). Synthesis of 
the mannose imidate is possible in seven steps from D-mannose following literature 
procedures.
91,92
 The synthesis was conducted on a large scale so that additional imidate 
18, not required for the production of the target mannose trisaccharide conjugate 16, can 
be used in the synthesis of the heptasaccharide conjugate 1 and other derivatives (Scheme 
7). 
 
 
Scheme 7: Uses for the mannose imidate building block 18. 
 
The first step in the synthesis of the mannose imidate 18 (Scheme 8) was the 
benzoylation of D-mannose which proceeded in 96% yield to give per-benzoylated 
mannose 29.
*
 Treatment of benzoylated mannose 29 with HBr and acetic acid resulted in 
the glycosyl bromide 30. The crude bromide 30 was then converted to the corresponding 
orthoester 31 by reaction with MeOH and 2,6-lutidine before removal of the benzoyl 
groups using standard Zemplén conditions
109
 (NaOMe, MeOH, pH ≈ 9) to give the triol 
*
 Previously synthesised in the group (Dr Stocker) 
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orthoester 20 in 68% yield over 3 steps.
*
 Benzylation of triol 20 resulted in benzyl 
protected orthoester 32 in an 81% yield. Successful introduction of the three benzyl 
groups was confirmed by the appearance of three characteristic AB systems in the 
1
H 
NMR spectrum of 32 (3-O-Bn 4.88 and 4.83 ppm, 4-O-Bn 4.91 and 4.65 ppm, and 6-O-
Bn 4.44 and 4.41 ppm). Opening of the 1,2-orthoester using acetic acid and water gave 
the 2-O-benzoyl protected lactol 33 in 82% yield. Successful opening of the 1,2-
orthoester was seen in the 
1
H NMR of 33 by the disappearance of the methoxyl protons 
and the downfield shift of H-2, resulting from newly formed electron withdrawing 2-O-
benzoate (from δH2 = 4.70,  to δH2 = 5.63). The appearance of a broad OH stretch (3343 
cm
-1
) in the IR spectrum was also observed. A small amount (8%) of the anomeric α-O-
acetate 34 was also formed during the opening of the 1,2-orthoester. Anomeric acetate 
protection was confirmed by the HMBC between the O-Ac carbonyl carbon (168.6 ppm) 
and both the anomeric proton (6.26 ppm, J1,2 = 2.2 Hz) and the O-Ac methyl protons 
(2.11 ppm) as well as electrospray ionisation high resolution mass spectrometry 
(HRMS(ESI)) analysis (m/z calcd. for [C36H36O8+Na]
+
: 619.2308, obsd.: 619.2324). The 
synthesis of mannose imidate 18 was completed by treatment of lactol 33 with 
trichloroacetonitrile and 1,8-diazabicyclo[5.4.0]undec-7-ene (DBU) which resulted in the 
thermodynamic α-imidate product 18 (δH1α = 6.43, J1,2 = 2.1 Hz) in 89% yield. 
Conversion to the acetimidate was confirmed by the presence of the diagnostic CCl3 
carbon peak in the 
13
C NMR spectrum at 90.1 ppm and the introduction of the singlet NH 
peak at 8.70 ppm in the 
1
H NMR spectrum. The imidate was obtained as a colourless oil 
that crystallised overnight upon storage in the freezer. In total 5.76 g of the imidate donor 
18 was synthesised, which was stored in the freezer until required. 
 
*
 The mannose orthoester 20 was synthesised from per-benzoylated mannose 29 in conjunction with a 
summer research student. 
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Scheme 8: Seven step synthesis of the mannose imidate building block 18. 
 
 
2.1.2 Synthesis of the Mannose Acceptor 
The mannose acceptor 19, required to form the mannose trisaccharide 17, is accessible in 
one step from the triol orthoester 20, an intermediate in the mannose imidate synthesis. It 
has been shown by members of our group that direct glycosylation of triol orthoester 20 
does not result in the desired trisaccharide.
110
 Instead it results in the formation of the O-
methyl glycoside of the mannose imidate donor due to the instability of the orthoester in 
the presence of TMSOTf, which is used as the activator in the bis-glycosylation reaction. 
 
Opening of the 1,2-orthoester of 20 using camphorsulfonic acid (CSA) in the presence of 
excess benzyl alcohol resulted in the formation of the α-anomeric benzyl protected 
acceptor 19 (δH1α = 5.05, J1,2 = 1.4 Hz) in 46% yield (Scheme 9).
*
 Successful opening to 
produce the benzyl glycoside 19 resulted in the introduction of a characteristic AB 
system in the 
1
H NMR spectrum (1-O-Bn 4.74 and 4.56 ppm) as well as the downfield 
*
 The mannose acceptor 19 was synthesised from orthoester 20 in conjunction with a summer research 
student. 
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shift of H-2 (from δH2 = 4.74, to δH2 = 5.40) due to the 2-O-benzoate. The low yield 
obtained for the opening of the orthoester was surprising as no by-products were 
observed after aqueous workup, suggesting any by-product formed was water soluble. 
The low yield is most likely due to presence of water in the reaction resulting in 
hydrolysis to form lactol 35 (Scheme 9), which with four hydroxyls is likely to be 
removed during the aqueous workup. The reaction was not repeated as enough of the 
mannose acceptor 19 was produced. However, if the reaction were to be repeated more 
care needs to be taken to ensure the reaction is free from water. Although the 1,2-
orthoester was co-evaporated prior to the reaction, which was done under a nitrogen 
atmosphere, no precautions were taken to remove water from the benzyl alcohol. The 
benzyl alcohol should have been either co-evaporated with the 1,2-orthoester (b.p.(BnOH) = 
205°C) or distilled prior to use. The addition of molecular sieves would also have been 
beneficial, as would the use of freshly distilled dichloromethane (DCM) instead of DCM 
dried over molecular sieves. 
 
 
Scheme 9: Synthesis of the mannose acceptor 19. 
 
 
2.1.3 Synthesis of the Mannose Trisaccharide 
With both the mannose imidate donor 18 and the mannose triol acceptor 19 in hand 
synthesis of the mannose trisaccharide (Man3) 17 was attempted (Scheme 10). Although 
the acceptor has three free hydroxyls and only bis-glycosylation is desired it was 
expected that glycosylation would occur selectively at the C-3 and C-6 hydroxyls.
86-90,111
 
The thought was that the more reactive and accessible primary C-6 hydroxyl would react 
first followed by glycosylation at the more reactive C-3 hydroxyl, in preference of the C-
4 hydroxyl, as the C-4 hydroxyl is now more sterically hindered and has been shown to 
be to be inherently unreactive.
86,112
  There is literature precedent for selective [1→3], 
[1→6] bis-glycosylations of mannose acceptors that are only protected at the anomeric 
  31 
position with both mannose and other donors.
86-90,111
 Selective glycosylation at O-3 and 
O-6 is achievable as the C-4 hydroxyl of mannose is inherently unreactive as previously 
mentioned.
86
 There is also literature precedent that selective [1→6] mono-glycosylation 
can be achieved on mannose acceptors that are again only protected at the anomeric 
position.
113
 In these studies, imidate and bromide donors are the most commonly used 
and all of the donors have been either acetate or benzoate protected.  
 
 
Scheme 10: Synthesis of the mannose trisaccharide 17. 
 
The initial attempt at forming trisaccharide 17 involved the coupling of triol acceptor 19 
with three equivalents of donor 18 using TMSOTf (0.1 equiv.) as the activating agent at   
-40°C. The complete consumption of the triol acceptor was seen after 2 hours by TLC 
analysis (ethyl acetate/light petroleum ether, 1/1, v/v) so the reaction was quenched with 
triethylamine. Gradient column chromatography of the crude reaction mixture using both 
ethyl acetate/light petroleum ether (1/20→1/2, v/v) and DCM/light petroleum ether 
(1/3→1/0, v/v) columns on silica gel was unsuccessful in purifying the mixture of 
products produced. It was impossible to determine if any trisaccharide had been produced 
via interpretation of the 
1
H NMR spectrum of the inseparable mixture, therefore 
HRMS(ESI) analysis was obtained, which confirmed the presence of trisaccharide (m/z 
calcld. for [C88H86O19+Na]
+
: 1469.5661, obsd.: 1469.5651). Although HRMS(ESI) 
confirmed the presence of trisaccharide it does not provide information on the 
glycosylation pattern and indeed there may be a mixture of trisaccharides. 
 
As the product mixture of the first reaction was seemingly inseparable it was decided to 
repeat the glycosylation reaction. This time fewer equivalents of donor (2.7 equiv.) were 
used but activation conditions were kept the same (0.1 equiv. TMSOTf). The thought was 
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that with fewer equivalents of donor the glycosylation would be more regioselective due 
to the lower concentration of donor present and may result in a more easily separable 
mixture of products. The second reaction was followed more closely via TLC. This time 
DCM was used to develop the TLC instead of ethyl acetate/lightpetroleum ether, 1/1, v/v, 
as it produced better separation of the acceptor and donor as well as the products. After 
two hours at -40°C, TLC analysis (DCM) showed the complete consumption of acceptor 
and the formation of 2 higher running product spots. TLC analysis after 4 hours at -40°C 
still showed the presence of two potential product spots. It was assumed that the lower Rf 
product was mono-glycosylated product (most likely glycosylated on the more reactive 
primary C-6 hydroxyl) and that the higher Rf product was bis-glycosylated product. The 
reaction was therefore allowed to warm to 0°C and stirred for a further 3 hours until 
complete disappearance of the lower Rf product was observed. Purification of the reaction 
mixture was attempted using gradient column chromatography (DCM/light petroleum 
ether, 1/3→1/0, v/v). However, this again did not lead to the separation of the mixture of 
products formed. 
 
As normal phase gradient column chromatography had so far been unsuccessful in the 
separation of the reaction mixtures, separation using Sephadex
®
 LH-20 size-exclusion 
chromatography (bead size 25-100μ) was attempted. At this stage it was not known 
which products were present in the inseparable reaction mixture; it was assumed there 
would be a mixture of mono-, di-, tri-, and potentially tetrasaccharides. Both inseparable 
reaction mixtures were combined and loaded onto the Sephadex size-exclusion column 
which was eluted with DCM/methanol, 1/1, v/v. Size-exclusion chromatography did not 
produce purified trisaccharide; however, hydrolysed donor 33 was successfully separated 
from the reaction mixture, which was the last eluted compound from the column. Again 
all fractions that contained mixtures of products were combined. TLC analysis of this 
mixture was conducted in order to find a solvent system that gave the best separation. It 
was found that when the TLC was developed in ethyl acetate/toluene, 1/6, v/v the mixture 
contained at least four different products. Gradient column chromatography was 
attempted once again, this time using ethyl acetate/toluene, 1/30→1/10, v/v. The products 
were again eluted as mixtures and even fractions that appeared to contain one product via 
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TLC analysis (ethyl acetate/toluene, 1/6, v/v) were seen to be mixtures via interpretation 
of their 
1
H NMR spectra. However to our surprise and relief, the last compound eluted in 
the 1/10 ethyl acetate/toluene fractions (Rf 0.47 (ethyl acetate/toluene, 1/6, v/v)) was pure 
by 
1
H NMR analysis and appeared to contain three α-anomeric protons (δH1α = 5.37, J1,2 = 
1.7 Hz, δH1α = 5.08, J1,2 = 1.7 Hz, δH1α = 5.06, J1,2 =1.7 Hz). HRMS(ESI) analysis 
confirmed that it was a trisaccharide produced by the bis-glycosylation of acceptor 19 by 
donor 18 (m/z calcld. for [C88H86O19+Na]
+
: 1469.5661, obsd.: 1469.5668) and analysis of 
the HMBC spectrum confirmed that the pure product was in fact the desired [1→3], 
[1→6] linked mannose trisaccharide 17 (Figure 7). The first fractions eluted from the 
ethyl acetate/toluene column (Rf 0.71 (ethyl acetate/toluene, 1/6, v/v)) also appeared to be 
a single compound by TLC analysis, however, the 
1
H NMR spectrum clearly showed it 
was a mixture of products. The HRMS(ESI) of this mixture showed it contained both 
[1→1] donor-donor coupled by-product 36 (m/z calcld. for [C68H66O13+Na]
+
: 1113.4401, 
obsd.: 1113.4390) and tetrasaccharide 37 (resulting from tri-glycosylation) (m/z calcld. 
for [C122H118O25+Na]
+
: 2005.7860, obsd.: 2005.7854) (Scheme 11). The other fractions 
were not analysed by HRMS(ESI) but did not contain the desired product according to 
TLC analysis. 
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Figure 7: HMBC of the mannose trisaccharide 17 confirming the [1→3], [1→6] glycosylation 
pattern. 
 
 
Scheme 11: Products resulting from the mannose trisaccharide coupling reaction. 
 
C-1′ C-1″ 
H-1″ 
H-6a 
C-6 
H-6b 
H-1′ 
C-3 
H-3 
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The desired product 17 was obtained in a very low yield (0.097 g, 11%), along with a 
significant amount of tetrasaccharide (0.340 g, 29%). However, the selective [1→3], 
[1→6] bis-glycosylations reported in literature also do not have excellent yields and are 
typically around 30% with some reported yields as low as 17%.
86-90,111
 As the amount of 
trisaccharide 17 that was produced was sufficient for deprotection and subsequent 
coupling to bead/protein, the selective [1→3], [1→6] bis-glycosylation was not attempted 
again. Selective [1→3], [1→6] bis-glycosylation is also not required in the synthesis of 
the larger heptasaccharide, and other derivatives containing the Man3(GlcNAc)2 
pentasaccharide core, as the C-4 hydroxyl of the mannose acceptor (38 or 39) is benzyl 
protected in the proposed strategy (Scheme 12). 4-O-Benzyl protection is required 
because once bis-glycosylation has been achieved, the fully protected oligosaccharide (40 
or 41) is converted into the corresponding imidate, which requires that the only free 
hydroxyl be the anomeric hydroxyl at the reducing end of the sugar. 
 
 
Scheme 12: Mannose bis-glycosylation strategy for producing the heptasaccharide and 
Man3(GlcNAc)2 pentasaccharide core containing derivatives. 
 
However, if the reaction were to be conducted again the amount of donor used would be 
decreased to two equivalents, to reduce and hopefully prevent the formation of 
tetrasaccharide. On closer examination of the literature it was discovered that over- 
glycosylation has been observed when more than two equivalents of donor are used.
86
 In 
the attempted [1→3], [1→6] bis-glycosylation it was initially thought that tri-
glycosylation would not occur as once bis-glycosylation had occurred, presumably at the 
C-3 and C-6 hydroxyls due to literature precedent, the C-4 hydroxyl was deemed to be 
too sterically crowded to react, as well as the fact that the C-4 hydroxyl in mannose has 
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been shown to be inherently unreactive.
112
 This unfortunately was not the case as the 
yield of tetrasaccharide was nearly three times that of the desired trisaccharide. The high-
reactivity of the donor used in our attempted bis-glycosylation may also have played a 
part in the over glycosylation that was observed. The donor we used contained three 
benzyl groups, as well as the O-2-benzoyl group required for neighbouring group 
participation to give the desired α-glycosylation. All of the donors reported in literature 
used for selective [1→3], [1→6] bis-glycosylation of mannose have been either acetate 
or benzoate protected. Acetates and benzoates are “disarming” protecting groups due to 
their electron withdrawing nature whereas benzyl protecting groups are “arming” due to 
their electron donating properties.
114
 Therefore acetate and benzoate protected donors are 
less reactive than their benzyl protected counterparts as the ring oxygen (O-5) is less able 
to stabilise the oxacarbenium ion via resonance due to the electron withdrawing groups at 
C-4 and C-6.
114
 The more reactive benzyl protected donor was designed with production 
of the heptasaccharide in mind as regio-selectivity is not an issue in the bis-glycosylation 
and therefore the most reactive donor possible is desired in order to achieve the highest 
possible yield. 
 
 
2.1.4 Deprotection of the Mannose Trisaccharide 
Before the mannose trisaccharide 17 could be coupled to a bead or a protein it first had to 
be fully deprotected and then converted into the corresponding anomeric amine.  
Removal of the three O-benzoyl groups was achieved using Zemplén conditions
109
 to 
give 41 in a 74% yield (Scheme 13). Removal of the benzoyl groups was seen in the 
1
H 
NMR spectrum of 41 by the upfield shift of the three H-2 resonances from δ 5.77, 5.57, 
and 5.52 in the benzoylated starting material to δ 4.19-4.18 (m), 4.19-4.18 (m), and 4.07-
4.04 (m) in the deprotected product. Although the removal of all 3 benzoyl groups was 
slow and required three days to go to completion, the reaction was easily monitored with 
the di- and mono- benzoylated intermediates distinguishable via TLC analysis (Rf 0.34 
and 0.13 respectively (ethyl acetate/light petroleum ether, 1/2, v/v) ). It should be noted 
that extra care should be taken to ensure that the reaction does not become too basic when 
debenzoylation is attempted on the larger structures which contain the Man3(GlcNAc)2 
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pentasaccharide core. Alkali degradation of polysaccharides is a well known process and 
although it is rarely seen in fully protected structures,
115
 Nagorny et al.
77
 have recently 
reported that degradation was observed during de-acetylation of their dodecasaccharide 
43 which contains the Man3(GlcNHPhSO2)2 pentasaccharide core (Scheme 14). When 
using NaOH for de-acetylation they observed a significant amount of cleavage of either 
the Man [1→4] Glc(NHPhSO2) (to give 44) or the GlcNHPhSO2 [1→4] GlcNHPhSO2 
(to give 45) linkages present in the core pentasaccharide. They reported that formation of 
these “peeling reaction” by-products was “drastically reduced” when NaOMe was used 
instead of NaOH in the de-acetylation. 
 
 
Scheme 13: Deprotection of the mannose trisaccharide 17, resulting in the fully deprotected mannose 
trisaccharide 42. 
 
 
Scheme 14: Reported de-acetylation of dodecasaccharide 43 using NaOH by Nagorny et al.
77
, which 
resulted in the formation of the peeling reaction by-products 44 and 45 formed by 
cleavage of the Man [1→4] Glc(NHPhSO2) or the GlcNHPhSO2 [1→4] GlcNHPhSO2 
linkage respectively. 
 
  38 
The O-benzyl groups of 41 were then successfully removed via hydrogenation using 
Pd(OH)2/C in CHCl3: EtOH, 3:2 to give fully deprotected mannose trisaccharide 42, 
which was purified using C18 reverse phase chromatography resulting in a 95% yield 
(Scheme 13). The fully deprotected product was confirmed by the absence of all aromatic 
and benzyl AB system protons in the 
1
H NMR spectrum of 42 as well as HRMS(ESI) 
confirming the product was the correct molecular weight (m/z calcld. for 
[C18H32O16+Na]
+
: 527.1588, obsd.: 527.1594). The deprotected trisaccharide 42 was 
freeze dried from water in order to remove any excess traces of solvent in preparation of 
anomeric amine formation, resulting in 42 as a white amorphous powder. 
 
 
 
2.2 Synthesis of the FucGlcNAc Disaccharide 
 
2.2.1 Synthesis of the Thiofucose Building Block 
Synthesis of the thiofucose building block 22 was achieved in five steps from L-fucose 
following modified literature procedures (Scheme 15).
102,103
 Firstly, L-fucose was per-
acetylated using acetic anhydride-pyridine in accordance with Ruttens et al.‟s 
procedure.
103
 Acetic anhydride-pyridine was used for acetylation as Ruttens et al. 
reported excessive furanose formation (ca. 30% based on TLC observations) when they 
used Ichikawa et al.‟s116 method involving acetic anhydride-NaOAc. Acetylation 
proceeded smoothly resulting in the formation of both α and β per-acetylated 
fucopyranoses 46 in a 1:2 ratio respectively, based on integration of 
1
H NMR signals 
(δH1α = 6.34, J1,2 = 2.7 Hz and δH1β = 5.68, J1,2 = 8.3 Hz). The formation of minor amounts 
of α and β per-acetylated fucofuranoses (total ca. 12%, based on integration in 1H NMR 
spectrum, δH1β = 6.31, J1,2 = 4.6 Hz and δH1α = 6.19, J1,2 = 0 Hz) was also observed via 
1
H 
NMR. The percentage of furanose products formed is in accordance with that obtained by 
Ruttens et al. (ca. 7%, based on 
1
H NMR) when using acetic anhydride-pyridine. The 
crude acetylated product was treated with HBr in acetic acid, resulting in the formation of 
the α-bromide 47 (δH1α = 6.69, J1,2 = 3.9 Hz). The bromide was used without purification 
in a two step one pot procedure to convert the anomeric bromide into the corresponding 
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ethyl thiofucoside followed by de-acetylation to afford β-thiofucoside 48. Triol 48 was 
purified by column chromatography, which removed any furanose by-products, and re-
crystallised from diethyl ether resulting in a 68% yield over the 4 steps (Scheme 15). 
Benzylation of triol 48 produced the β-thiofucose building block 22 as a colourless oil, 
which was crystallised from light petroleum ether to give white needle-like crystals (82% 
yield) (δH1β = 4.40, J1,2 = 9.8 Hz). The synthesis of the fucose building block 22 was 
completed in 56% yield over five steps from L-fucose. The spectral data for the 
thiofucoside 22 is in accordance with literature.
117
 
 
 
Scheme 15: Synthesis of thiofucose building block 22. 
 
 
2.2.2 Synthesis of the FucGlcNAc Disaccharide 
With the thiofucose building block 22 and the previously prepared glucosazide building 
block 23 (synthesised in 6 steps from D-glucose, 39%)
118
 in hand, formation of the α-1,3-
linked FucGlcNAc disaccharide 21 was attempted (Scheme 16). The α-1,3-linked 
FucGlcNAc disaccharide 21 had been previously synthesised by the candidate during his 
Honours research project. However, the reaction had not been optimised and a large 
excess of donor was required in order to achieve an adequate yield and selectivity (2.6 
equiv. donor, 74%, α:β = 20.5:1). The use of a large excess of donor in glycosidation 
reactions, although not uncommon, is not desirable in this particular coupling reaction 
given the high cost of L-fucose in combination with the amount of disaccharide 21 
needed for the production of the heptasaccharide and all its truncated analogues. 
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Scheme 16: Reaction of thiofucose donor 22 with glucosazide acceptor 23 to form the FucGlcNAc 
disaccharide 21. Reaction conditions are given in Table 1. 
 
Though several conditions have been reported in the literature for the formation of α-
linked FucGlcNAc substrates, via the glycosylation between a suitably protected glucose 
acceptor and a thiofucose donor, the formation of an α-fucosyl linkage is not always 
straightforward, with literature yields varying from 26% to 99%.
98,119
 The difficulties 
encountered are often attributed to the increased acid lability of the α-fucosyl 
linkage.
72,100,101
 It has been found that ether-type (e.g. benzyl) protected fucose residues 
show an increased acid lability over unprotected or acetate protected fucose residues;
72
 
however for the formation of an α-linkage a non-participatory (e.g. ether) group at the C-
2 position of the fucose donor is mandatory. The enhanced lability of ether protected 
fucose residues is due to the ability of the ether groups to stabilise the positive charge of 
the glycosyl cation through inductive effects. The alpha selectivity of the glycosidation 
reaction is due to the anomeric effect which is especially strong for fucosides due to the 
absence of the 6-hydroxyl. 
 
The initial attempts at forming the α-1,3-linked FucGlcNAc disaccharide 21 during the 
candidate‟s Honours project involved activation of the thiol donor using triflic acid 
(TfOH) and N-iodosuccinimide (NIS) (Table 1, Entries 1-2).
96,98
 Although these 
activation conditions resulted in product formation, the yield and selectivity were rather 
disappointing (33%, α:β = 1.3:1). The α-1,3-linkage was confirmed via the HMBC 
spectrum which showed coupling between C-1′ of the fucose (97.6 ppm) and H-3 of the 
glucose (3.73 ppm) and also between the H-1′ of the fucose (5.39 ppm, d, J1,2 = 3.9 Hz,) 
and C-3 of the glucose (74.2 ppm); the molecular mass was confirmed by HRMS(ESI) 
(m/z calcld. for [C46H57O9N3Si+Na]
+
: 846.3762, obsd.: 846.3765). Unreacted acceptor 
was also recovered from these reactions (31%), however, no unreacted donor was 
recovered and there was a large amount of degradation observed via TLC analysis. The 
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low yield and decomposition were thought to be due to the acidic reaction conditions 
given the lability of the α-fucosyl linkage in acidic conditions. Therefore of the two other 
possible activation conditions the milder CuBr2, Bu4NBr activation (Ogawa conditions)
93
 
were chosen to be investigated over methyl trifluoromethanesulfonate activation.
99
 The 
use of Ogawa activation conditions resulted in an increase in both the yield and 
selectivity of the reaction. The best yield (74%) and selectivity (α:β = 20.5:1) were 
obtained during a small scale reaction (53 mg acceptor, 161 mg donor) (1% acceptor 
recovered) (Entry 4). However, the high yield and selectivity were achieved via the use of 
a large excess of donor (2.6 equiv.), and when the reaction was done with only 1.1 
equivalents of donor (104 mg acceptor, 129 mg donor) the yield was only 50% and 
selectivity was reduced (α:β = 13.1:1) (44% acceptor recovered) (Entry 3). The yield and 
selectivity (59%, α:β = 7.6:1) were also significantly compromised when the reaction was 
conducted on a large scale (0.651 g acceptor, 1.235 g donor), using a moderate and 
acceptable excess of donor (1.6 equiv.) (34% acceptor recovered) (Entry 5). Therefore, 
during this Masters project a way of producing gram quantities of the α-1,3-linked 
FucGlcNAc disaccharide 21 in good yields and selectivity, whilst using a moderate 
excess of donor, was required. 
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Table 1:  Initial attempts at forming the FucGlcNAc disaccharide 21. All reactions in this table 
were conducted during the candidate‟s Honours project.  
1
 All reactions used type 4A molecular sieves (MS) that were only activated by heating. Room temperature 
(RT), dichloromethane (DCM), dimethylformamide (DMF). 
2
 Product yields combined α and β.  
3
 α:β ratio based on the integration values for 1H NMR signals. 
 
With the isolation of hydrolysed donor and the recovery of unreacted acceptor from the 
glycosylation reactions it was thought that the variable yields and selectivities were due 
to the presence of water in the reaction mixture. Complete consumption of the donor was 
always observed via TLC analysis and no unreacted donor was ever recovered from the 
previous reactions (Table 1). With this in mind the reaction was repeated changing 
various factors with an effort to reduce the amount of water present. The amount of donor 
added was always kept between 1.6 and 1.8 equivalents. 
 
Previously the molecular sieves, which were added to the reaction in order to absorb any 
water present, had only been activated (removal of absorbed water) by heating. It was 
thought that heating alone may not have been sufficient to properly activate the molecular 
sieves, therefore resulting in the introduction of water to the reaction. The reaction was 
therefore attempted using molecular sieves that had been activated by heating under 
Entry Reaction 
Conditions
1
 
Time of 
Reaction 
Equivalents Yield
2
 Ratio
3
 
α:β Acceptor Donor 
1. NIS, TfOH (0.1 
equiv.), DCM, 
0°C 
2 hours 1 
0.1009 g 
1.1 
0.1245 g 
product: 0.0581 g 
               (28%) 
acceptor: 0.0289 g 
               (29%) 
1.5 : 1 
2. NIS, TfOH (0.1 
equiv.), DCM, 
0°C, 
20 min 1 
0.0859 g 
1.1 
0.1060 g 
product: 0.0568 g  
               (33%) 
acceptor: 0.0267 g 
               (31%) 
1.3 : 1 
3. Et4NBr, CuBr2, 
DMF : DCM 
(1:1), RT 
48 hours 1 
0.1044 g 
1.1 
0.1287 g 
product: 0.1054 g 
               (50%) 
acceptor: 0.0460 g 
               (44%) 
13.1 : 1 
4. Et4NBr, CuBr2, 
DMF : DCM 
(1:1),RT 
48 hours 1 
0.0529 g 
2.6 
0.1605 g 
product: 0.0795 g 
               (74%) 
acceptor: 0.0006 g 
               (1%) 
20.5 : 1 
5. Et4NBr, CuBr2, 
DMF : DCM 
(1:1), RT 
72 hours 1 
0.6507 g 
1.6 
1.2350 g 
product: 0.7813 g 
               (59%) 
acceptor: 0.2180 g 
               (34%) 
7.6 : 1 
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vacuum. This unfortunately did not result in an increased yield (42%, α:β = 17:1) and 
unreacted acceptor was again isolated (29%) along with the observation of hydrolysed 
donor via TLC analysis (Table 2, Entry 1). The coupling reaction was repeated without 
molecular sieves in order to determine whether they were a source of water. The reaction 
with no molecular sieves did not result in product formation and a lot of degradation was 
observed via TLC analysis (Table 2, Entry 2). From this it was obvious that the molecular 
sieves were vital in decreasing the amount of water in the reaction solution, present from 
other sources, to a level where product formation was possible. 
 
Table 2:  Attempts at forming the FucGlcNAc disaccharide 21. All reactions in this table were 
conducted during the candidate‟s Masters project.  
1
 All reactions were conducted at room temperature in DCM/DMF, 1/1, v/v. If molecular sieves (MS) were 
used in the reaction they were type 4A and were activated by heating under vacuum.  
2
 Product yields combined α and β.  
3
 α:β ratio based on the integration values for 1H NMR signals. 
 
Entry Reaction 
Conditions
1
 
Time of 
Reaction 
Equivalents Yield
2
 Ratio
3
 
α:β Acceptor Donor 
1. Et4NBr, CuBr2, 
MS 
50 hours 1 
0.2463 g 
1.7 
0.4822 g 
product: 0.2076 g 
               (28%) 
acceptor: 0.0705 g 
               (29%) 
17.0 : 1 
2. Et4NBr, CuBr2 
 
48 hours 1 
0.0200 g 
1.8 
0.0423 g 
product: 0 g 
               (0%) 
acceptor: not 
               calculated 
N/A 
3. Pr4NBr, CuBr2, 
(added in 
solution), 
Crushed MS  
72 hours 1 
0.4557 g 
1.8 
0.9625 g 
product: 0.3879 g 
               (42%) 
acceptor: 0.1940 g 
               (43%) 
donor: 0.3861 g 
               (40%) 
19.5 : 1 
4. Pr4NBr, CuBr2, 
(added in 
solution), 
MS 
60 hours 1 
0.5193 g 
1.8 
1.0897 g 
product: 0.7213 g 
               (69%) 
acceptor: not 
               calculated 
16.7 : 1 
5. Pr4NBr, CuBr2, 
MS 
60 hours 1 
0.1405 g 
1.8 
0.2970 g 
product: 0.2295 g 
               (81%) 
acceptor: non 
               isolated 
19.2 : 1 
6. Pr4NBr, CuBr2, 
MS 
50 hours 1 
0.4726 g 
1.6 
0.8664 g 
product: 0.8461 g 
               (89%) 
acceptor: non 
               isolated 
22.3 : 1 
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The reaction solvent is a potential source of water contamination. Ogawa conditions 
employ a mixture of dichloromethane (DCM) and dimethylformamide (DMF) as the 
reaction solvent. It was thought that the DMF was not a source of water as the donor and 
acceptor were co-evaporated together with DMF and on the final co-evaporation only 
half of the DMF is evaporated leaving the DMF used for the reaction. Any water present 
in the DMF should be removed in this half co-evaporation as DMF has a significantly 
higher boiling point than water (b.p. of DMF = 153°C). The DCM used thus far in the 
coupling reactions had been dried by storage over molecular sieves. As this drying 
method is potentially inadequate for glycosylation reactions the DCM used in subsequent 
reactions (Table 2, Entries 3-6) was instead freshly distilled over phosphorus pentoxide 
before use.  
 
The activators are also another possible source of water introduction, both via their 
absorption of water and also when they are added to the reaction flask as they are both 
solids and are added sequentially (Et4NBr followed by CuBr2 an hour later) after the 
donor and acceptor have been pre-stirred with molecular sieves for an hour. In all the 
previously conducted reactions Et4NBr had been used instead of the more commonly 
used Bu4NBr due to availability. The Et4NBr used was not fine white crystals as expected 
and instead it had agglomerated, indicating the potential absorption of water. Therefore 
the potentially wet Et4NBr was replaced with Pr4NBr from a freshly opened bottle. The 
CuBr2 was not thought to be a potential source of water as it was fine greyish black 
crystals as expected and it was observed that when CuBr2 absorbed atmospheric water it 
dissolved resulting in a green solution. 
 
The reaction was once again repeated, this time using freshly distilled DCM and the 
newly opened Pr4NBr. The molecular sieves were crushed prior to activation by heating 
under vacuum to give them a greater surface area and enable them to absorb more water. 
The Pr4NBr and CuBr2 were added in solution via a needle in an effort to reduce water as 
the septum had to be removed to add them as solids. They were co-evaporated together 
with DMF, dissolved in DCM, and stirred with crushed activated molecular sieves prior 
to addition. With the measures taken to ensure the reaction was as dry as possible the 
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yield was expected to be significantly higher. Surprisingly, the yield was still only 42% 
(α:β = 19.5:1), however, unreacted donor (40%) was recovered for the first time, as well 
as unreacted acceptor (43%) (Table 2, Entry 3), indicating that the amount of water 
present in the reaction had been significantly reduced and the low yield was due to 
incomplete reaction rather than hydrolysis of the donor. The incomplete activation of 
donor was thought to be due to insufficient activator being added. Although 3.2 
equivalents of both Pr4NBr and CuBr2 were used, as in all previous reactions, not all of 
the activator was transferred to the reaction flask due to the crushed molecular sieves. 
Some of the activator adhered to the crushed molecular sieves, which could not be 
transferred via syringe. During the reaction it was also observed that the usual deep 
purple black colour of the reaction solution faded, potentially indicating that the crushed 
molecular sieves were detrimental to activation. The reaction was repeated with the use 
of non-crushed molecular sieves, both in the reaction flask and pre-drying of the 
activators, whilst keeping the other reaction conditions constant. This resulted in the 
expected increase in yield (69%) whilst selectivity was relatively unchanged (α:β = 
16.7:1) (Table 2, Entry 4).  
 
The use of both freshly distilled DCM and dry Pr4NBr, instead of potentially wet Et4NBr, 
were thought to be the main contributing factors for the increase in yield rather than the 
addition of the reagents in solution via a needle. To prove this the reaction was repeated 
with activated molecular sieves but this time both Pr4NBr and CuBr2 were added as 
solids, maintaining a flow of nitrogen over the flask while the septum was lifted for 
addition. Our hypothesis was confirmed and the yield increased to 81% whilst 
maintaining good selectivity (α:β = 19.2:1) (Table 2, Entry 5). The increase in yield 
suggests that the co-evaporation and drying with molecular sieves actually increased the 
amount of water added to the reaction rather than reducing it. The reaction was repeated 
on a larger scale (0.47 g acceptor, 0.89 g donor, 1:1.6) using these reaction conditions 
which again resulted in an increase in yield (89%) and also gave slightly greater 
selectivity (α:β = 22.3:1) (Table 2, Entry 6).  
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The reaction conditions were successfully optimised to enable synthesis of the α-1,3-
linked FucGlcNAc disaccharide in an excellent yield and selectivity on both small and 
large scale. 
 
The α and β anomers were separated by column chromatography (ethyl acetate/light 
petroleum ether, 1/17, v/v). Although they are indistinguishable via TLC, as they have 
the same Rf (Rf = 0.52, ethyl acetate/light petroleum ether, 1/5, v/v), the β anomer is 
eluted before the α anomer. Fractions must be individually analysed by 1H NMR in order 
to determine the α:β ratio and therefore which fractions should be combined. 
Unfortunately unreacted acceptor (Rf = 0.36, ethyl acetate/light petroleum ether, 1/5, v/v) 
was also co-eluted with the α and β anomers in the ethyl acetate/light petroleum ether, 
1/17, v/v fractions which is surprising given their difference in Rf values. If there was 
unreacted acceptor present in the crude reaction mixture Sephadex
®
 LH-20 size exclusion 
chromatography (eluted with DCM/methanol, 1/1, v/v) was first used to separate the 
product and unreacted acceptor. Purification by size exclusion chromatography was also 
able to successfully separated unreacted donor, and hydrolysed donor from the product. 
 
 
2.2.3 Synthesis of the FucGlcNAc Acceptor 
At this stage the α-1,3-linked FucGlcNAc disaccharide 21 could either be deprotected 
and coupled to a bead or protein, or the benzylidene protecting group could be selectively 
opened to give the acceptor required for the creation of the heptasaccharide 27.  
 
Selective opening of the 4,6-benzylidene to give the C-4 hydroxyl was achieved using 
Ratner et al.‟s120 procedure of triethylsilane (TES-H), trifluoroacetic acid (TFA), and 
trifluoroacetic anhydride (TFAA) to give disaccharide acceptor 26 as a colourless oil in 
78% yield (Scheme 17). We were very pleased that this reaction proceeded so smoothly 
given the lability of the α-fucose residue under acidic conditions. The reaction was 
extremely selective as none of the possible C-6 hydroxyl by-product was observed. 
Selective opening to give the free hydroxyl at C-4, and C-6 O-benzyl protection was 
confirmed by the HMBC correlation between C-6 (69.7 ppm) and the methylene protons 
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of the benzyl protecting group (4.61 and 4.57 ppm) and also between the benzyl 
methylene carbon (73.6 ppm) and both C-6 methylene hydrogens (3.77 and 3.66 ppm) 
(see Appendix, pg XV). The molecular weight was confirmed via HRMS(ESI) which 
confirmed that the C-4 hydroxyl was now unprotected (m/z calcld. For 
[C46H59O9N3Si+Na]
+
: 848.3918, obsd.: 848.3919). Though the selective opening of the 
4,6-benzylidene to afford the C-4 free hydroxyl with a Brønsted acid is largely empirical, 
it is thought that the 4-O-benzylidene oxygen is more basic than the oxygen at the 6-
position and is therefore preferentially protonated. The use of a sterically bulky Lewis 
acid however, instead of a Brønsted acid, results in co-ordination to the less sterically 
hindered 6-O position leading to selective benzylidene opening to give a free hydroxyl at 
the 6 position.
121
 
 
 
Scheme 17:  Selective opening of the FucGlcNAc disaccharide to give the disaccharide acceptor 26. 
 
 
 
2.3 Synthesis of the GlcNAc(Fuc)GlcNAc Trisaccharide 
 
2.3.1 Synthesis of the Glucose Azide Donor 
The glucose azide donor 25 was successfully synthesised from the previously prepared 
glucose azide acceptor 23
118
 in three steps. The first step was benzylation of the C-3 
hydroxyl (Scheme 18). Benzylation of 23 using NaH, BnBr, and TBAI resulted in fully 
protected glucose building block 49 as a colourless oil, which subsequently crystallised 
upon refrigeration (86% yield).  
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Scheme 18: Synthesis of the fully protected glucosazide 49.  
 
Next the anomeric TBDMS ether was selectively deprotected using HF.pyridine to 
quantitatively give lactol 50 as a white amorphous powder following purification by 
column chromatography (Scheme 19). The removal of the silyl protecting group was seen 
in the 
1
H NMR spectra by the disappearance of the silyl methyl protons. The appearance 
of an OH stretch (3403 cm
-1
) in the IR spectrum was also observed.  
 
 
Scheme 19:  Synthesis of the acetimidate donor 25 from the fully protected glucosazide 49. 
 
Conversion of lactol 50 to the trichloroacetimidate donor 25, was achieved in a 99% yield 
using trichloroacetonitrile (Cl3CCN) in the presence of a catalytic amount of caesium 
carbonate. The α-anomer was a colourless oil, while the β-anomer was a white powder. 
Conversion to the acetimidate was confirmed by the presence of the diagnostic peak of 
the CCl3 carbon in the 
13
C NMR spectrum at 90.8 (α) and 90.5 (β) ppm and the 
introduction of the singlet NH peak at 8.75 (α) and 8.77 (β) ppm in the 1H NMR 
spectrum. 
 
 
2.3.2 Attempted Synthesis of the Glc(N3)(Fuc)Glc(N3) Trisaccharide 
With the successful synthesis of both the acetimidate donor 25 and the disaccharide 
acceptor 26, synthesis of the GlcNAc(Fuc)GlcNAc trisaccharide 24 was attempted. A β-
1,4-linkage was required. However, as the acetimidate donor 25 does not possess a 
participating group at C-2, which would result in the formation of the β-linkage due to 
neighbouring group participation, participating solvent effects were employed in an 
attempt to favour β-selectivity.107 The use of acetonitrile at low temperatures in the 
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presence of a suitable activator results in the fast formation of the α-nitrilium-nitrile 
conjugate 51 (irrespective of the anomeric stereochemistry of the donor) due to the 
anomeric effect (Figure 8).
107
 This α-nitrilium-nitrile conjugate in turn blocks the α-face 
leading to more selective formation of a β-glycoside.107 
 
 
Figure 8: The α-nitrilium-nitrile conjugate which leads to higher selectivity in the formation of β-
glycosides by blocking the α-face. 
 
Coupling of acetimidate donor 25 and disaccharide acceptor 26 (3:1 equiv. respectively) 
was attempted using TMSOTf (0.1 equiv.) as the activator and acetonitrile as a 
participatory solvent, at -40°C (Scheme 20). Unfortunately no product was formed and 
unreacted acceptor (43%) and hydrolysed donor were recovered from the reaction 
mixture.  
 
 
Scheme 20: Attempted reaction of the acetimidate donor 25 with disaccharide acceptor 26 to form the 
GlcNAc(Fuc)GlcNAc trisaccharide 24. 
 
 
2.3.3 Glc(N3)Glc(N3) Disaccharide Model Glycosidation 
Due to the value of the disaccharide acceptor 26, the conditions for the formation of the 
β-1,4-linkage were further investigated using the less valuable glucose azide acceptor 52. 
The glucose azide acceptor was previously synthesised by the candidate
118
 and was 
accessible in one step from the fully protected building block 49 via selective opening of 
the 4,6-benzylidene using TES, TFA, and TFAA to give a free hydroxyl at C-4 (Scheme 
21). 
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Scheme 21:  Previously conducted synthesis of the glucosazide acceptor 52 from fully protected 
glucosazide 49. 
 
Coupling of acetimidate donor 25 and glucosyl acceptor 52 to form disaccharide 53 
(Scheme 22) was initially attempted using the same conditions as were used for the 
attempted formation of trisaccharide 24 in order to determine whether the disaccharide 
acceptor was solely responsible for the failed reaction. Activation with TMSOTf (0.1 
equiv.) using 1.6 equivalents of donor and freshly distilled acetonitrile as the participating 
solvent, at -40°C (Table 3, Entry 1) did not result in product formation. This was 
fortunate as it meant that the disaccharide acceptor was not solely responsible for the lack 
of product formation. Although no product was formed, unreacted acceptor (98%) and 
unreacted donor (31%) were isolated along with hydrolysed donor. The recovery of 
unreacted donor indicated that the donor was not properly activated. The coupling was 
repeated this time using 0.3 equivalents of TMSOTf in order to achieve more complete 
activation of the donor (Table 3, Entry 2). Unfortunately this resulted in degradation of 
the donor rather than product formation.  
 
 
Scheme 22: Reaction of the acetimidate donor 25 with glucosyl acceptor 52 to form the 
GlcNAcGlcNAc disaccharide 53. Reaction conditions are given in Table 3 below. 
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Table 3:  Attempts at forming the Glc(N3)Glc(N3) disaccharide 53.  
1
 Type 4A molecular sieves were used in all reactions and were activated by heating under vacuum.  
2
 Product yields combined α and β.  Hydrolysed donor was observed for all reactions. 
3
 α:β ratio based on the integration values for 1H NMR signals. 
4
 Trimethylsilyl protected acceptor. 
 
It was thought that if the temperature of the reaction was lower upon the addition of 
TMSOTf the donor would be less likely to degrade. As acetonitrile has a freezing point of 
-45°C a different participating solvent was required if the reaction was to be attempted at 
lower temperatures. Propionitrile was chosen as it has a freezing point of -92°C and also 
has the ability to form the α-nitrilium-nitrile conjugate as acetonitrile does. Unfortunately 
the donor and acceptor did not dissolve in propionitrile so a 1:1 mixture of propionitrile 
and DCM was used. The reaction was done at -78°C with 0.4 equivalents of TMSOTf 
(initially 0.2 equiv. were added with another 0.2 equiv added after an hour) (Table 3, 
Entry Reaction 
Conditions
1
 
Time & 
Temp. 
Equivalents Yield
2
 Ratio
3
 
α:β Acceptor Donor 
1. TMSOTf 
(0.1 equiv), 
MeCN 
 
45 mins 
-40°C 
1 
0.1000 g 
1.6 
0.1714 g 
product: 0 g 
               (0%) 
acceptor: 0.0980 g 
               (98%) 
donor: 0.0531 g 
               (31%) 
N/A 
2. TMSOTf 
(0.3 equiv), 
MeCN 
 
90 mins 
-40°C 
1 
0.0966 g 
1.5 
0.1522 g 
product: 0 g 
               (0%) 
acceptor: not 
               calculated 
N/A 
3. TMSOTf 
(0.4 equiv), 
EtCN/DCM,  
1/1 
 
90 mins 
-78°C 
1 
0.0800g 
1.5 
0.1267 g 
product: 0 g 
               (0%) 
acceptor: 0.0290 g 
               (36%) 
TMS-acc
4
: 0.0345 g 
               (38%) 
donor: 0.0465 g 
               (37%) 
N/A 
4. TMSOTf 
(0.1 equiv), 
MeCN 
 
30 mins 
-40°C 
2.5 hours 
0°C 
2 hours 
RT 
1 
0.0657 g 
2.0 
0.1388 g 
product: 0.0134 g 
               (12%) 
acceptor: 0.0506 g 
               (77%) 
1 : 3.3 
5. TMSOTf 
(0.1 equiv), 
MeCN 
 
30 mins 
0°C 
6 hours 
RT 
1 
0.0500 g 
2.0 
0.1093 g 
product: 0.0190 g 
               (23%) 
acceptor: 0.0350 g 
               (70%) 
1 : 2.8 
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Entry 3). TLC analysis was promising with the formation of a higher Rf product (Rf = 
0.76, ethyl acetate/light petroleum ether, 1/5, v/v). Unfortunately this higher Rf product 
was not the desired disaccharide 53 and was instead trimethylsilyl (TMS) protected 
acceptor (0.08 ppm, s, 9H, 3 x Me TMS). Unreacted donor and acceptor were also 
isolated along with hydrolysed donor, indicating that the reaction temperature was too 
low for complete donor activation.  
 
As activation below -45°C did not result in product formation the solvent was switched 
back to acetonitrile because propionitrile required the use of DCM which does not act as 
a participatory solvent. The next reaction (Table 3, Entry 4) was activated with 0.1 
equivalents of TMSOTf at -40°C. The reaction was kept at -40°C for 30 minutes at which 
time TLC analysis showed formation of the TMS protected acceptor as well as a potential 
product spot (Rf = 0.56, ethyl acetate/light petroleum ether, 1/5, v/v). The reaction was 
then warmed to 0°C and stirred for a further 2.5 hours, after which the TMS protected 
acceptor was no longer present by TLC analysis and the intensity of the potential product 
spot had increased. The reaction was then allowed to stir for a further 2 hours at room 
temperature. Fortunately the potential product spot was in fact product, which was 
confirmed by HRMS(ESI) (m/z calcld. for [C46H56O9N6Si+Na]
+
: 887.3776, obsd.: 
887.3767) but unfortunately the yield was only 12% and the selectivity only slightly 
favoured the desired β-anomer (α:β = 1:3.3, based on integration of 1H NMR signals, H-
1′-α 5.65 ppm, J1-2 = 4.2 Hz, H-1′-β 4.41 ppm, J1-2 = 8.1 Hz). Unreacted acceptor (77%) 
and hydrolysed donor were also isolated. As warming the reaction to 0°C resulted in the 
disappearance of TMS protected acceptor, it was thought that activation at 0°C would 
result in an increased yield as the TMS protected acceptor would be unstable at this 
temperature and therefore give the acceptor more chance to react with the donor before 
donor hydrolysis occurred. Activation at 0°C with 0.1 equivalents of TMSOTf followed 
by warming to room temperature after 30 minutes (Table 3, Entry 5) resulted in an 
increase in yield to 23%, which is still well below acceptable especially given the low 
selectivity (α:β = 1:2.8). Unreacted acceptor (70%) and hydrolysed donor were again 
isolated. 
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The limited success with β-1,4-glycosidation involving the glucose azide donor was 
thought to be due to the poor reactivity of the acceptor combined with the instability of 
the activated donor thus resulting in donor hydrolysis before glycosylation could occur. 
Being able to achieve high yields with significant β-selectivity is extremely important for 
this glycosidation as it is the final glycosylation in the proposed synthesis of the 
heptasaccharide 27 and any other Man3(GlcNAc)2 containing truncations (Scheme 23). 
An alternative strategy was therefore needed to increase either the reactivity of the 
acceptor or the stability of the activated donor. Of the two possible options it was easiest 
to increase the stability of the activated donor through the use of a participating 
protecting group on the amino function at C-2. This would enable neighbouring group 
participation, which should result in the increased stability of the activated donor and also 
greater β-selectivity compared to solvent stabilisation with acetonitrile. 
 
 
Scheme 23: Proposed final β-1,4-glycosidation in the formation of the heptasaccharide 27. 
 
Choosing a suitable participating protecting group required careful consideration. 
Although it would appear desirable to use N-acetyl protection, as both the target 
glycoconjugates contain N-acetyl groups, there are several reasons why this is 
problematic. First, the presence of a Lewis basic acetamide group during glycosylations 
can be problematic as it can interact with the Lewis acid used for thioglycoside and 
imidate donor activation. In addition, the presence of a 2-acetamido group in glycosyl 
donors is problematic as it may result in the formation of a stable oxazoline (A, Figure 9) 
instead of the desired glycoside.
122
 The oxazoline can be reactivated using strong acid 
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and high temperatures, but this often results in degradation and lower glycosylation 
yields.
122
 Lastly, it has been shown that the reactivity of the C-4 hydroxyl in N-
acetylglucosamine derivatives is reduced due to the presence of the electron withdrawing 
acetate group.
123,124
 This is an issue as coupling to the C-4 hydroxyl is required in 
forming the donor for the heptasaccharide and other Man3(GlcNAc)2 containing 
truncations. The other two main participating amine protecting groups used in 
carbohydrate chemistry are the phthalimido (N-Phth) group (B, Figure 9) and the 2,2,2-
trichloroethoxycarbonylamino (N-Troc) group (C, Figure 9). There are several 
disadvantages with using the phthalimido group. Though the phthalimido group does not 
form an oxazoline during glycosylation reactions, protection of the amine with this group 
requires two steps and its deprotection is sometimes problematic as it requires harsh 
conditions (strongly basic conditions and elevated temperatures), which can result in low 
yields of the deprotected product.
122
 The phthalimido group is also sterically bulky which 
can cause glycosylation problems at C-3 of phthalimido protected glucosamines, which 
was taken into consideration when the initial protecting group strategy was devised. 
Instead the Troc group was chosen as it can be installed in one step from the unprotected 
amine and can be removed at room temperature in a high yield with zinc powder under 
acidic conditions.
125
 It also does not form an oxazoline during glycosylation reactions and 
Koizumi et al. have reported significantly improved glycosylation yields using Troc 
protected donors as compared to phthalimido protected donors, which they reasoned was 
due to steric hindrance from the phthalimido group.
126
 Azide protection had been initially 
chosen over Troc protection because a conserved amine protection strategy was desired 
as it requires fewer deprotection steps and it was thought that azide protection would be 
compatible with both donor and acceptor GlcNAc units. It was thought that the Troc 
protecting group, being a carbamate which is electron withdrawing, would result in a less 
reactive acceptor, than the corresponding azide, as it has been shown that the C-4 
hydroxyl of 2-azido-2-deoxy-glucopyranosides is more reactive than the electron 
withdrawing N-phthalimido (N-Phth) and N-acetyl (N-Ac) glucosaminopyranoside 
derivatives.
124
 Azides can also be easily converted to an amine by a number of different 
reductive conditions (e.g. hydrogenation, or Staudinger reduction)
127,128
 and it was 
thought the β-glycosidic bond could be successfully installed using acetonitrile as a 
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participating solvent.
107
 However, the work described above indicated this strategy was 
unfruitful. 
 
 
Figure 9:  A: Stable oxazoline formed during glycosylation when using a glycosyl donor with a 2-
acetamido group. B: Phthalimido (Phth) protected glucosamine. C: 2,2,2-trichloroethyl 
chloroformate (Troc) protected glucosamine. 
 
 
2.3.4 Synthesis of the Troc Protected Donor 
Synthesis of the Troc protected donor started with conversion of the fully protected 
glucose azide 49 into the corresponding Troc protected glucosamine 54 in a two step one 
pot reaction (Scheme 24). The azide was first reduced to an amine via Staudinger 
reduction with PMe3. When complete reduction of the azide was observed via TLC 
analysis 2,2,2-trichloroethyl chloroformate (TrocCl) was added, resulting in the N-Troc 
protected compound 54 (79% yield). The methylene protons of the Troc group were 
observed as a multiplet at 4.71-4.63 ppm along with the introduction of the NH resonance 
at 5.03 ppm (d, 1H, J2,NH = 6.9 Hz, NH) in the 
1
H NMR spectrum.  
 
 
Scheme 24: Formation of the fully protected N-Troc building block 54. 
 
With N-Troc conversion complete the N-Troc imidate donor was synthesised using the 
methodology that was used to create the azide donor (Scheme 25). Conversion to the 
lactol 55 using HF.pyridine proceeded in 90% yield, and the subsequent treatment with 
trichloroacetonitrile and caesium carbonate (cat.) resulted in the N-Troc imidate 56 in a 
99% yield.  
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Scheme 25: Synthesis of the N-Troc imidate 56 from the N-Troc building block 54. 
 
 
2.3.5 Glc(NHTroc)Glc(N3) Disaccharide Model Glycosidation 
The β-1,4-glycosidation reaction was re-attempted, this time with the hopefully more 
robust N-Troc imidate donor (Scheme 26). DCM was used as the reaction solvent as the 
Troc group controls β-selectivity through neighbouring group participation. The reaction 
with 1.8 equivalents of donor was activated at -40°C using 0.1 equivalents of TMSOTf 
and was allowed to warm up to -10°C before it was quenched after an hour and 15 
minutes. The use of the N-Troc instead of the azide donor resulted in a significant 
increase in yield (74%) and only the β-anomer was formed. This suggests that 
participation from the N-Troc group resulted in a more stable donor allowing it to react 
with the acceptor before being hydrolysed. The β-linkage was confirmed by the J1′,2′ 
coupling constant of 8.5 Hz and the molecular weight of the product was confirmed by 
HRMS(ESI) (m/z calcld. for [C49H59O11N4Cl3Si+Na]
+
: 1035.2913, obsd.: 1035.2908). 
 
 
Scheme 26: Successful coupling between the N-Troc imidate donor 56 and the glucose azide acceptor 
52. 
 
 
2.3.6 Glc(NHTroc)(Fuc)Glc(N3) Trisaccharide Glycosidation 
After the success of forming the β-1,4-linkage with the glucose azide monosaccharide 
acceptor 52 in good yield and selectivity, attention was once again turned to the 
formation of the β-1,4-linked trisaccharide (Scheme 27). The reaction was again activated 
at -40°C with 0.1 equivalents of TMSOTf. The reaction temperature was maintained at    
-40°C as the partial consumption of acceptor was observed via TLC analysis after 20 
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minutes, with the complete consumption of acceptor seen after an hour and 10 minutes. 
To our delight only pure β-product was formed in a good yield of 72%, with the use of 
only 1.5 equivalents of donor. The observation of the anomeric proton of the newly 
installed Glc(NHTroc) residue at 4.41 ppm (d, 1H, J1″,2″ = 7.9 Hz) in the 
1
H NMR 
spectrum along with confirmation of the product‟s mass by HRMS(ESI) (m/z calcld. for 
[C69H81O15N4Cl3Si+Na]
+
: 1361.4431 obsd.: 1361.4424) confirmed successful formation 
of trisaccharide 58.  
 
 
Scheme 27: Successful coupling between the N-Troc imidate donor 56 and the disaccharide acceptor 
26. 
 
The successful formation of the β-1,4-linkage present in both disaccharide 57 and 
trisaccharide 58 in good yields with complete β-selectivity was an important milestone in 
the consideration of forming the larger structures containing the Man3(GlcNAc)2 
pentasaccharide core. Our studies have shown that the C-2 amine of the donor must have 
a protecting group that is capable of neighbouring group participation in order to prevent 
hydrolysis before glycosidation can occur. The use of N-Troc protection also resulted in 
the completely stereoselective formation of the β-product. This is extremely useful as 
mixtures of α and β anomers can be difficult to separate, cf. the FucGlc(N3) disaccharide 
21, not to mention the increase in yield associated with selective formation of the desired 
anomer.  
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2.4 Feasibility of N-Troc Protected Acceptor 
 
2.4.1 Synthesis of the Glc(NHTroc) Acceptor 
Due to the requirement for N-Troc protection of the donor in the formation of the β-1,4-
linkage between the two GlcNAc residues the feasibility of using an N-Troc protected 
acceptor was also investigated as a conserved protection group strategy is favoured as 
less deprotection steps are required. The feasibility of an N-Troc protected acceptor was 
explored for both the formation of the α-1,3-fucosyl linkage and the β-1,4-glucosylamine 
linkage. 
 
The first step was formation of the N-Troc protected acceptor required for the α-1,3-
fucose coupling. The previously used azide acceptor 23 was converted into the N-Troc 
acceptor 59 via Staudinger reduction and subsequent Troc protection of the resulting 
amine (Scheme 28). The two step one pot methodology that was used for Troc 
conversion of the fully protected building block was used for formation of N-Troc 
acceptor 59. Troc conversion was achieved in 61% yield. In an attempt to increase this 
yield two other methodologies were attempted. Both still involved Staudinger reduction 
of the azide, however, the reaction was subjected to aqueous work up before the crude 
amine 60 was Troc protected. Treatment of the crude amine with TrocCl in pyridine 
afforded N-Troc acceptor 59 in 46% yield along with formation of the di-Troc side 
product 61 in 25% (Troc protection of the C-3 hydroxyl and the C-2 amine). Reaction of 
the crude amine with TrocCl and N,N-diisopropylethylamine (DIPEA) achieved N-Troc 
protection with the highest yield in 73% with no di-Troc side product observed. 
 
 
Scheme 28: The three methodologies attempted for formation of N-Troc acceptor 59. 
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2.4.2 Formation of the FucGlc(NHTroc) Disaccharide Acceptor 
With the N-Troc protected acceptor in hand, formation of the α-1,3-fucosyl linkage was 
attempted (Scheme 29). The reaction was conducted using the optimised reaction 
conditions that were used in forming the α-1,3-fucosyl linkage with the azide acceptor. 
Our theory that the electron withdrawing nature of the N-Troc group would result in a 
poorer acceptor and thus reduce the success of the glycosylation was correct. The 
glycosidation was attempted twice and both times resulted in significantly reduced yields 
(58% and 42%) compared to glycosidation with the azide acceptor (89%). The selectivity 
was however comparable (α:β = 16.8:1) and the anomers were separated via column 
chromatography using DCM as the eluent. 
 
 
Scheme 29: Synthesis of the N-Troc protected disaccharide acceptor 63. 
 
The 4,6-benzylidene of N-Troc disaccharide 62 was then selectively opened with TES, 
TFA, and TFAA to give the N-Troc disaccharide acceptor 63 in 60% yield (Scheme 29). 
Again the opening was 100% regioselective with none of the C-6 hydroxyl product 
observed.  
 
 
2.4.3 Synthesis of the Disaccharide N-Troc Donor 
The fully protected N-Troc disaccharide 64 had been synthesised by another member of 
the research group as an intermediate in the production of the Man3Glc(NTroc) 
pentasaccharide donor 65 and the Man3(Xyl)Glc(NTroc) pentasaccharide donor 66 
(Scheme 30). Comparison of the N-Troc and azide disaccharide acceptors was conducted 
using the disaccharide donor 67 instead of the previously used N-Troc monosaccharide 
donor 56 because it provides a better comparison to glycosidation with the larger tetra- 
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and pentasaccharide donors. Conversion of the disaccharide 64 into the corresponding 
imidate donor 67 was achieved via HF.pyridine mediated TBDMS ether deprotection to 
give lactol 68 (92% yield), followed by imidate formation with trichloroacetonitrile and 
caesium carbonate (50% yield) (Scheme 30). Several attempts were made at forming the 
imidate, however, the yields obtained were much lower than when forming either the 
Glc(N3) or Glc(Troc) imidate donors (both 99% yields). Although TLC analysis showed 
complete conversion to the disaccharide imidate, impure starting material was isolated 
after column chromatography, indicating that hydrolysis occurred during purification. No 
hydrolysis was observed when purifying either of the monosaccharide donors suggesting 
that the disaccharide donor is less stable. It has since been shown by members within our 
research group that using a silica column that is pre-neutralised with 1% triethylamine in 
DCM reduces the acid catalysed hydrolysis of imidates during purification. 
 
 
Scheme 30: Synthesis of the disaccharide imidate donor 67 from disaccharide 64, which can also be 
used for the synthesis of tetrasaccharide donor 65 and the pentasaccharide donor 66. 
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2.4.4 Comparison of the N-Troc  and Azide Disaccharide Acceptors 
Coupling of the disaccharide imidate donor 67 was attempted with both the azide and the 
Troc protected acceptors (Scheme 31). Both couplings were activated at -40°C with 0.1 
equivalents of TMSOTf in freshly distilled DCM with activated molecular sieves. The 
reactions were then allowed to warm to room temperature before being quenched when 
TLC analysis showed complete consumption of donor. TLC analysis of the Troc acceptor 
reaction showed a large amount of donor hydrolysis and it appeared that formation of 
product had been unsuccessful. In order to determine if any product had been formed the 
crude reaction mixture was analysed using HRMS(ESI), which unfortunately did not 
detect the presence of any product. On the other hand TLC analysis of the azide acceptor 
reaction, despite also showing a large amount of donor hydrolysis, showed the formation 
of a higher Rf compound (Rf = 0.71 ethyl acetate/toluene, 1/6, v/v) which was thought to 
be product. Unfortunately after purification by column chromatography this higher Rf 
compound was not isolated, suggesting that it was most likely TMS protected acceptor 
which was hydrolysed during purification. Thus both reactions using the disaccharide 
donor were unsuccessful. The couplings were not reattempted due to the limited 
availability of the disaccharide imidate donor. 
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Scheme 31: Attempted coupling of the disaccharide imidate donor 67 with both the azide and the 
Troc protected acceptors (26 and 63 respectively). 
 
It was thought that both couplings failed due to the quality of the TMSOTf used. The 
successful synthesis of the fully protected hexasaccharide 71, using the azide protected 
disaccharide acceptor 26, has since been conducted in our research group using freshly 
distilled TMSOTf (Scheme 32). The exact conditions for this reaction are yet to be 
optimised. 
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Scheme 32: Successful formation of the fully protected hexasaccharide 70 using the disaccharide 
azide acceptor 26. Reaction not yet optimised. (Conducted by another member of our 
group). 
 
Another comparison of Troc and azide acceptors was conducted by another member of 
our group. The Troc protected disaccharide 64 required for the synthesis of the tetra- and 
pentasaccharide donors, 65 and 66 respectively, was initially synthesised via 
glycosidation of thiol donor 72 with azide acceptor 52 (99% yield), followed by 
subsequent Troc conversion of the resulting azide disaccharide 73 (Scheme 33). As it is 
desirable to minimise the number of protecting group manipulations required after 
coupling, glycosidation was attempted using the Troc protected acceptor 74 (Scheme 33). 
Coupling to the Troc protected acceptor was considerably less successful than to the 
azide acceptor with yields of less than 10% obtained. Given this knowledge combined 
with the reduced yields obtained in forming the α-1,3-fucosyl linkage with a Troc 
protected acceptor (Section 2.4.2), azide protection of the proximal GlcNAc residue was 
chosen, even despite the associated increase in deprotection steps required due to the 
presence of both azide and Troc protected amines. 
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Scheme 33: Comparison of the azide 52 and Troc 74 acceptors in the formation of the β-1,4-linkage. 
(Conducted by another member of our group). 
 
 
 
2.5 Deprotection of the FucGlc(N3) Disaccharide 
 
2.5.1 Initial Deprotection Strategy 
With the decision that azide protection was favoured over Troc protection for the 
proximal GlcNAc residue, deprotection and acetamide formation of the fully protected 
FucGlc(N3) disaccharide 21 was attempted. As complete deprotection was desired, the 
removal of several different protecting groups with one reaction was favoured. With this 
in mind the first step in the deprotection strategy was removal of the benzyl and 
benzylidene protecting groups as well as reduction of the azide to an amine by 
hydrogenation using Pd(OH)2 (Scheme 34). It was also hoped that conversion of the 
azide to the desired acetamide could be achieved during hydrogenation as there is 
literature precedent for in situ acetylation of amines during hydrogenation by the addition 
of acetic anhydride.
129-132
 Hydrogenation of disaccharide 21 was conducted in a Fisher-
Porter bottle with 4 bars of hydrogen pressure and Pd(OH)2 in chloroform/ethanol/acetic 
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anhydride, 1/1/0.1, v/v/v. From the 
1
H NMR spectrum of the crude reaction mixture it 
appeared that removal of the benzyl and benzylidene protecting groups was successful. 
However, it was difficult to tell if acetylation of the amine was complete so the crude 
reaction mixture was re-subjected to acetic anhydride to ensure complete acetylation. 
K2CO3 was used as the added base instead of pyridine to prevent acetylation of the 
hydroxyl groups. This resulted in the acetamide 75 in 61% yield over the two steps. The 
appearance of the characteristic acetamide methyl group singlet at 1.99 ppm in the 
1
H 
NMR spectrum of 75 showed acetylation of the amine had occurred and HRMS(ESI) 
confirmed the product was of the correct molecular weight (m/z calcld. for 
[C20H39O10NSi+Na]
+
: 504.2235 obsd.: 504.2244). Unfortunately, when the reaction was 
reattempted on a larger scale (93 mg instead of 21 mg) using the same conditions, the 
desired product was not formed. The presence of α and β-L-fucose was observed in the 
1
H NMR spectrum (δH1α = 5.17, J1,2 = 3.9 Hz and δH1β = 4.52, J1,2 = 7.8 Hz) of the crude 
hydrogenation reaction mixture along with other unidentifiable by-products. The addition 
of acetic anhydride could have resulted in the production of acetic acid due to water 
present in the Pd(OH)2/C catalyst, leading to the cleavage of the acid labile fucose 
residue. However, the reduction of azides by hydrogenation requires the presence of 
some acid to protonate the resulting amine in order to prevent it from co-ordinating to 
and poisoning the palladium catalyst.
133
 Although the larger scale reaction was 
unsuccessful the material from the first reaction was continued with. The last step in the 
full deprotection was removal of the TBDMS ether. Previously when TBDMS removal 
had been required for conversion to the corresponding imidate donor it was achieved 
using HF.pyridine. However, an alternative strategy was needed as the use of HF.pyridine 
requires an aqueous workup, from which recovery of the fully deprotected product would 
be impossible. Corey and Venkateswarlu have reported the removal of a TBDMS ether 
using acetic acid/water/THF, 3/1/1, v/v/v at room temperature.
134
 These reaction 
conditions were used as they do not require an aqueous workup and instead the reaction 
mixture can be concentrated in vacuo (Scheme 34). No reaction was observed according 
to TLC analysis at room temperature so the solution was heated to 65°C for six hours. 
This resulted in the formation of base-line material according to TLC analysis 
(DCM/methanol/ethanol/NH3 (30% aq.), 15/2/2/1, v/v/v/v). Although from the 
1
H NMR 
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spectrum of the crude reaction mixture it seemed as though some of the fully deprotected 
product 76 had been formed, it also contained β-L-fucose (δH1β = 4.52, J1,2 = 7.8 Hz) and 
unreacted starting material. HRMS(ESI) confirmed that there was product present in the 
crude reaction mixture (m/z calcld. for [C14H25O10N+Na]
+
: 390.1376 obsd.: 390.1378). 
Unfortunately the presence of β-L-fucose indicated hydrolysis of the α-1,3-linkage. 
Although the glycosidic bond of deprotected α-fucose residues is known to be more 
stable under acidic conditions than that of the corresponding benzyl protected residue, it 
appeared that it was not stable enough to withstand the conditions required for TBDMS 
removal. Due to the difficulties encountered with cleavage of the acid labile α-fucose 
residue during the deprotection, an alternative strategy was required which did not use 
acid at elevated temperatures.  
 
 
Scheme 34: Initial deprotection strategy for the FucGlc(N3) disaccharide 21. 
 
 
2.5.2 Revised Deprotection Strategy 
Nagorny et al. also used TBDMS ether protection for the reducing anomeric centre of 
their dodecasaccharide.
77
 Their deprotection strategy involved conversion of the 
protected C-2 amine groups into the corresponding acetamides, followed by removal of 
the anomeric TBDMS, then cleavage of the acetate groups before removal of the benzyl 
protecting groups, resulting in the fully deprotected sugar. The adaption of Nagorny et 
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al.‟s strategy to our disaccharide has two advantages over our initial strategy. Firstly, 
although they used phthalimide protecting groups instead of an azide, the selective 
conversion of the azide to the desired acetamide would reduce the problems associated 
with hydrogenation as acid would not be required to protonate the resulting amine, thus 
reducing the chance of α-fucose hydrolysis. Secondly, by removing the TBDMS 
protecting group earlier in the deprotection strategy HF.pyridine can be used as the 
resulting lactol can be isolated from an aqueous workup. 
 
The first step in the revised deprotection strategy was conversion of the azide to an 
acetamide. As Staudinger reduction of the azide was previously successful during the 
synthesis of the Troc imidate donor it was attempted on the fully protected FucGlc(N3) 
disaccharide. Conversion of the azide 21 to the acetamide 78 was successfully achieved 
in 79% yield over two steps via Staudinger reduction (PMe3, NaOH) followed by 
acetylation of the crude amine with acetic anhydride and pyridine (Scheme 35). However, 
when the reaction was scaled up (240 mg instead of 33 mg) the yield decreased to 42% 
and the urea 79 was also isolated in 25% yield. The formation of urea by-product, 
although surprising, can be rationalised by amine 80 reacting with either carbonate or 
bicarbonate anions during the reduction (CO2 is absorbed by NaOH resulting in Na2CO3) 
or during the aqueous workup (saturated aqueous NaHCO3), resulting in carbamate 81. 
This carbamate can then react with acetic anhydride to produce anhydride 82 which can 
undergo nucleophilic attack by amine 80 to give the observed urea byproduct 79 (Scheme 
35). Conversion to the acetamide was repeated (120 mg scale) whilst trying to minimise 
carbamate formation. A freshly made solution of KOH was used instead of NaOH (KOH 
absorbs less CO2 than NaOH) and saturated aqueous NaHCO3 was not used during the 
work up. Disappointingly this resulted in only a 38% yield of the desired acetamide 78 
and the formation of several unidentifiable by-products. 
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Scheme 35: Synthesis of acetamide 78 using Staudinger reduction and the proposed mechanism for 
the formation of the urea by-product 79.  
 
As the Staudinger reduction method was too unreliable, an alternative strategy for 
converting the azide to the acetamide was required. Koizumi et al. have recently reported 
the conversion of both an azido group and a Troc group, in the same step, to their 
corresponding acetamido moieties using zinc, acetic acid and acetic anhydride at room 
temperature.
126
 As this methodology would be very useful in the deprotection of our 
larger carbohydrates, bearing both a Troc and an azido group, the reaction was attempted 
on the azide containing disaccharide 21 (Scheme 36). Unfortunately the reaction was 
unsuccessful both times it was attempted. Although some product was isolated (26%), 
neither reaction went to completion, despite stirring for 24 hours (Koizumi et al. reported 
completion of the reaction after 1 hour), and the formation of several by-products was 
also observed. The by-products were not fully characterised due to purification 
difficulties. Although the reaction mixture was purified via column chromatography 
(ethyl acetate/light petroleum ether, 1/10 → 1/3, v/v), one of the by-products was 
inseparable from unreacted starting material (Rf = 0.61 ethyl acetate/light petroleum 
ether, 1/5, v/v) and the other two were co-eluted (Rf = 0.18 ethyl acetate/light petroleum 
ether, 1/5, v/v). The by-products were tentatively assigned using HRMS(ESI) analysis as: 
the 2-O-acetate 83 (eluted with starting material) (m/z calcld. for [C48H60O11Si+Na]
+
: 
863.3803 obsd.: 863.3806), the 2,6-di-O-acetate 84 (m/z calcld. for [C43H58O12Si+Na]
+
: 
817.3595 obsd.: 817.3604), and the elimination product 85 (m/z calcld. for 
  69 
[C41H54O10Si+Na]
+
: 757.3384 obsd.: 757.3395) (acetylation of O-6, instead of O-4 was 
assumed due to the greater reactivity of primary hydroxyls) (Scheme 36). 
 
Scheme 36: Attempted synthesis of acetamide 78 using Zn, AcOH and Ac2O with the tentatively 
assigned by-products 83, 84 and 85.  
 
Due to difficulties with the zinc reaction it was clear another method was required. On 
further investigation it was discovered that thioacetic acid has been successfully used in 
the deprotection of carbohydrates to convert azides directly to the corresponding 
acetamide.
135-138
 Thioacetic acid conversion has been shown to be compatible with both 
benzylidene protection and benzyl protected α-1,3-linked fucose residues.136 It has also 
been used on carbohydrates bearing both azide and N-Troc groups to selectively convert 
the azide to an acetamide before zinc mediated cleavage of the Troc group was 
conducted.
137,138
 The FucGlc(N3) disaccharide 21 was treated with thioacetic acid and 
pyridine (1/1, v/v) to afford the acetamide 78 in an acceptable yield of 62% (Scheme 37). 
Conversion of the azide to the acetamide was seen in the IR spectrum of 78 by the 
disappearance of the strong absorption at 2111 cm
-1
, associated with the asymmetric 
stretching vibration of the azide, and the introduction of a strong absorption at 1660 cm
-1
 
associated with the C=O stretch of the newly formed amide. 
 
 
Scheme 37: Successful synthesis of acetamide 78 using AcSH and pyridine. 
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With a reliable way of converting the azide to an acetamide, attention was then turned 
towards removal of the TBDMS ether. To our relief the previously used HF.pyridine 
method was compatible with the benzyl protected α-1,3-fucose residue and resulted in 
lactol 86 in an excellent yield of 98% (Scheme 38). The final deprotection step was 
removal of the benzylidene and benzyl groups. It was hoped that hydrogenation would 
now be successful as the azide has already been converted to an acetamide. 
Hydrogenation of lactol 86 was attempted using Pd(OH)2 as the catalyst and 
chloroform/ethanol, 3/2, v/v as the solvent. Unfortunately, although the removal of the 
benzylidene and benzyl groups was successful to give fully deprotected disaccharide 76, 
the 
1
H NMR spectrum of the crude reaction mixture also showed the presence of β-L-
fucose (δH1β = 4.52, J1,2 = 7.8 Hz) and α/β-N-acetylglucosamine (δH1α = 5.16, J1,2 = 3.4 Hz 
and δH1β = 4.67, J1,2 = 8.3 Hz) indicating that hydrolysis had once again occurred during 
hydrogenation. It was thought that the use of chloroform resulted in the acidic conditions 
responsible for cleaving the α-fucose residue. Purification of disaccharide 76 was 
attempted using C18 and C8 reverse phase chromatography but it was not possible to 
remove the α/β-L-fucose and α/β-N-acetylglucosamine. Therefore the hydrogenation was 
reattempted using ethanol/ethyl acetate, 1/1, v/v. Ethyl acetate was used because the 
starting material was insoluble in straight ethanol and Matsuoka et al. successfully used 
ethyl acetate in the hydrogenation of a trisaccharide which also contained a benzyl 
protected α-fucose residue.138 To our relief hydrogenation using ethanol/ethyl acetate was 
successful with no hydrolysis by-products observed, resulting in disaccharide 76 in 92% 
yield (Scheme 38). 
 
 
Scheme 38: Successful deprotection of the fully protected acetamide 78 resulting in the fully 
deprotected FucGlcNAc disaccharide 76. 
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2.6 Deprotection of the Glc(Troc)(Fuc)Glc(N3) Trisaccharide 
 
2.6.1 Achieved Deprotection Reactions 
With the successful deprotection of the FucGlcNAc disaccharide achieved, attention was 
given to deprotecting the Glc(Troc)(Fuc)Glc(N3) trisaccharide 58. The first step in the 
deprotection was conversion of the azide to the corresponding acetamide. The azide must 
be converted before the Troc group as during the FucGlcNAc deprotection it was shown 
that the azide was incompatible with the Troc deprotection conditions (Zn, acetic acid). 
Treatment of azide 58 with thioacetic acid in pyridine resulted in the successful 
conversion to acetamide 87 in 71% yield (Scheme 39). The molecular weight of the 
acetamide 87 was confirmed by HRMS(ESI) (m/z calcld. for [C71H85O16N2Cl3Si+Na]
+
: 
1377.4632 obsd.: 1377.4646). The N-acetyl methyl protons were observed in the 
1
H 
NMR spectrum of 87 as a singlet at 1.72 ppm as well as the disappearance of the azide 
absorption (2111 cm
-1
) from the IR spectrum, confirming conversion of the azide to the 
acetamide. 
 
 
Scheme 39: Successful synthesis of acetamide 87 using AcSH and pyridine. 
 
 
2.6.2 Future Work - Proposed Deprotection Strategy 
The full deprotection of the GlcNAc(Fuc)GlcNAc trisaccharide 87 requires three more 
steps. The next step in the deprotection sequence is the conversion of the N-Troc group of 
87 to the corresponding N-acetate 88 (Scheme 40). The N-Troc group can be removed via 
treatment with zinc and acetic acid and the resulting amine can be acetylated in situ by 
the addition of acetic anhydride.
137
 The two remaining deprotection steps have already 
been conducted and optimised on the FucGlcNAc dimer. They are removal of the 
anomeric silyl protecting group using HF.pyridine resulting in lactol 89, followed by 
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hydrogenation using Pd(OH)2/C as the catalyst and ethanol/ethyl acetate as the solvent to 
give the fully deprotected trisaccharide 90. 
 
 
Scheme 40: Proposed deprotection strategy for the GlcNAcFucGlcNAc trisaccharide. 
 
 
 
2.7 Anomeric Amine Formation 
 
2.7.1 N-Acetylglucosamine 
The formation of the β-anomeric amine is a key component in the synthesis of any N-
linked glycoprotein or glycoconjugate. The most commonly used procedure for 
converting anomeric hydroxyls into β-glycosylamines (Scheme 41), especially in the 
synthesis of glycosylamines of complex synthetic oligosaccharides, is the Kochetkov 
amination reaction.
80
 This involves treating the fully deprotected sugar with a large 
excess of ammonium bicarbonate in water. As the reaction occurs in aqueous media, the 
β-amino product is favoured due to the extended hydrogen bonding network. The excess 
ammonium bicarbonate is removed via repeated lyophilisation to give the β-anomeric 
glycosylamine. Another method recently developed by Likhosherstov uses ammonium 
carbonate in methanol and involves precipitation of the product as the carbamic acid 
salt.
139
 This salt is then converted to the desired free amine by base treatment or high 
  73 
vacuum. Kochetkov‟s method was chosen for anomeric amine conversion as 
Likhosherstov‟s method required precipitation and filtration of the carbamic acid salt 
which is impractical given the small scale we will be conducting the amination reactions 
on (< 20 mg).  
 
 
Scheme 41: Anomeric conversion of N-acetylglucosamine (91) to form the anomeric amine 92.  
 
Although the Kochetkov method is widely used, numerous variations of this method have 
been reported which involve changes to the temperature and duration of the reaction, the 
ammonium bicarbonate concentration, the sugar concentration, and the use or absence of 
aqueous ammonia.
76,77,80,140-142
 The incomplete conversion of starting material and 
formation of by-products are known to be potential problems during this reaction.
80,140
 
The main by-products for this conversion of 91 into 92 are the diglycosylamine 93 and 
the glycosylcarbamate 94 (Figure 10). The formation of the diglycosylamine 93 is more 
prevalent at high temperatures, especially above 50°C and when the concentration of the 
reactant sugar is above 0.5 molL
-1
.
140
 Fortunately, although the formation of 
diglycosylamine is undesirable, the presence of dimer does not interfere with subsequent 
acylations.
143
 The formation of the carbamate 94 is a consequence of the ammonium 
bicarbonate and increases at higher concentrations of ammonium bicarbonate although it 
is not considered problematic as it is in equilibrium with the desired amine product and 
the equilibrium is shifted by evaporation, lyophilisation, and dilution.
140
 Another problem 
with the formation of anomeric glycosylamines is their instability. They have been 
known to dimerise upon storage (especially at room temperature) and are prone to 
hydrolysis in acidic or neutral aqueous solution, which makes purification and 
characterisation extremely difficult.
80,140,144
 Therefore, complex glycosylamines are often 
used without purification and are only characterised via mass spectrometry after removal 
of ammonium bicarbonate via lyophilisation.
77,142
 It should also be noted that the reaction 
vessel should be opened periodically during the reaction to allow the liberated CO2 to 
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escape, as Kochetkov and co-workers reported yields of < 30% when the vessel was 
sealed throughout the reaction.
80
 
 
 
Figure 10: Possible by-products from the anomeric amine conversion reaction. 
 
In order to determine the optimum conditions for the anomeric conversion, six different 
variations of the Kochetkov reaction were conducted on N-acetylglucosamine (91), while 
thought was given to the fact that the synthesis of the larger glycosylamines would be 
conducted using < 20 mg of starting material. A summary of the six conditions used to 
form N-acetyl glucosamine is shown in Table 4. Entries 1, 2, and 3 were based on 
Nagorny et al.‟s conversion of a dodecasaccharide to the corresponding anomeric 
amine.
77
 Their reaction used only 11 mg (4.23 μmol) of starting material with 6 g of 
ammonium bicarbonate in 5 mL of water and was stirred for three days at 40°C. Entry 4 
was based on both Wang et al.
76
 and Miller et al.‟s142 synthesis, which were both 
conducted at room temperature for 3 and 6 days respectively, using quantities of 
oligosaccharide, ammonium bicarbonate, and water comparable to that of Nagorny et al. 
Entry 5 was based on Shin et al.
141
 and Vetter and Gallop‟s143 procedure which used 
saturated aqueous ammonium bicarbonate with addition of a small amount of ammonium 
bicarbonate to maintain saturation. Lastly entry 6 was based on Lubineau et al.‟s140 
procedure in which the sugar (0.2 M) and ammonium bicarbonate (0.2 M) were dissolved 
in 16 M aqueous ammonia and left for 36 hours at 42°C. 
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Table 4: Different reaction conditions attempted for the anomeric amine conversion reaction. 
1
 Ratios are based on the integration values for the 
1
H NMR signals of the anomeric protons. Product 
includes both amine 92 and carbamate 94 as the carbamate is in equilibrium with amine.
140
 Starting 
material includes both α and β starting material. 1H NMR values in D2O (δ 4.79): amine product (δH1β 
4.13, J = 9.3 Hz), carbamate (δH1β 4.71, J = 9.7 Hz), α-starting material (δH1α 5.15, J = 3.4 Hz), β-starting 
material (δH1β 4.66, J = 8.5 Hz). 
 
After each reaction was complete the water and ammonium bicarbonate were removed 
via repeated lyophilisation until a constant weight was reached. Unfortunately for entries 
1-5 it was not possible to remove all of the ammonium bicarbonate by repeated 
lyophilisation (10 times), with between 70 and 100 mg remaining. All samples were 
analysed by 
1
H NMR spectroscopy to determine the ratio of starting material to product 
and whether any by-products were formed. The best results were achieved when a large 
excess of ammonium bicarbonate was used, and the reaction was conducted at 40°C 
(entries 1-3). As well as resulting in the poorest conversion the use of aqueous ammonia 
(entry 6) also resulted in several by-products that were not seen in the other reactions. 
These by-products were not characterised but were thought to be either the dimer 93 
and/or products produced via either the Amadori rearrangement
145-147
 and/or the Lobry-de 
Bruyn-van Ekenstein Reaction
148
 due to the presence of excess ammonia. 
 
Entry Reaction 
Conditions 
Time of 
Reaction 
Temperature Ratio
1
 
Product:Starting Material 
1. 91 (0.0047 g), 
NH4HCO3 (6 g), 
H2O (5 mL) 
6 days 40°C 3.5 : 1 
2. 91 (0.1090 g), 
NH4HCO3 (6 g),  
H2O (5 mL) 
6 days 40°C 5.2 : 1 
3. 91 (0.0051 g), 
NH4HCO3 (6 g), 
H2O (5 mL) 
3 days 40°C  3.3: 1 
4. 91 (0.0051 g), 
NH4HCO3 (6 g),  
H2O (5 mL) 
6 days 20°C 1.9 : 1 
5. 91 (0.2247 g), 
NH4HCO3 (0.7 g),  
NH4HCO3 (5 mL, sat. aq) 
3 days 40°C 1.6 : 1 
6. 91 (0.2200 g, 0.2 M), 
NH4HCO3 (0.08 g 0.2M), 
NH3 (5 mL, aq, 35%) 
24 hours 40°C 0.1 : 1 
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The crude reaction mixture of entry 2 was purified using a Dowex H
+
 cation exchange 
resin column. Unreacted starting material was eluted with water and the desired 
glucosamine 92 was eluted with 5% aqueous ammonia. β-Glycosylamine 92 was 
obtained as a white amorphous solid after lyophilisation in a 68% yield. 31% of the 
starting material was also recovered, indicating that product hydrolysis had occurred 
under the acidic aqueous purification conditions (product:starting material, pre-column: 
5.2:1, post-column: 2.2:1). Purification was required to remove the residual ammonium 
bicarbonate as the presence of ammonia in the subsequent acylation step is problematic 
because it reacts with the activated acid thus reducing the efficiency of the coupling 
reaction.
143
 The presence of unreacted starting material is not an issue in subsequent 
acylation reactions as the amine functionality is more nucleophilic and thus reacts 
preferentially.
143
 Vetter and Gallop have reported that residual ammonium bicarbonate 
remaining after repeated lyophilisation can be removed by warming the glycosylamine in 
methanol until gas evolution ceases, followed by evaporation in vacuo.
143
 
 
 
2.7.2 FucGlcNAc and Man3 Anomeric Amine Formation 
With the method for forming an anomeric amine optimised, attention was turned back to 
the fully deprotected sugars 42 and 76. The fully deprotected sugars, 42 (4.7 mg) and 76 
(12.2 mg), were each dissolved in 5 mL of water and 6 g of ammonium bicarbonate was 
added to each reaction before the solutions were stirred for 6 days. The excess water and 
ammonium bicarbonate was removed by repetitive lyophilisation to yield the anomeric 
amines 95 and 96 (Scheme 42). Conversion to the respective glycosylamines was 
confirmed by HRMS(ESI) analysis (95 m/z calcld. for [C18H33O15N+H]
+
: 504.1928, 
obsd.: 504.1930, 96 m/z calcld. for [C14H26O9N2+H]
+
: 367.1717, obsd.: 367.1723). The 
glycosylamines, 95 and 96, were not futher characterised due to the previously mentioned 
difficulties with characterising glycosylamines. 
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Scheme 42: Anomeric conversion of the Man3 trisaccharide 42 and the FucGlcNAc disaccharide 76 to 
form the anomeric amines 95 and 96 respectively.  
 
 
 
2.8 Future Work 
 
2.8.1 Proposed Strategy for the Coupling to Latex Beads and/or Proteins 
With the successful synthesis of all three glycosylamines (GlcNAc monomer 92, 
FucGlcNAc 96, and Man3 95) the final step is conjugation to either a protein or 
fluorescent latex bead via carboxylic acid residues (Scheme 43). The formation of the 
glycoconjugates was not conducted by the candidate due to time constraints. Coupling of 
the glycosylamines to the chosen proteins (KLH and OVA), which have had their native 
glycans cleaved, can be conducted using the procedures developed by Cohen-Anisfeld 
and Lansbury for the formation of β-N-linked glycopeptides.83 These conditions have 
proved successful in the synthesis of a number of β-N-linked glycopeptides, most notably 
in the work of Danishefsky and co-workers who have successfully attached synthetic 12-, 
13-, and 15-mer oligosaccharides to synthetic peptides.
76,77,79
 The conditions developed 
by Cohen-Anisfeld and Lansbury involve treatment of the glycosylamine and 
peptide/protein with HBTU and hydroxybenzotriazole (HOBt) in dimethyl sulfoxide 
(DMSO). HBTU is used as the peptide coupling reagent. HOBt is used to prevent 
racemisation of the peptide and it also reduces formation of the aspartimide by-product. 
N,N-Diisopropylethylamine (DIPEA) can also be used in the reaction to deprotonate the 
carboxylic acid. However, in the case of peptides that are particularly prone to 
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aspartimide formation it is often not added as it increases aspartimide formation.
83
 When 
DIPEA is not added the glycosylamine acts as the base to deprotonate the carboxylic 
acid. The reaction is conducted in DMSO as opposed to water as glycosylamines are 
readily hydrolysed under acidic or neutral aqueous condition.
143
 Once formed the 
glycoproteins can be analysed using NMR analysis
149
 and matrix-assisted laser 
desorption/ionization-time-of-flight (MALDI-TOF) mass spectrometry.
150
 Coupling of 
the glycosylamines to the carboxylic acid modified fluorescent beads can also be 
achieved using the procedures for coupling to proteins. However, as protein racemisation 
and aspartimide formation are not an issue when coupling to fluorescent beads, HOBt 
does not need to be added and also DIPEA can be added without the worry of increased 
aspartimide formation. The loading of the carbohydrates onto the fluorescent beads can 
be determined using the Morgan-Elson Assay.
151-154
 Once the glycoconjugates are 
formed, they will be tested for their ability to bias the Th response to a Th2 immune 
response using IL4/GFP reporter mice. This testing will be conducted at the Malaghan 
Institute of Medical Research, Wellington, New Zealand. 
 
 
Scheme 43: Proposed strategy for coupling the β-glycosylamines to either a protein or a fluorescent 
latex bead using the methodology developed by Cohen-Anisfeld and Lansbury.
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CONCLUSION 
 
In this Masters project, significant progress was made towards the synthesis of the three 
target glycoconjugates 14, 15, and 16, with the successful synthesis of the three preceding 
glycosylamines. During the efforts towards the synthesis of the Man3 glycoconjugate 16 
significant quantities of the mannose imidate building block 18 were produced. The gram 
quantities synthesised will be used by other members of our group for the synthesis of the 
target heptasaccharide glycoconjugates and other target glycoconjugates containing the 
Man3(GlcNAc)2 pentasaccharide core. The mannose imidate building block was also 
shown to successfully give the desired α-linkage due to neighbouring group participation 
of the 2-O-benzoyl group. 
 
En route to the FucGlcNAc glycoconjugate 15, formation of the α-1,3-fucose linkage was 
successfully optimised to enable both excellent yields and selectivity (89%, α:β = 22.3:1) 
on a large scale. Excess FucGlc(N3) disaccharide 21 was produced which will be used by 
other members of our group in the synthesis of the target heptasaccharide 
glycoconjugates. The 4,6-benzylidene of the FucGlc(N3) was also successfully opened 
100% regioselectively to give the desired C-4 hydroxyl that is required for the formation 
of the larger carbohydrates. 
 
It was determined that N-Troc protection of donor was required when forming the β-1,4-
linkage between the two GlcNAc residues. Low yields and poor selectivity (23%, α:β = 
1:2.8) were obtained with the initially proposed azide donor. The use of the N-Troc 
protected donor resulted in formation of the desired β-linkage selectively. The discovery 
that N-Troc protection is required for successful glycosylation was an important finding 
as this coupling is the last glycosylation reaction in forming the larger oligosaccharide 
structures. It was also determined that GlcNAc acceptors with azide protection resulted in 
higher glycosylation yields than their N-Troc protected counterparts. Therefore azide 
protection was still favoured for the reducing end GlcNAc residue. 
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The Man3 trisaccharide 17 and FucGlc(N3) disaccharide 21 were both successfully fully 
deprotected. The conditions that were optimised for the deprotection of both sugars have 
established the deprotection strategy for the heptasaccharide and other larger truncations. 
The only reaction required for deprotection of the heptasaccharide that was not tested was 
the conversion of the N-Troc group to an N-acetate. The optimum conditions for the 
conversion of the GlcNAc monomer to the corresponding β-glycosylamine were 
determined and were used for conversion of the fully deprotected FucGlc disaccharide 76 
and Man3 trisaccharide 42 to their corresponding β-glycosylamines 96 and 95. These 
conditions can be used for the synthesis of other target glycosylamines. 
 
The knowledge gained and the intermediate compounds synthesised during this project 
will aid in the synthesis of the heptasaccharide glycoconjugate 1 and other truncated 
glycoconjugates which are being synthesised as part of the broader project looking at 
determining the molecular triggers of asthma. The synthesis of the three glycoconjugates 
proposed in this report will enable the first detailed insight into the relationship between 
N-glycan structure and Th2 bias. This will increase the understanding of the asthmatic 
Th2 response and may lead to the identification of specific enzyme targets that will aid in 
the treatment and prevention of asthma and allergy.  
 
 
  81 
EXPERIMENTAL 
 
General 
Unless otherwise stated the following conditions apply. Reactions were conducted in flame-dried or oven-
dried glassware, under an inert atmosphere, using dry solvents. DCM was freshly distilled from phosphorus 
pentoxide, and toluene was stored over sodium. Acetic acid (AR, Univar), acetic anhydride (AR, Peking 
Chemical Works), pyridine (PA, Roth) and chloroform (AR, BDH) were used as received. Acetonitrile was 
freshly distilled from calcium hydride and THF was freshly distilled from lithium aluminium hydride. 
Methanol and DMF were distilled and stored over molecular sieves (3Å). Ethyl acetate was distilled prior 
to use. Ethyl acetate and petroleum ether used for column chromatography were of technical grade and 
distilled prior to use. Concentration of solutions in vacuo was achieved using a rotary evaporator fitted to a 
vacuum pump, with a bath temperature of 45°C. Residual solvents were removed using an Edwards 
E2M1.5 oil pump. Reaction progress was monitored using TLC performed on ALUGRAM SIL G/UV254 
TLC plates using UV radiation (254 nm) and/or 10% (v/v) sulfuric acid in methanol dip with subsequent 
heating to visualise the compounds. Purification by column chromatography was conducted using glass 
columns packed with silica gel (Pure Science Silica Gel 60, 40-63 micron) as the stationary phase and the 
solvent system as indicated. Purification by reverse phase column chromatography was conducted using 
either C8 (Accu BOND II OCTYL cartridges, 500 mg, 3 mL) or C18 (Accu BOND II ODS-C18 cartridges, 
500 mg, 3 mL) pre-packed cartridges from Agilent Technologies as stated and the solvent system as 
indicated. Purification by size exclusion chromatography was conducted using a glass column (180 cm 
heigh and 1.9 cm wide) packed with lipophilic Sephadex (Sigma Aldrich Sephadex
®
 LH-20, 25-100 
microns). Melting points (Mp) were obtained on a Gallenkamp Melting Point Apparatus. Optical rotation 
measurements were recorded using a Perkin-Elmer 241 Polarimeter at the sodium D-line at the stated 
temperature in a 1 dm, jacketed cell. IR spectra were recorded as thin films from CHCl3 or MeOH solutions 
using a Bruker Tensor 27 FTIR spectrometer ATR and are reported in wavenumbers (cm
-1
). NMR spectra 
were recorded at 20°C in CDCl3 or D2O as indicated with a Varian Unity Inova 500 spectrometer (
1
H and 
13
C at 500 and 125 MHz respectively). 
1
H-NMR data is presented as follows: chemical shift expressed in 
ppm, multiplicity (s, singlet; bs, broad singlet; d, doublet; t, triplet; q, quartet; m, multiplet – range given; 
mc, mulitplet centered – broad undefined peak), number of protons, coupling constants (J) in Hertz, 
assignment of proton(s). Assignments are based on COSY, HSQC, and HMBC correlations. The 
1
H-NMR 
spectra are referenced to the residual solvent peak, 7.26 ppm for CDCl3 and 4.79 ppm for D2O. The 
13
C-
NMR are referenced to the solvent peak, 77.16 ppm for CDCl3 (
13
C-NMR measured in D2O were not 
manually referenced). 
13
C-NMR spectra were proton decoupled. HRMS were recorded on a Waters Q-TOF 
Premier Tandem Mass Spectrometer using postive electro-spray ionisation. 
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2,3,4,6-Tetra-O-benzoyl-α-D-mannopyranosyl bromide (30). Penta-benzoyl 
mannose 29 (13.50 g, 19.27 mmol) was dissolved in DCM (26 mL). After cooling the 
solution to 0°C, acetic anhydride (1.45 mL, 15.23 mmol, 0.80 equiv.) was slowly 
added to the solution followed by HBr (27.0 mL, 33% in AcOH, 163.8 mmol, 8.5 
equiv.)  The reaction mixture was allowed to stir at room temperature for 16 h upon which TLC-analysis 
(ethyl acetate) showed completion of the reaction. The reaction mixture was neutralised with sat. aq. 
NaHCO3 and NaHCO3 (s), extracted three times with Et2O (50 mL each), washed with water (3 times), 
brine, dried (MgSO4), filtered and concentrated in vacuo to yield crude bromide 30 as a dark yellow oil 
(13.25 g) which was used without further purification. Rf 0.35 (ethyl acetate). 
 
3,4,6-Tri-O-benzoyl-1,2-O-(α-methoxybenzylidene)--D-mannopyranose 
(31).  All of the crude bromide, 30, from the previous reaction (13.25 g, ~19.27 
mmol) was dissolved in DCM (14 mL) and methanol (14 mL) and placed under 
a nitrogen atmosphere. 2,6-Lutidine (6.90 mL, 69.6 mmol, 3.6 equiv.) was 
slowly added and the reaction mixture was allowed to stir for 16 hours. Once 
TLC-analysis (ethyl acetate) showed completion of the reaction, the reaction mixture was neutralised with 
sat. aq. NaHCO3, extracted with DCM, washed with brine, dried (MgSO4), filtered and concentrated in 
vacuo to yield crude orthoester 31 as a yellow oil (13.38 g) which was used without further purification. Rf 
0.59 (ethyl acetate).  
 
1,2-O-(α-Methoxybenzylidene)--D-mannopyranose (20).  All of the crude 
orthoester, 31, from the previous reaction (13.38 g, ~19.27 mmol) was dissolved 
in DCM (18 mL) and methanol (71 mL). The pH of the solution was adjusted to 
pH  9 by the addition of sodium methoxide (11.5 mL, 0.5M in MeOH). The 
reaction was stirred for 20 h until TLC-analysis (ethyl acetate) showed complete 
debenzoylation of the starting compound. The reaction mixture was concentrated in vacuo and purified by 
column chromatography (methanol in ethyl acetate, 0% → 2%, v/v) to yield 20 as a colourless oil (3.89 g, 
68% over 3 steps). Rf 0.16 (ethyl acetate); 
1
H-NMR (500 MHz, CDCl3):  7.62-7.60 (m, 2H, CH arom.), 
7.40-7.37 (m, 3H, CH arom.), 5.65 (d, 1H, J1,2 = 2.9 Hz, H-1), 4.74 (t, 1H, J1,2 = J2,3 = 3.0 Hz, H-2), 3.82-
3.79 (m, 2H, H-3 and H-4), 3.70-3.67 (m, 2H, H-6a and H-6b), 3.35-3.32 (m, 1H, H-5), 3.32 (s, 3H, CH3 
OMe). 
 
3,4,6-Tri-O-benzyl-1,2-O-(α-methoxybenzylidene)--D-mannopyranose 
(32). Orthoester 20 (1.94 g, 6.50 mmol) was coevaporated three times with 
DMF, for the final coevaporation the solution was partially concentrated 
concentrated leaving  33 mL DMF  and placed under a nitrogen atmosphere. 
After cooling the solution to 0°C, benzyl bromide (2.78 mL, 23.4 mmol, 3.6 
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equiv.), sodium hydride (slow addition) (1.01 g, 60 % in oil, 25.4 mmol, 3.9 equiv.) and TBAI (cat.) were 
added and the reaction mixture was allowed to stir for 4 h at room temperature. TLC-analysis (ethyl 
acetate/light petroleum ether, 1/2, v/v) showed completion of the reaction. The reaction mixture was 
quenched with methanol at 0°C, concentrated in vacuo, dissolved in ethyl acetate, washed with water and 
brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column chromatography (ethyl 
acetate/light petroleum ether, 1/20 → 1/2, v/v) yielded 32 as a colourless oil (2.99 g, 81%). Rf 0.35 (ethyl 
acetate/light petroleum ether, 1/2, v/v); []D
20
 = -27.4 (c 1.0, CHCl3); IR (thin film): 3062, 3031, 2911, 
2866, 1496, 1453, 1365, 1273, 1089, 1059, 1026, 984, 915, 837, 796, 734, 696 cm
-1
; 
1
H-NMR (500 MHz, 
CDCl3):  7.72-7.70 (m, 2H, CH arom.), 7.46-7.44 (m, 2H, CH arom.), 7.39-7.24 (m, 16H, CH arom.), 5.51 
(d, 1H, J1,2 = 3.0 Hz, H-1), 4.91 (d, 1H, Ja,b = 11.7 Hz, CH-a 4-O-Bn), 4.88 (d, 1H, Ja,b = 12.0 Hz, CH-a 3-
O-Bn), 4.83 (d, 1H, Ja,b = 12.2 Hz, CH-b 3-O-Bn), 4.70 (t, 1H, J1,2 = J2,3 = 3.1 Hz, H-2), 4.65 (d, 1H, Ja,b = 
11.0 Hz, CH-b 4-O-Bn), 4.44 (d, 1H, Ja,b = 12.2 Hz, CH-a 6-O-Bn), 4.41 (d, Ja,b = 12.0 Hz, 1H, CH-b 6-O-
Bn), 3.96 (t, 1H, J3,4 = J4,5 = 9.1 Hz, H-4), 3.86 (dd, 1H, J2,3 = 3.9, J3,4 = 9.2 Hz, H-3), 3.68 (dd, 1H, J5,6a = 
4.8, J6a,6b = 10.9 Hz, H-6a), 3.59 (dd, 1H, J5,6b = 2.4, J6a,6b = 11.0 Hz, H-6b), 3.51 (ddd, 1H, J4,5 = 9.0, J5,6a = 
4.8, J5,6b = 2.4 Hz, H-5), 3.29 (s, 3H, CH3 OMe); 
13
C-NMR (125 MHz, CDCl3):  138.5 (Ci arom. 6-O-Bn), 
138.4 (Ci arom. 4-O-Bn), 138.0 (Ci arom. 3-O-Bn), 136.7 (Ci arom.), 129.2 (CH arom.), 128.6 (CH arom.), 
128.5 (CH arom.), 128.4 (CH arom.), 128.2 (CH arom.), 128.1 (CH arom.), 128.1 (CH arom.), 128.1 (CH 
arom.), 127.9 (CH arom.), 127.6 (CH arom.), 127.5 (CH arom.), 126.9 (CH arom.), 122.6 (Cq orthoester), 
98.0 (C-1), 78.6 (C-3), 76.5 (C-2), 75.2 (CH2 4-O-Bn), 75.2 (C-5), 74.4 (C-4), 73.3 (CH2 6-O-Bn), 72.2 
(CH2 3-O-Bn), 69.2 (C-6), 51.5 (CH3 OMe); HRMS(ESI) m/z calcld. for [C35H36O7+Na]
+
: 591.2359, obsd.: 
591.2369. 
 
2-O-Benzoyl-3,4,6-tri-O-benzyl-/-D-mannopyranose (33). Orthoester 32 
(3.25 g, 5.87 mmol) was dissolved in acetic acid/water (100 mL, 4/1, v/v) and the 
reaction mixture was stirred for 3 h. When TLC-analysis (ethyl acetate/light 
petroleum ether, 1/3, v/v) showed completion of the reaction, water was added 
and the white precipitate that formed was extracted 3 times with diethyl ether. The organic layers were 
combined and washed with sat. aq. Na2CO3 and brine, dried (MgSO4), filtered and concentrated in vacuo. 
Purification by column chromatography (ethyl acetate/light petroleum ether, 1/5 → 1/1, v/v) yielded 33 as a 
colourless oil (2.60 g, 82%). Rf 0.20/0.12 (/) (ethyl acetate/light petroleum ether, 1/3, v/v); IR (thin film): 
3343, 3088, 3064, 3031, 2929, 2903, 2868, 1721, 1496, 1453, 1362, 1269, 1177 1070, 1043, 1027, 975, 
9115, 826, 793, 749, 737, 711, 698 cm
-1
; (NMR data given for the α-anomer only, as only trace amounts of 
the β-anomer were detectable) 1H-NMR (500 MHz, CDCl3):  8.08-8.06 (m, 2H, CH arom.), 7.58-7.54 (m, 
1H, CH arom.), 7.41-7.23 (m, 15H, CH arom.), 7.19-7.18 (m, 2H, CH arom.), 5.63 (dd, 1H, J1,2 = 1.9, J2,3 = 
2.9 Hz, H-2), 5.35 (s, 1H, H-1), 4.88 (d, 1H, Ja,b = 11.0 Hz, CH-a 4-O-Bn), 4.79 (d, 1H, Ja,b = 11.3 Hz, CH-
a 3-O-Bn), 4.67 (d, 1H, Ja,b = 12.0 Hz, CH-a 6-O-Bn), 4.58 (d, 1H, Ja,b = 11.0 Hz, CH-b 3-O-Bn), 4.55 (d, 
Ja,b = 12.2 Hz, 1H, CH-b 6-O-Bn), 4.53 (d, 1H, Ja,b = 11.2 Hz, CH-b 4-O-Bn), 4.17 (dd, 1H, J2,3 = 3.2, J3,4 = 
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9.3 Hz, H-3), 4.13 (ddd, 1H, J4,5 = 9.8, J5,6a = 4.6, J5,6b = 2.2 Hz, H-5), 3.96 (t, 1H, J3,4 = J4,5 = 9.6 Hz, H-4), 
3.79-3.77 (m, 2H, H-6a and H-6b), 3.26 (bs, 1H, 1-OH); 
13
C-NMR (125 MHz, CDCl3):  165.9 (C=O 2-O-
Bz), 138.4 (Ci arom. 4-O-Bn), 138.3 (Ci arom. 6-O-Bn), 138.1 (Ci arom. 3-O-Bn), 133.3 (Ci arom. O-Bz), 
130.1 (CH arom.), 128.5 (CH arom.),  128.5 (CH arom.), 128.2 (CH arom.), 127.9 (CH arom.), 127.8 (CH 
arom.), 127.8 (CH arom.), 127.8 (CH arom.), 92.7 (C-1), 77.9 (C-3), 75.3 (CH2 4-O-Bn), 74.7 (C-4), 73.6 
(CH2 6-O-Bn), 71.7 (CH2 3-O-Bn), 71.6 (C-5), 69.6 (C-6), 69.5 (C-2); HRMS(ESI) m/z calcld. for 
[C34H34O7N3Si+Na]
+
: 577.2202, obsd.: 577.2205. 
 
 2-O-Benzoyl-3,4,6-tri-O-benzyl--D-mannopyranosyl 
trichloroacetimidate (18). Hemiacetal 33 (2.51 g, 4.65 mmol) was 
coevaporated three times with toluene and dissolved in DCM (24 mL) under 
a nitrogen atmosphere. After cooling the solution to 0°C, 
trichloroacetonitrile (2.33 mL, 23.2 mmol, 5.0 equiv.) and DBU (0.070 mL, 
0.465 mmol, 0.1 equiv) were added and the reaction was stirred for 1.5 h. After TLC-analysis (ethyl 
acetate/light petroleum ether, 1/2, v/v) showed completion of the reaction, the reaction mixture was passed 
through a silica plug (eluted with ethyl acetate/light petroleum ether, 1/1, v/v), concentrated in vacuo to 
give a pale yellow oil and purified by column chromatography (ethyl acetate/light petroleum ether, 1/10 → 
1/1, v/v) to yield 18 as a colourless oil which crystalised upon refridgeration (2.82 g, 89%, 99% based on 
starting material recovered). The imidate was stored in the freezer until it was used. Rf 0.52 (ethyl 
acetate/light petroleum ether, 1/2, v/v); IR (thin film): 3342, 3065, 3032, 2929, 2859, 1725, 1675, 1602, 
1521, 1497, 1454, 1362, 1318, 1264, 1166, 1095, 1070, 1028, 973, 910, 839, 797, 733, 709, 699 cm
-1
; 
1
H-
NMR (500 MHz, CDCl3):  8.70 (s, 1H, NH), 8.08 (dd, J = 8.3 Hz, 2H, CH arom. 2-O-Bz), 7.57 (t, Jm,p = 
7.5, 1H, CH arom. 2-O-Bz), 7.39-7.21 (m, 17H, CH arom.), 6.41 (d, 1H, J1,2 = 3.2 Hz, H-1), 5.74 (dd, 1H, 
J2,3 = 2.4 Hz  J1,2 = 3.2 Hz, H-2), 4.89 (d, 1H, Ja,b = 10.7 Hz, CH-a 4-O-Bn), 4.81 (d, 1H, Ja,b = 11.4 Hz, 
CH-a 3-O-Bn), 4.74 (d, 1H, Ja,b = 12.0 Hz, CH-a 6-O-Bn), 4.62 (d, 1H, Ja,b = 12.0 Hz, CH-b 3-O-Bn), 4.60 
(d, 1H, Ja,b = 11.2 Hz, CH-b 4-O-Bn), 4.54 (d, Ja,b = 11.9 Hz, 1H, CH-b 6-O-Bn), 4.25 (t, 1H, J3,4 = J4,5 = 
9.7 Hz, H-4), 4.16 (dd, 1H, J2,3 = 3.2 Hz,  J3,4 = 9.5 Hz, H-3), 4.05 (ddd, 1H, J5,6b = 1.7 Hz,  J5,6a = 3.4 Hz,  
J4,5 = 9.8 Hz, H-5), 3.92 (dd, 1H, J5,6a = 3.4 Hz,  J6a,6b = 11.2 Hz, H-6a), 3.78 (dd, 1H, J5,6b = 1.7 Hz,  J6a,6b = 
11.3 Hz, H-6b); 
13
C-NMR (125 MHz, CDCl3):  165.6 (C=O 2-O-Bz), 160.2 (C=N), 138.6 (Ci arom. 6-O-
Bn), 138.2 (Ci arom. 4-O-Bn), 137.7 (Ci arom. 3-O-Bn), 133.5 (Ci arom. O-Bz), 130.2 (CH arom.), 129.6 
(CH arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 
128.0 (CH arom.), 128.0 (CH arom.), 127.6 (CH arom.), 95.5 (C-1), 90.9 (CCl3), 77.4 (C-3), 75.7 (CH2 4-
O-Bn), 74.7 (C-5), 73.8 (C-4), 73.6 (CH2 6-O-Bn), 72.0 (CH2 3-O-Bn), 68.7 (C-6), 67.8 (C-2). HRMS(ESI) 
m/z calcld. for [C36H34O7NCl3+Na]
+
: 720.1299, obsd.: 720.1299. 
 
2-O-Benzoyl-1-O-benzyl-α-D-mannopyranose (19). Orthoester 20 (0.049 g, 0.166 
mmol) was coevaporated three times with toluene and dissolved in DCM (0.90 mL) 
  85 
under a nitrogen atmosphere. Benzyl alcohol (0.17 mL, 16.6 mmol, 10 equiv.) and CSA (0.001 g, 0.004 
mmol, 0.03 equiv.) was added and the reaction was stirred for 18 h. After TLC-analysis (ethyl acetate) 
showed completion of the reaction, the reaction was quenched with 0.10 mL triethylamine, washed with 
NaHCO3 and brine, dried (MgSO4), and concentrated in vacuo. Purification by column chromatography 
(ethyl acetate/light petroleum ether, 1/5 → 1/0, v/v) yielded 19 as a colourless oil (0.028 g, 46%). Rf 0.34 
(ethyl acetate);  IR (thin film): 3401, 3033, 3016, 2908, 2893, 1654, 1431, 1317, 1272, 1215, 1118, 1068, 
1027, 976, 713 cm
-1
; 
1
H-NMR (500 MHz, CDCl3): δ 8.04-8.02 (m, 2H, CH arom.), 7.60-7.56 (m, 1H, CH 
arom.), 7.47-7.43 (m, 2H, CH arom.), 7.39-7.30 (m, 4H, CH arom.), 7.18-7.14 (m, 1H, CH arom.), 5.40 
(dd, 1H, J1,2 = 1.7, J2,3 = 3.4 Hz, H-2), 5.05 (d, 1H, J1,2 = 1.7 Hz, H-1), 4.74 (d, 1H, Ja,b = 11.8 Hz, CH-a 
Bn), 4.56 (d, 1H, Ja,b = 11.7 Hz, CH-b Bn), 4.19 (dd, 1H, J3,4 = 9.5, J2,3 = 3.4 Hz, H-3), 4.03 (t, 1H, J3,4 = J-
4,5 = 9.7 Hz, H-4), 3.90 (d, 2H, J5,6 = 3.7 Hz, H-6a and H-6b), 3.76 (dt, 1H, J4,5 = 9.8 Hz, J5,6 = 3.6 Hz, H-
5), 
13
C-NMR (125 MHz, CDCl3) δ 166.2 (C=O 2-O-Bz), 136.7 (C arom.), 129.8 (CH arom.), 129.3 (CH 
arom.), 129.0 (CH arom.), 128.6 (CH arom.), 128.6 (CH arom.), 128.2 (CH arom.), 128.1 (CH arom.), 
128.0 (CH arom.), 125.3 (CH arom.), 97.2 (C-1), 72.6 (C-2), 72.0 (C-5), 70.6 (C-3), 69.8 (CH2 Bn), 68.6 
(C-4), 62.3 (C-6); HRMS(ESI) m/z calc. for [C20H22O7+Na]
+
: 397.1264, obsd.: 397.1262. 
 
Benzyl 2-O-benzoyl-3,6-di-O-(2-O-benzoyl-3,4,6-tri-O-benzyl--D-
mannopyranosyl)--D-mannopyranoside (17). Triol acceptor 19 (0.225 
g, 0.601 mmol) and acetimidate donor 18 (1.203 g, 1.722 mmol, 2.9 
equiv.) were coevaporated three times with toluene and dissolved in 
DCM (3.5 mL) under a nitrogen atmosphere. After cooling the solution 
to -40°C, TMSOTf (0.011 mL, 0.060 mmol, 0.1 equiv.) was added 
dropwise and the reaction was stirred for 2 h. After TLC-analysis (ethyl 
acetate/toluene, 1/6, v/v) showed completion of the reaction, the reaction 
mixture was quenched with triethylamine (0.2 mL) at -40°C. The reaction mixture was then diluted with 
ethyl acetate and washed with sat. aq. NaHCO3 and brine, dried (MgSO4), filtered and concentrated in 
vacuo. Purification by column chromatography using both ethyl acetate/light petroleum ether (ethyl 
acetate/light petroleum ether, 1/20 → 1/2, v/v) and DCM/light petroleum ether (DCM/light petroleum 
ether, 1/3 → 1/0, v/v) as the eluents was unsuccessful, as was purification by Sephadex® LH-20 size-
exclusion chromatography (DCM/methanol, 1/1, v/v). However, purification by column chromatography 
using ethyl acetate/toluene (ethyl acetate/toluene, 1/30 → 1/10, v/v) successfully yielded the trisaccharide 
17 as a colourless oil (0.097 g, 11%). Rf 0.47 (ethyl acetate/toluene, 1/6, v/v); []D
20
 = -9.7 (c 1.0, CHCl3); 
IR (thin film): 3464, 3088, 3064, 3031, 2929, 2867, 1721, 1602, 1585, 1496, 1453, 1360, 1317, 1267, 1210, 
1176, 1109, 1097, 1072, 1044, 1028, 1002, 980, 911, 844, 803, 737, 711, 698 cm
-1
; 
1
H-NMR (500 MHz, 
CDCl3):  8.08-8.04 (m, 2H, CH arom. OBz), 8.00-7.98 (m, 1H, CH arom. OBz), 7.59-7.51 (m, 2H, CH 
arom.), 7.43-7.08 (m, 42H, CH arom.), 5.77 (dd, 1H, J1″,2″ = 2.0, J2″,3″ = 3.0 Hz, H-2″), 5.57 (dd, 1H, J1′,2′ = 
2.2, J2′,3′ = 2.9 Hz, H-2′), 5.52 (dd, 1H, J1,2 = 1.7, J2,3 = 2.4 Hz, H-2), 5.37 (d, 1H, J1′,2′ = 1.7 Hz, H-1′), 5.08 
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(d, 1H, J1,2 = 1.7 Hz, H-1), 5.06 (d, 1H, J1″,2″ = 1.7 Hz, H-1″), 4.86 (d, 1H, Ja,b = 10.7 Hz, CH-a 4″-O-Bn), 
4.78 (d, 1H, Ja,b = 11.0 Hz, CH-a 3″-O-Bn), 4.77 (d, 1H, Ja,b = 11.3 Hz, CH-a 4′-O-Bn), 4.74 (d, 1H, Ja,b = 
12.0 Hz, CH-a 6″-O-Bn), 4.71 (d, 1H, Ja,b = 10.7 Hz, CH-a 6′-O-Bn), 4.70 (d, 1H, Ja,b = 12.0 Hz, CH-a 1-
O-Bn), 4.63 (d, 1H, Ja,b = 12.2 Hz, CH-b 6″-O-Bn), 4.57 (d, 1H, Ja,b = 11.3 Hz, CH-a 3′-O-Bn), 4.55 (d, 1H, 
Ja,b = 11.8 Hz, CH-b 1-O-Bn), 4.54 (d, 1H, Ja,b = 10.8 Hz, CH-b 4″-O-Bn), 4.48 (d, 1H, Ja,b = 11.5 Hz, CH-
b 3″-O-Bn), 4.47 (d, 1H, Ja,b = 11.0 Hz, CH-b 4′-O-Bn), 4.47 (d, 1H, Ja,b = 11.9 Hz, CH-b 6′-O-Bn), 4.33 
(d, 1H, Ja,b = 10.9 Hz, CH-b 3′-O-Bn), 4.28-4.27 (m, 2H, H-3 and H-4), 4.14 (dd, 1H, J2″,3″ = 3.2, J3″,4″ = 9.3 
Hz, H-3″), 4.12 (dd, 1H, J5,6a = 3.9, J6a,6b = 11.5 Hz, H-6a), 4.08 (ddd, 1H, J4″,5″ = 9.8, J5″,6b″ = 2.2, J5″,6a″ = 
4.4 Hz, H-5″), 4.05 (t, 1H, J3′,4′ = J4′,5′ = 9.5 Hz, H-4′), 4.01 (t, 1H, J3″,4″ = J4″,5″ = 9.3 Hz, H-4″), 3.97-3.93 
(m, 2H, H-3′ and H-5′), 3.86-3.81 (m, 3H, H-5, H-6a″, and H-6b″), 3.78 (dd, 1H, J5,6b = 2.2, J6a,6b = 11.0 
Hz, H-6b), 3.75-3.69 (m, 2H, H-6a′, H-6b′); 13C-NMR (125 MHz, CDCl3):  165.8 (C=O 2-O-Bz), 165.7 
(C=O 2′-O-Bz), 165.7 (C=O 2″-O-Bz), 138.9 (Ci arom. O-Bn), 138.7 (Ci arom. O-Bn), 138.3 (Ci arom. O-
Bn), 138.3 (Ci arom. O-Bn), 138.2 (Ci arom. O-Bn), 138.1 (Ci arom. O-Bn), 137.1 (Ci arom. 1-O-Bn), 
133.4 (Ci arom. O-Bz), 133.3 (Ci arom. O-Bz), 133.2 (Ci arom. O-Bz), 130.1 (CH arom.), 130.1 (CH 
arom.), 129.9 (CH arom.), 128.7 (CH arom.),  128.6 (CH arom.), 128.6 (CH arom.), 128.5 (CH arom.), 
128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.2 (CH arom.), 128.1 (CH 
arom.), 128.1 (CH arom.), 128.1 (CH arom.), 128.0 (CH arom.), 127.9 (CH arom.), 127.8 (CH arom.), 
127.7 (CH arom.), 127.7 (CH arom.), 127.7 (CH arom.), 127.6 (CH arom.), 127.5 (CH arom.), 127.4 (CH 
arom.), 99.8 (C-1′), 98.3 (C-1″), 97.2 (C-1), 79.1 (C-3″), 78.1 (C-3′), 77.6 (C-3), 75.6 (CH2 4″-O-Bn), 74.6 
(C-4″ and CH2 4′-O-Bn), 74.2 (C-4′), 73.6 (CH2 6′-O-Bn and CH2 6″-O-Bn), 72.6 (C-2), 72.5 (C-5′), 72.3 
(C-5″), 71.9 (CH2 3″-O-Bn), 71.9 (C-5 and CH2 3′-O-Bn), 69.8 (CH2 1-O-Bn), 69.5 (C-2′), 69.3 (C-2″), 
69.2 (C-6″), 69.0 (C-6′), 67.1 (C-4), 66.7 (C-6); HRMS(ESI) m/z calcld. for [C88H86O19+Na]
+
: 1469.5661, 
obsd.: 1469.5668. 
 
Benzyl 3,6-di-O-(3,4,6-tri-O-benzyl--D-mannopyranosyl)--D-
mannopyranoside (41). Trisaccharide 17 (0.0842, 0.058 mmol) was 
dissolved in DCM/MeOH (2 mL, 1/1, v/v). After addition of sodium 
methoxide until the solution was pH  9 (0.40 mL, 0.04M in MeOH), the 
reaction was stirred for 3 days until TLC-analysis (ethyl acetate) showed 
complete debenzoylation of the starting compound. The reaction mixture 
was neutralised with Dowex H
+
, filtered and concentrated in vacuo. 
Purification by column chromatography (ethyl acetate/light petroleum 
ether, 2/1 → 5/1, v/v) yielded 41, as a colourless oil (0.0491 g, 74%). Rf 0.63 (ethyl acetate); []D
20
 = 38.4 
(c 1.0, CHCl3); IR (thin film): 3436, 3088, 3063, 3031, 2920, 2871, 1496, 1454, 1364, 1319, 1267, 1210, 
1041, 1027, 983, 909,  842, 816, 733, 697 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.37-7.14 (m, 35H, CH 
arom.), 5.08 (d, 1H, J1′,2′ = 1.5 Hz, H-1′), 4.97 (d, 1H, J1″,2″ = 1.5 Hz, H-1″), 4.82 (d, 1H, Ja,b = 11.2 Hz, CH-
a 4′-O-Bn), 4.81 (d, 1H, Ja,b = 10.8 Hz, CH-a 4″-O-Bn), 4.71-4.63 (m, 7H, H-1, CH-a 1-O-Bn, CH-a 3′-O-
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Bn, CH-b 3′-O-Bn, CH-a 3″-O-Bn, CH-b 3″-O-Bn , and CH-a 6″-O-Bn), 4.55 (d, 1H, Ja,b = 12.2 Hz, CH-b 
6″-O-Bn), 4.53-4.47 (m, 4H, CH-b 4′-O-Bn, CH-b 4″-O-Bn, CH-a 6′-O-Bn, and CH-b 6′-O-Bn), 4.43 (d, 
1H, Ja,b = 11.7 Hz, CH-b 1-O-Bn), 4.23 (ddd, 1H, J4′,5′ = 10.0, J5′,6b′ = 9.8, J5′,6a′ = 1.4 Hz, H-5′), 4.19-4.18 
(m, 2H, H-2 and H-2″), 4.07-4.04 (m, 2H, H-6a and H-2′), 3.95 (t, 1H, J3,4 = J4,5 = 9.8 Hz, H-4), 3.94-3.90 
(m, 3H, H-5, H-3′, and H-3″), 3.85 (t, 1H, J3″,4″ = J4″,5″ = 9.3 Hz, H-4″), 3.81 (dd, 1H, J2,3 = 3.1, J3,4 = 9.6 
Hz, H-3), 3.80 (dd, 1H, J5′,6a′ = 1.5, J6a′,6b′ = 9.7 Hz, H-6a′), 3.75-3.72 (m, 3H, H-5″, H-6a″, and H-6b″), 
3.67 (dd, 1H, J5,6b = 1.9, J6a,6b = 10.7 Hz, H-6b), 3.58 (dd, 1H, J3′,4′ = 8.8, J4′,5′ = 10.0 Hz, H-4′), 3.50 (dd, 
1H, J5′,6b′ = 8.6, J6a′,6b′ = 9.8 Hz, H-6b′), 2.47 (bs, 3H, 3xOH); 
13
C-NMR (125 MHz, CDCl3):  138.2 (Ci 
arom. O-Bn), 138.1 (Ci arom. O-Bn), 138.1 (Ci arom. O-Bn), 138.0 (Ci arom. O-Bn), 137.8 (Ci arom. O-
Bn), 137.4 (Ci arom. O-Bn), 137.4 (Ci arom. 1-O-Bn), 128.7 (CH arom.), 128.6 (CH arom.), 128.6 (CH 
arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.3 (CH arom.), 128.2 (CH arom.), 
128.2 (CH arom.), 128.1 (CH arom.), 128.0 (CH arom.), 128.0 (CH arom.), 128.0 (CH arom.), 128.0 (CH 
arom.), 128.0 (CH arom.), 127.9 (CH arom.), 127.8 (CH arom.), 100.6 (C-1′), 99.8 (C-1), 99.5 (C-1″), 82.3 
(C-3), 80.3 (C-3′), 80.3 (C-3″), 75.4 (CH2 4″-O-Bn), 75.0 (CH2 4′-O-Bn), 74.8 (C-4′), 74.5 (C-4″), 73.8 
(CH2 6′-O-Bn), 73.5 (CH2 6″-O-Bn), 72.5 (CH2 3″-O-Bn), 72.1 (CH2 3′-O-Bn), 71.6 (C-5′), 71.4 (C-5″), 
71.2 (C-5), 69.7 (C-6′), 69.0 (CH2 1-O-Bn), 69.0 (C-2 and C-2′), 68.9 (C-6″), 68.4 (C-2″), 66.4 (C-6), 65.6 
(C-4); HRMS(ESI) m/z calcld. for [C67H74O16+Na]
+
: 1157.4875, obsd.: 1157.4882. 
 
3,6-di-O-(-D-mannopyranosyl)-/β-D-mannopyranose (42). To a 
solution of trisaccharide 41 (0.0360 g, 0.0317 mmol) in CHCl3/EtOH 
(0.50 mL, 3/2, v/v) was added Pd(OH)2/C (0.0050 g, 20% catalyst, 
0.0071 mmol, 0.2 equiv.). The reaction mixture was placed under a H2 
atmosphere and stirred for 3 days, with extra Pd(OH)2/C (0.0050 g) 
added after 24 h. After TLC-analysis (30% MeOH in ethyl acetate) 
showed completion of the reaction, the reaction mixture was filtered 
over celite, washed though with MeOH and H2O, and concentrated in 
vacuo. Purification by C18 reverse phase column chromatography (MeOH in H2O, 0% → 2%, v/v) yielded 
fully deprotected trisaccharide 42 as a white amorphous solid after lyophilisation (0.0152 g, 95%). Rf 
0.19/0.13 (/) (30% MeOH in ethyl acetate, v/v); IR (thin film): 3323, 2935, 1454, 1377, 1274, 1048, 
1019, 974, 918, 881, 809 cm
-1
; 
1
H-NMR (600 MHz, D2O):  5.09 (s, 1H), 5.07 (s, 2H), 4.87 (s, 1H), 4.86 
(s, 1H), 4.85 (s, 1H), 4.04-3.30 (m, 36H); 
13
C-NMR (150 MHz, D2O):  102.3, 102.1, 99.3, 99.3, 94.1, 
93.6, 80.5, 78.2, 73.9, 73.2, 73.2, 72.5, 72.5, 70.7, 70.6, 70.4, 70.4, 70.2, 70.2, 69.9, 69.7, 69.7, 66.6, 66.6, 
66.6, 65.6, 65.5, 65.3, 65.2, 62.4, 60.8, 60.8; HRMS(ESI) m/z calcld. for [C18H32O16+Na]
+
: 527.1588, 
obsd.: 527.1583. 
 
 
1,2,3,4-Tetra-O-acetyl-/β-L-fucopyranose (46). L-Fucose (4.00 g, 24.4 mmol) 
was dissolved in acetic anhydride/pyridine (75 mL, 1/2, v/v) and the reaction 
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mixture was stirred for 18 h. TLC-analysis (ethyl acetate) showed complete acetylation of the starting 
material. The reaction mixture was concentrated in vacuo, coevaporated three times with toluene, 
redissolved in ethyl acetate, washed with water and brine, dried (MgSO4), filtered and concentrated in 
vacuo. The crude per-acetylated product 46 as a mixture of anomers (α:β, 1.9:1) (8.4 g) was used without 
further purification. Rf 0.61 (both anomers) (ethyl acetate);  
1
H-NMR (500 MHz, CDCl3):  6.34 (d, 1H, J1,2 
= 2.7 Hz, α-H-1), 5.68 (d, 1H, J1,2 = 8.3 Hz, β-H-1), 5.36-5.30 (m, 4H, α-H-2, α-H-3, α-H-4, β-H-2), 5.27 
(d, 1H, J3,4 = 3.5 Hz, β-H-4), 5.07 (dd, 1H, J2,3 = 10.5, J3,4 = 3.4 Hz, β-H-3), 4.27 (q, 1H, J5,6 = 6.6 Hz, α-H-
5), 3.95 (q, 1H, J5,6 = 6.4 Hz, β-H-5), 2.19 (s, 3H, CH3 β-O-Ac), 2.18 (s, 3H, CH3 α-O-Ac), 2.16 (s, 3H, 
CH3 α-O-Ac), 2.12 (s, 3H, CH3 β-O-Ac), 2.04 (s, 3H, CH3 β-O-Ac), 2.02 (s, 3H, CH3 α-O-Ac), 2.00 (s, 3H, 
CH3 α-O-Ac), 1.99 (s, 3H, CH3 β-O-Ac), 1.23 (d, 3H, J5,6 = 6.4 Hz, CH3 β-H-6), 1.16 (d, 3H, J5,6 = 6.6 Hz, 
CH3 α-H-6). 
 
2,3,4-Tri-O-acetyl--L-fucopyranosyl bromide (47). Crude 46 (8.4 g, 24.4 mmol) 
was dissolved in DCM (16 mL) and the solution cooled to 0°C. HBr (16 mL, 33% in 
AcOH) was then added slowly and the reaction mixture was stirred for 30 min at 0°C. 
The reaction mixtue was then stirred for a further 1 h 45 min at room temperature. 
After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed completion 
of the reaction, the reaction mixture was codistilled four times with toluene, resulting in crude fuco-
bromide 47 as a viscous yellow oil (9.05 g) which was used without further purification. Rf 0.48 (ethyl 
acetate/light petroleum ether, 1/1, v/v); 
1
H-NMR (500 MHz, CDCl3):  6.69 (d, 1H, J1,2 = 3.9 Hz, H-1), 
5.41 (dd, 1H, J2,3 = 10.8, J3,4 = 3.5 Hz, H-3), 5.36 (dd, 1H, J3,4 = 3.1, J4,5 = 1.2 Hz, H-4), 5.03 (dd, 1H, J1,2 = 
3.9, J2,3 = 10.7 Hz, H-2), 4.40 (q, 1H, J5,6 = 6.4 Hz, H-5), 2.17 (s, 3H, CH3 4-O-Ac), 2.11 (s, 3H, CH3 2-O-
Ac), 2.01 (s, 3H, CH3 3-O-Ac), 1.22 (d, 3H, J5,6 = 6.3 Hz, CH3 H-6); 
13
C-NMR (125 MHz, CDCl3):  170.4 
(C=O 4-O-Ac), 170.3 (C=O 2-O-Ac), 170.0 (C=O 3-O-Ac), 89.4 (C-1), 70.1 (C-4), 69.9 (C-5), 68.6 (C-3), 
68.0 (C-2), 20.9 (CH3 2-O-Ac), 20.8 (CH3 3-O-Ac), 20.7 (CH3 4-O-Ac), 15.7 (C-6). 
 
Ethyl -L-thiofucopyranoside (48). To a solution of sodium hydride (2.40 g, 60% in 
oil, 60.0 mmol, 2.5 equiv.) in DME (doubly distilled from lithium aluminium 
hydride) (53 mL) at 0°C was added ethanethiol (5.40 mL, 101 mmol, 4.1 equiv.) 
slowly with vigorous stirring. After stirring for 30 min, a solution of crude bromide 
47 (9.01 g, 24.4 mmol) in DME (doubly distilled from lithium aluminium hydride) (27 mL) was added. The 
reaction mixture was allowed to stir for 3.5 h at room temperature. After TLC-analysis (ethyl acetate/light 
petroleum ether, 1/1, v/v) showed complete formation of the thioether, MeOH (80 mL) and NaOMe were 
added to the reaction mixture until the pH was >9. The reaction mixture was stirred for a further 18 h. TLC-
analysis (15% MeOH in ethyl acetate) showed complete de-acetylation. The reaction mixture was 
neutralised with Dowex H
+
, filtered, washed with MeOH, and concentrated in vacuo. Purification by 
column chromatography (methanol in DCM, 0% → 10%, v/v) yielded 48 as a colourless oil (3.43 g, 68%, 4 
steps) which was crystallised from diethyl ether to yield white fluffy crystals. Rf 0.42 (15% methanol in 
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ethyl acetate); Mp 60.0-66.5˚C (from Et2O); []D
20
 = 34.6 (c 1.0, CHCl3); IR (thin film): 3376, 2978, 
2930, 2870, 1652, 1544, 1497, 1454, 1378, 1263, 1161, 1090, 1044, 1027, 995, 910, 864, 808, 729, 697, 
667 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  4.32-4.27 (m, 1H, H-1), 3.79 (d, 1H, J3,4 = 2.5 Hz, H-4), 3.68 (qd, 
1H, J5,6 = 6.6, J4,5 = 1.0 Hz, H-5), 3.64-3.60 (m, 2H, H-2 and H-3), 2.80-2.68 (m, 2H, CH-a SEt and CH-b 
SEt), 2.36 (bs, 3H, 3 x OH), 1.34 (d, 3H, J5,6 = 6.6 Hz, CH3 H-6), 1.32 (t, 3H, JCH2,CH3 = 7.3 Hz, CH3 SEt); 
13
C-NMR (125 MHz, CDCl3):  86.1 (C-1), 75.2 (C-3), 74.9 (C-5), 71.8 (C-4), 70.5 (C-2), 24.7 (CH2 SEt), 
16.8 (C-6), 15.4 (CH3 SEt); HRMS(ESI) m/z calcld. for [C8H16O4S+Na]
+
: 231.0667, obsd.: 231.0665. 
 
Ethyl 2,3,4-tri-O-benzyl--L-thiofucopyranoside (22). Thiofucoside 48 (1.13 g, 
5.44 mmol) was coevaporated three times with DMF, for the final coevaporation the 
solution was partially concentrated concentrated leaving 27 mL DMF, and placed 
under a nitrogen atmosphere. After cooling the solution to 0°C, benzyl bromide (2.33mL, 19.6 mmol, 3.6 
equiv.), sodium hydride (0.849 g, 60% in oil, 21.2 mmol, 3.9 equiv.) and TBAI (cat.) were added and the 
reaction mixture was allowed to stir for 17 h at room temperature. After TLC-analysis (ethyl acetate/light 
petroleum ether, 1/5, v/v) showed completion of the reaction, the reaction mixture was quenched with 
methanol, concentrated in vacuo, dissolved in ethyl acetate, washed with water and brine, dried (MgSO4), 
filtered and concentrated in vacuo. Purification by column chromatography (ethyl acetate/light petroleum 
ether, 1/35 → 1/10, v/v) yielded 22 as a colourless oil which crystallised upon refrigeration (2.14 g, 82%). 
Rf 0.36 (ethyl acetate/light petroleum ether, 1/5, v/v); Mp 51.0-52.1˚C; Lit.
117
 Mp 53˚C; []D
24
 = 6.0 (c 1.0, 
CHCl3); IR (thin film): 3088, 3063, 3030, 2977, 2929, 2868, 1497, 1454, 1357, 1208, 1165, 1125, 1089, 
1067, 1048, 912, 876, 697, 667 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.42-7.28 (m, 15H, CH arom.), 5.00 
(d, 1H, Ja,b = 11.7 Hz, CH-a 4-O-Bn), 4.91 (d, 1H, Ja,b = 10.0 Hz, CH-a 2-O-Bn), 4.81 (d, 1H, Ja,b = 10.3 
Hz, CH-b 2-O-Bn), 4.78 (d, 1H, Ja,b = 11.7 Hz, CH-a 3-O-Bn), 4.75 (d, 1H, Ja,b = 12.0 Hz, CH-b 3-O-Bn), 
4.71 (d, 1H, Ja,b = 11.7 Hz, CH-b 4-O-Bn), 4.40 (d, 1H, J1,2 = 9.8 Hz, H-1), 3.83 (t, 1H, J1,2 = J2,3 = 9.5 Hz, 
H-2), 3.62 (d, 1H, J3,4 = 2.9 Hz, H-4), 3.57 (dd, 1H, J2,3 = 9.3, J3,4 = 2.7 Hz, H-3), 3.49 (q, 1H, J5,6 = 6.3 Hz, 
H-5), 2.79 (dq, 1H, Ja,b = 12.5, Ja,CH3 = 7.6 Hz, CH-a SEt), 2.72 (dq, 1H, Ja,b = 12.5, Jb,CH3 = 7.6 Hz, CH-b 
SEt), 1.31 (t, 3H, JCH2,CH3 = 7.6 Hz, CH3 SEt), 1.21 (d, 3H, J5,6 = 6.3 Hz, CH3 H-6); 
13
C-NMR (125 MHz, 
CDCl3):  138.8 (Ci arom. 4-O-Bn), 138.6 (Ci arom. 3-O-Bn), 138.5 (Ci arom. 2-O-Bn), 128.6 (CH arom.), 
128.4 (CH arom.), 128.3 (CH arom.), 128.3 (CH arom.), 127.8 (CH arom.), 127.8 (CH arom.), 127.7 (CH 
arom.), 127.6 (CH arom.), 85.1 (C-1), 84.6 (C-3), 78.5 (C-2), 76.6 (C-4), 75.8 (CH2 2-O-Bn), 74.7 (C-5), 
74.6 (CH2 4-O-Bn), 73.0 (CH2 3-O-Bn), 24.8 (CH2 SEt), 17.4 (C-6), 15.1 (CH3 SEt); HRMS(ESI) m/z 
calcld. for [C29H34O4S+Na]
+
: 501.2076, obsd.: 501.2079. 
 
2-Azido-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-
benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy--D-
glucopyranose (21). Glucosazide acceptor 23 (0.473 g, 1.160 
mmol) and thiofucoside donor 22 (0.866 g, 1.810 mmol, 1.6 equiv.) 
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were coevaporated three times with DMF, on the final co-evaporation the solution was concentrated to half 
volume leaving 12 mL of DMF. DCM (24 mL) was added and the solution stirred for 1.5 h in the presence 
of molecular sieves (type 4A) under a nitrogen atmosphere. Tetrapropylammonium bromide (0.988 g, 
3.711 mmol, 3.2 equiv.) and copper(II) bromide (0.829 g, 3.711 mmol, 3.2 equiv.) were added and stirring 
was continued for 50 h. After TLC-analysis (ethyl acetate/toluene, 1/6, v/v) showed completion of the 
reaction, the reaction mixture was poured into sat. aq. NaHCO3, extracted with ethyl acetate and washed 
with sat. aq. NH4Cl, and brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/17, v/v) yielded disaccharide 21 (0.810 g, 85%) as a 
colourless oil. Rf 0.68 (ethyl acetate/toluene, 1/6, v/v); []D
20
 = -66 (c 0.1, CHCl3); IR (thin film): 3063, 
3029, 2930, 2860, 2111, 1455, 1361, 1262, 1217, 1180, 1099, 1040, 1000, 916, 841, 764 cm
-1
; 
1
H-NMR 
(500 MHz, CDCl3):  7.41-7.23 (m, 20H, CH arom.), 5.46 (s, 1H, PhCH), 5.39 (d, 1H, J1′,2′ = 3.9 Hz, H-1′), 
4.90 (d, 1H, Ja,b = 11.5 Hz, CH-a 4′-O-Bn), 4.85 (d, 1H, Ja,b = 11.5 Hz, CH-a 3′-O-Bn), 4.85 (d, 1H, Ja,b = 
12.0 Hz, CH-a 2′-O-Bn), 4.77 (d, 1H, Ja,b = 12.0 Hz, CH-b 2′-O-Bn), 4.71 (d, 1H, Ja,b = 11.5 Hz, CH-b 3′-
O-Bn), 4.55 (d, 1H, Ja,b = 11.5 Hz, CH-b 4′-O-Bn), 4.68 (d, 1H, J1,2 = 7.6 Hz, H-1), 4.27 (dd, 1H, J5,6a = 
4.9, J6a,6b = 10.5 Hz, H-6a), 4.08 (q, 1H, J5′,6′ = 6.1 Hz, H-5′), 4.05 (dd, 1H, J1′,2′ = 3.9, J2′,3′ = 10.3 Hz, H-2′), 
3.91 (dd, 1H, J2′,3′ = 10.3, J3′,4′ = 2.9 Hz, H-3′), 3.76 (t, 1H, J5,6b = J6a,6b = 10.5 Hz, H-6b), 3.73 (t, 1H, J2,3 = 
J3,4 = 9.5 Hz, H-3), 3.63 (t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4), 3.52 (dd, 1H, J1,2 = 7.8, J2,3 = 9.8 Hz, H-2), 3.50 
(d, 1H, J3′,4′ = 2.4 Hz, H-4′), 3.43 (td, 1H, J4,5 = J5,6b = 9.5, J5,6a = 4.9 Hz, H-5), 0.94 (s, 9H, 3  CH3 Si
t
Bu), 
0.69 (d, 3H, J5′,6′ = 6.3 Hz, CH3 H-6′), 0.17 (s, 3H, CH3 SiMea), 0.16 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 
MHz, CDCl3):  139.1 (Ci arom. 3′-O-Bn), 138.8 (Ci arom. 4′-O-Bn), 138.5 (Ci arom. 2′-O-Bn), 137.3 (Ci 
arom. PhCH), 129.3 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 128.3 (CH 
arom.), 128.2 (CH arom.), 128.1 (CH arom.), 127.7 (CH arom.), 127.6 (CH arom.), 127.5 (CH arom.), 
127.5 (CH arom.), 126.4 (CH arom.), 102.2 (PhCH), 98.1 (C-1), 97.6 (C-1′), 79.6 (C-4), 79.5 (C-3′), 78.0 
(C-4′), 75.8 (C-2′), 75.0 (CH2 4′-O-Bn), 74.2 (C-3), 73.2 (CH2 2′-O-Bn and CH2 3′-O-Bn), 69.5 (C-2), 68.8 
(C-6), 66.9 (C-5), 66.5 (C-5′), 25.7 (CH3 Si
t
Bu), 18.1 (Cq Si
t
Bu), 16.2 (C-6′), -4.2 (CH3 SiMea), -4.9 (CH3 
SiMeb); HRMS(ESI) m/z calcld. for [C46H57O9N3Si+Na]
+
: 846.3762, obsd.: 846.3765.  
 
2-Azido-6-O-benzyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-
1-O-tert-butyldimethylsilyl-2-deoxy--D-glucopyranose (26). 
Disaccharide 21 (0.288 g, 0.350 mmol) was coevaporated three 
times with toluene and dissolved in DCM (1.75 mL). The solution 
was stirred for 1 h in the presence of molecular sieves (type 4A) 
under a nitrogen atmosphere. After cooling the solution to 0°C, triethylsilane (0.333 mL, 2.097 mmol, 6.0 
equiv.) was added and the reaction mixture was stirred for 10 mins. TFAA (0.049 mL, 0.350 mmol, 1.0 
equiv.) followed by TFA (0.135 mL, 1.748 mmol, 5.0 equiv.) were then added and the reaction mixture 
was stirred for 30 mins at 0°C. The reaction mixture was allowed to warm to room temperature and stirred 
for a further 2 h. After TLC-analysis (ethyl acetate/toluene, 1/6, v/v) showed completion of the reaction, the 
  91 
reaction mixture was neutralised with sat. aq. NaHCO3 and the aqueous layer extracted twice with DCM. 
The organic layers were combined, dried (MgSO4), filtered and concentrated in vacuo. Purification by 
column chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/7, v/v) yielded 26 as a colourless oil 
(0.225 g, 78%). Rf 0.56 (ethyl acetate/toluene, 1/6, v/v); []D
24
 = -35.4 (c 1.0, CHCl3); IR (thin film): 
3410, 3089, 3064, 3031, 2929, 2857, 2110, 1497, 1454, 1389, 1361, 1311, 1255, 1206, 1170, 1133, 1081, 
1063, 1027, 958, 839, 783, 735, 696 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.40-7.27 (m, 20H, CH arom.), 
5.04 (d, 1H, J1′,2′ = 3.9 Hz, H-1′), 4.99 (d, 1H, Ja,b = 11.2 Hz, CH-a 4′-O-Bn), 4.87 (d, 1H, Ja,b = 12.0 Hz, 
CH-a 3′-O-Bn), 4.78 (d, 1H, Ja,b = 11.7 Hz, CH-a 2′-O-Bn), 4.76 (d, 1H, Ja,b = 11.7 Hz, CH-b 2′-O-Bn), 
4.76 (d, 1H, Ja,b = 12.2 Hz, CH-b 3′-O-Bn), 4.65 (d, 1H, Ja,b = 11.5 Hz, CH-b 4′-O-Bn), 4.61 (d, 1H, Ja,b = 
12.2 Hz, CH-a 6-O-Bn), 4.57 (d, 1H, Ja,b = 12.2 Hz, CH-b 6-O-Bn), 4.50 (d, 1H, J1,2 = 7.6 Hz, H-1), 4.14-
4.09 (m, 2H, H-2′ and H-5′), 3.94 (dd, 1H, J2′,3′ = 10.0, J3′,4′ = 2.7 Hz, H-3′), 3.77 (dd, 1H, J5,6a = 2.5, J6a,6b = 
11.0 Hz, H-6a), 3.67 (s, 1H, H-4′), 3.66 (dd, 1H, J5,6b = 5.6, J6a,6b = 10.7 Hz, H-6b), 3.49 (t, 1H, J3,4 = J4,5 = 
8.8 Hz, H-4), 3.38 (ddd, 1H, J4,5 = 9.6, J5,6a = 2.6, J5,6b = 5.4 Hz, H-5), 3.32 (dd, 1H, J1,2 = 7.6, J2,3 = 10.0 
Hz, H-2), 3.24 (dd, 1H, J2,3 = 10.0, J3,4 = 8.5 Hz, H-3), 1.13 (d, 3H, J5′,6′ = 6.4 Hz, CH3 H-6′), 0.93 (s, 9H, 3 
 CH3 Si
t
Bu), 0.17 (s, 3H, CH3 SiMea), 0.16 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  138.9 (Ci 
arom. 3′-O-Bn), 138.5 (Ci arom. 2′-O-Bn), 138.5 (Ci arom. 4′-O-Bn), 138.4 (Ci arom. 6-O-Bn), 128.6 (CH 
arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 128.0 (CH arom.), 
127.8 (CH arom.), 127.8 (CH arom.), 127.7 (CH arom.), 127.7 (CH arom.), 127.6 (CH arom.), 98.4 (C-1′), 
97.4 (C-1), 85.0 (C-3), 78.8 (C-3′), 77.6 (C-4′), 75.8 (C-2′), 75.1 (C-5), 75.0 (CH2 4′-O-Bn), 73.6 (CH2 6-
O-Bn), 73.3 (2′-O-Bn and 3′-O-Bn), 69.7 (C-6), 69.3 (C-4), 68.1 (C-5′), 67.2 (C-2), 25.8 (CH3 Si
t
Bu), 18.1 
(Cq Si
t
Bu), 16.8 (C-6′), -4.1 (CH3 SiMea), -5.1 (CH3 SiMeb); HRMS(ESI) m/z calcld. For 
[C46H59O9N3Si+Na]
+
: 848.3918, obsd.: 848.3919.  
 
2-Azido-3-O-benzyl-4,6-O-benzylidene-1-O-tert-butyldimethylsilyl-
2-deoxy--D-glucopyranose (49). Glucosazide 23 (1.06 g, 2.60 mmol) 
was coevaporated three times with DMF, on the final co-evaporation 
the solution was concentrated to half volume leaving 13 mL of DMF. 
The solution was placed under a nitrogen atmosphere. After cooling the solution to 0°C, benzyl bromide 
(0.372 mL, 3.13 mmol, 1.2 equiv.), sodium hydride (0.125 g, 60 % in oil, 3.13 mmol, 1.2 equiv.) and TBAI 
(cat.) were added and the reaction mixture was allowed to stir for 2.5 h at room temperature. TLC-analysis 
(ethyl acetate/light petroleum ether, 1/5, v/v) showed completion of the reaction. The reaction mixture was 
quenched with methanol, concentrated in vacuo, dissolved in ethyl acetate, washed with water, sat. aq. 
NaHCO3 and brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/10, v/v) yielded 49 as a colourless oil which 
formed white crystals upon standing (1.11 g, 86%). Rf 0.66 (ethyl acetate/light petroleum ether, 1/5, v/v); 
Mp 100.6-101.5˚C; []D
20
 = -81.5 (c 1.0, CHCl3); IR (thin film): 3091, 3066, 3035, 2956, 2930, 2884, 
2859, 2110, 1454, 1389, 1364, 1256, 1179, 1096, 1003, 919, 841, 784 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  
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7.49-7.47 (m, 2H, CH arom.), 7.40-7.38 (m, 5H, CH arom.), 7.35-7.26 (m, 3H, CH arom.), 5.57 (s, 1H, 
PhCH), 4.91 (d, 1H, Ja,b = 11.2 Hz, CH-a Bn), 4.80 (d, 1H, Ja,b = 11.2 Hz, CH-b Bn), 4.59 (d, 1H, J1,2 = 7.8 
Hz, H-1), 4.30 (dd, 1H, J5,6a = 5.1, J6a,6b = 10.5 Hz, H-6a), 4.08 (t, 1H, J5,6b = J6a,6b = 10.3 Hz, H-6b), 3.72 
(t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4), 3.52 (t, 1H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.39 (td, 1H, J4,5 = J5,6b = 10.0, J5,6a = 
5.1 Hz, H-5), 3.38 (dd, 1H, J1,2 = 7.6, J2,3 = 9.5 Hz, H-2), 0.95 (s, 9H, 3  CH3 Si
t
Bu), 0.17 (s, 3H, CH3 
SiMea), 0.16 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  138.1 (Ci arom. Bn), 137.3 (Ci arom. 
PhCH), 129.2 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.0 (CH arom.), 
126.2 (CH arom.), 101.5 (PhCH), 97.6 (C-1), 81.8 (C-4), 78.9 (C-3), 75.0 (CH2 Bn), 68.9 (C-2), 68.7 (C-6), 
66.5 (C-5), 25.7 (CH3 Si
t
Bu), 18.1 (Cq Si
t
Bu), -4.2 (CH3 SiMea), -5.1 (CH3 SiMeb); HRMS(ESI) m/z calcld. 
for [C26H35O5N3Si+Na]
+
: 520.2244, obsd.: 520.2240. 
 
2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-/-D-glucopyranose (50). 
Glucosazide 49 (0.79 g, 1.59 mmol) was dissolved in THF (18.0 mL) in a 
plastic vial. After addition of HF.pyridine (1.99 mL, 70% in pyridine, 14.1 
mmol, 8.8 eq.), the reaction mixture was left for 22 h. After TLC-analysis 
(ethyl acetate/light petroleum ether, 1/7, v/v) showed complete deprotection, the reaction mixture was 
neutralised with sat. aq. NaHCO3, extracted with ethyl acetate three times, washed with brine, dried 
(MgSO4), filtered and concentrated in vacuo. Purification by column chromatography (ethyl acetate/light 
petroleum ether, 1/10 → 1/3, v/v) yielded lactol 50 as a white amorphous solid upon concentration in vacuo 
(0.63 g, quantitative) as a 1:1 mixture of α- and β-isomers. Rf 0.09 (ethyl acetate/light petroleum ether, 1/7, 
v/v); []D
21
 = -48.1 (c 1.0, CHCl3); IR (thin film): 3403, 3089, 3065, 3034, 2914, 2872, 2110, 1497, 1454, 
1371, 1314, 1277, 1171, 1093, 997, 916, 750, 697 cm
-1
; α-50: 1H-NMR (500 MHz, CDCl3):  7.51-7.47 
(m, 2H, CH arom.), 7.42-7.37 (m, 5H, CH arom.), 7.36-7.28 (m, 3H, CH arom.), 5.60 (s, 1H, PhCH), 5.30 
(t, 1H, JOH,1 = J1,2 = 3.4 Hz, H-1), 4.97 (d, 1H, Ja,b = 11.0 Hz, CH-a Bn), 4.81 (d, 1H, Ja,b = 11.0 Hz, CH-b 
Bn), 4.29 (dd, 1H, J5,6a = 5.1, J6a,6b = 10.3 Hz, H-6a), 4.13 (td, 1H, J4,5 = J5,6b = 9.9, J5,6a = 4.9 Hz, H-5), 
4.11 (t, 1H, J2,3 = J3,4 = 9.5 Hz, H-3), 3.75 (t, 1H, J5,6b = J6a,6b = 10.3 Hz, H-6b), 3.73 (t, 1H, J3,4 = J4,5 = 9.4 
Hz, H-4), 3.50 (ddd, 1H, JOH,2 = 1.2, J1,2 = 3.7, J2,3 = 10.0 Hz, H-2), 2.88 (dd, 1H, JOH,1 = 3.3, JOH,2 = 1.1 
Hz, OH); 
13
C-NMR (125 MHz, CDCl3):  137.9 (Ci arom. Bn), 137.3 (Ci arom. PhCH), 129.2 (CH arom.), 
128.6 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.1 (CH arom.), 126.1 (CH arom.), 101.6 
(PhCH), 92.9 (C-1), 82.9 (C-4), 76.3 (C-3), 75.2 (CH2 Bn), 68.6 (C-6), 63.7 (C-2), 62.9 (C-5); β-50: 
1
H-
NMR (500 MHz, CDCl3):  7.51-7.47 (m, 2H, CH arom.), 7.42-7.37 (m, 5H, CH arom.), 7.36-7.28 (m, 3H, 
CH arom.), 5.59 (s, 1H, PhCH), 4.94 (d, 1H, Ja,b = 11.2 Hz, CH-a Bn), 4.80 (d, 1H, Ja,b = 11.2 Hz, CH-b 
Bn), 4.68 (dd, 1H, JOH,1 = 5.4, J1,2 = 8.0 Hz, H-1), 4.34 (dd, 1H, J5,6a = 5.1, J6a,6b = 10.5 Hz, H-6a), 3.80 (t, 
1H, J5,6b = J6a,6b = 10.3 Hz, H-6b), 3.74 (t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4), 3.62 (t, 1H, J2,3 = J3,4 = 9.4 Hz, H-
3), 3.45 (td, 1H, J4,5 = J5,6b = 9.7, J5,6a = 5.0 Hz, H-5), 3.42 (dd, 1H, J1,2 = 8.1, J2,3 = 9.3 Hz, H-2), 3.36 (d, 
1H, JOH,1 = 5.4 Hz, OH); 
13
C-NMR (125 MHz, CDCl3):  137.8 (Ci arom. Bn), 137.2 (Ci arom. PhCH), 
129.3 (CH arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.1 (CH arom.), 126.1 (CH 
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arom.), 101.5 (PhCH), 96.7 (C-1), 81.7 (C-4), 79.2 (C-3), 75.1 (CH2 Bn), 69.1 (C-6), 67.5 (C-2), 66.6 (C-
5); HRMS(ESI) m/z calcld. for [C20H21O5N3+Na]
+
: 406.1379, obsd.: 406.1381. 
 
2-Azido-3-O-benzyl-4,6-O-benzylidene-2-deoxy-/β-D-
glucopyranosyl trichloroacetimidate (25). Lactol 50 (0.100 g, 0.26 
mmol) was coevaporated three times with toluene and dissolved in 
DCM (1 mL) under a nitrogen atmosphere. After addition of 
molecular sieves (type 4A), trichloroacetonitrile (0.131 mL, 1.30 mmol, 5.0 equiv.) and caesium carbonate 
(cat.), the reaction was stirred for 20 h. After TLC-analysis (ethyl acetate/light petroleum ether, 1/4, v/v) 
showed completion of the reaction, the reaction mixture was filtered, concentrated in vacuo and purified by 
column chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/5, v/v) to yield 25-α as a colourless 
oil and 25-β as a white amorphous solid upon concentration in vacuo (0.1371 g, 99%). The imidate was 
stored in the freezer until it was used. α-25: Rf 0.45 (ethyl acetate/light petroleum ether, 1/4, v/v); IR (thin 
film): 3339, 3090, 3066, 3034, 2934, 2868, 2112, 1674, 1454, 1371, 1281, 1135, 1069, 1019, 988, 910, 
837, 796, 748, 698 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  8.75 (s, 1H, NH), 7.52-7.49 (m, 2H, CH arom.), 
7.43-7.30 (m, 8H, CH arom.), 6.38 (d, 1H, J1,2 = 3.7 Hz, H-1), 5.63 (s, 1H, PhCH), 5.04 (d, 1H, Ja,b = 10.7 
Hz, CH-a Bn), 4.85 (d, 1H, Ja,b = 10.7 Hz, CH-b Bn), 4.35 (dd, 1H, J5,6a = 5.1, J6a,6b = 10.5 Hz, H-6a), 4.19 
(t, 1H, J2,3 = J3,4 = 9.5 Hz, H-3), 4.07 (td, 1H, J4,5 = J5,6b = 10.0, J5,6a = 5.0 Hz, H-5), 3.85 (t, 1H, J3,4 = J4,5 = 
9.5 Hz, H-4), 3.79 (t, 1H, J5,6b = J6a,6b = 10.5 Hz, H-6b), 3.73 (dd, 1H, J1,2 = 3.7, J2,3 = 9.8 Hz, H-2); 
13
C-
NMR (125 MHz, CDCl3):  161.0 (C=N), 137.7 (Ci arom. Bn), 137.0 (Ci arom. PhCH), 129.3 (CH arom.), 
128.6 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.2 (CH arom.), 126.0 (CH arom.), 101.6 
(PhCH), 95.0 (C-1), 90.8 (CCl3), 82.3 (C-4), 76.4 (C-3), 75.4 (CH2 Bn), 68.7 (C-6), 65.3 (C-5), 62.5(C-2); 
β-25: Rf 0.53 (ethyl acetate/light petroleum ether, 1/4, v/v); IR (thin film): 3323, 3088, 3066, 3035, 2920, 
2868, 2853, 2110, 1678, 1453, 1369, 1303, 1279, 1209, 1068, 1027, 914, 837, 804, 735, 695 cm
-1
; 
1
H-NMR 
(500 MHz, CDCl3):  8.77 (s, 1H, NH), 7.50-7.47 (m, 2H, CH arom.), 7.43-7.29 (m, 8H, CH arom.), 5.59 
(s, 1H, PhCH), 5.72-5.70 (m, 1H, H-1), 4.96 (d, 1H, Ja,b = 11.2 Hz, CH-a Bn), 4.83 (d, 1H, Ja,b = 11.2 Hz, 
CH-b Bn), 4.41 (dd, 1H, J5,6a = 4.9, J6a,6b = 10.5 Hz, H-6a), 3.83 (t, 1H, J5,6b = J6a,6b = 10.5 Hz, H-6b), 3.82-
3.78 (m, 1H, H-4), 3.74-3.68 (m, 2H, H-2 and H-3), 3.58 (td, 1H, J4,5 = J5,6b = 10.0, J5,6a = 4.9 Hz, H-5); 
13
C-NMR (125 MHz, CDCl3):  161.1 (C=N), 137.7 (Ci arom. Bn), 137.1 (Ci arom. PhCH), 129.3 (CH 
arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.3 (CH arom.), 128.1 (CH arom.), 126.1 (CH arom.), 
101.6 (PhCH), 96.9 (C-1), 90.5 (CCl3), 81.3 (C-4), 79.2 (C-3), 75.2 (CH2 Bn), 68.5(C-6), 67.1 (C-5), 65.7 
(C-2). 
 
2-Azido-4-O-(2-azido-3-O-benzyl-4,6-O-
benzylidene-2-deoxy--D-glucopyranosyl)-3,6-di-O-
benzyl-1-O-tert-butyldimethylsilyl-2-deoxy--D-
glucopyranose (53). Glucosazide acceptor 52 (0.050 
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g, 0.100 mmol) and acetimidate donor 25 (0.109g, 0.200 mmol, 2.0 equiv.) were coevaporated three times 
with toluene and dissolved in acetonitrile (1.0 mL) under a nitrogen atmosphere. The solution was stirred 
for 1 h in the presence of molecular sieves (type 4A). After cooling the solution to 0°C, TMSOTf (0.0018 
mL or 1.8 μL, 0.010 mmol, 0.1 equiv.) was added dropwise and the reaction mixture was stirred for 30 
mins. The reaction mixture was allowed to warm to room temperature and stirred for a further 18 h. After, 
TLC-analysis (ethyl acetate/light petroleum ether, 1/5, v/v) showed completion of the reaction, the reaction 
mixture was quenched with triethylamine (0.1 mL), diluted with ethyl acetate, washed with sat. aq. 
NaHCO3, brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/10, v/v) yielded disaccharide 53 as a 1:2.8 
mixture of α- and β-isomers as a colourless oil (0.019 g, 23%). The α- and β-isomers were separated by 
column chromatography (DCM) (α-Rf 0.37 (DCM), β-Rf 0.18 (DCM)). Rf 0.48 (ethyl acetate/light 
petroleum ether, 1/5, v/v); []D
24
 = -43.6 (c 1.0, CHCl3); IR (thin film): 3066, 3034, 2927, 2857, 2110, 
1497, 1455, 1363, 1275, 1219, 1171, 1094, 1068, 1029, 1003, 965, 840, 773, 697 cm
-1
; 
1
H-NMR (500 
MHz, CDCl3):  7.48-7.46 (m, 2H, CH arom.), 7.41-7.28 (m, 18H, CH arom.), 5.49 (s, 1H, PhCH), 4.90 (d, 
1H, Ja,b = 11.0 Hz, CH-a 3′-O-Bn), 4.85 (d, 1H, Ja,b = 10.7 Hz, CH-a 3-O-Bn), 4.76 (d, 1H, Ja,b = 11.5 Hz, 
CH-b 3′-O-Bn), 4.74 (d, 1H, Ja,b = 11.2 Hz, CH-b 3-O-Bn), 4.70 (d, 1H, Ja,b = 12.2 Hz, CH-a 6-O-Bn), 4.51 
(d, 1H, Ja,b = 12.0 Hz, CH-b 6-O-Bn), 4.50 (d, 1H, J1,2 = 7.6 Hz, H-1), 4.41 (d, 1H, J1′,2′ = 8.1 Hz, H-1′), 
4.12 (dd, 1H, J5′,6a′ = 5.1, J6a′,6b′ = 10.5 Hz, H-6a′), 4.06-4.02 (m, 1H, H-4), 3.93 (dd, 1H, J5,6a = 3.3, J6a,6b = 
11.4 Hz, H-6a), 3.73 (dd, 1H, J5,6b = 1.6, J6a,6b = 11.1 Hz, H-6b), 3.60 (t, 1H, J3′,4′ = J4′,5′ = 9.3 Hz, H-4′), 
3.44 (t, 1H, J5′,6b′ = J6a′,6b′ = 10.4 Hz, H-6b′), 3.43 (t, 1H, J2′,3′ = J3′,4′ = 9.2 Hz, H-3′), 3.41 (ddd, 1H, J4,5 = 
9.8, J5,6b = 1.7, J5,6a = 3.2 Hz, H-5), 3.35-3.30 (m, 2H, H-2 and H-3), 3.34 (dd, 1H, J1′,2′ = 8.3, J2′,3′ = 9.5 Hz, 
H-2′), 3.10 (td, 1H, J4′,5′ = J5′,6b′ = 9.6, J5′,6a′ = 5.0 Hz, H-5′), 0.94 (s, 9H, 3  CH3 Si
t
Bu), 0.17 (s, 3H, CH3 
SiMea), 0.16 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  138.7 (Ci arom. 3-O-Bn), 138.2 (Ci 
arom. 6-O-Bn), 138.0 (Ci arom. 3′-O-Bn), 137.4 (Ci arom. PhCH), 129.2 (CH arom.), 128.6 (CH arom.), 
128.6 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.1 (CH arom.), 128.0 (CH 
arom.), 128.0 (CH arom.), 127.9 (CH arom.), 127.8 (CH arom.), 126.2 (CH arom.), 101.5 (PhCH), 101.4 
(C-1′), 97.3 (C-1), 81.9 (C-4′), 81.2 (C-3), 79.4 (C-3′), 76.6 (C-4), 75.3 (CH2 3-O-Bn), 75.1 (C-5), 75.0 
(CH2 3′-O-Bn), 73.7 (CH2 6-O-Bn), 68.7 (C-6′), 68.5 (C-2), 68.3 (C-6), 66.9 (C-2′), 66.2 (C-5′), 25.8 (CH3 
Si
t
Bu), 18.2 (Cq Si
t
Bu), -4.1 (CH3 SiMea), -4.9 (CH3 SiMeb); HRMS(ESI) m/z calcld. for 
[C46H56O9N6Si+Na]
+
: 887.3776, obsd.: 887.3767. 
 
3-O-Benzyl-4,6-O-benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy-
2-(2,2,2-trichloroethoxycarbonylamido)--D-glucopyranose (54). 
Glucosazide 49 (0.0356 g, 0.0715 mmol) was dissolved in THF (3.60 
mL). Sodium hydroxide (0.50 mL, 1M (aq), 0.50 mmol, 7 equiv.) and trimethyl phosphine (0.43 mL, 1M in 
THF, 0.43 mmol, 6 equiv.) was added and the reaction mixture was stirred for 2 h at room temperature. 
After TLC-analysis (ethyl acetate/light petroleum ether, 1/5, v/v) showed complete reduction of the azide 
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starting material, 2,2,2-trichloroethyl chloroformate (0.050 mL, 0.363 mmol, 5 equiv.) was added and the 
reaction mixture was then stirred for a further 3 h, with extra 2,2,2-trichloroethyl chloroformate (0.050 mL, 
0.363 mmol, 5 equiv.) added after 2.5 h. When TLC-analysis (ethyl acetate/light petroleum ether, 1/5, v/v) 
showed completion of the reaction the reaction mixture was washed with sat. aq. NaHCO3 and brine, dried 
(MgSO4), filtered and concentrated in vacuo.  Purification by column chromatography (ethyl acetate/light 
petroleum ether, 1/30 → 1/20, v/v) yielded 54 as a colourless oil (0.0364 g, 79%). Rf 0.35 (ethyl 
acetate/light petroleum ether, 1/5, v/v); []D
18
 = -40.2 (c 1.0, CHCl3); IR (thin film): 3338, 3066, 3034, 
2954, 2930, 2858, 1717, 1541, 1498, 1453, 1388, 1320, 1282, 1248, 1182, 1128, 1084, 1013, 978, 912, 
839, 783, 733, 696 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.51-7.49 (m, 2H, CH arom.), 7.42-7.36 (m, 3H, 
CH arom.), 7.32-7.27 (m, 5H, CH arom.), 5.58 (s, 1H, PhCH), 5.03 (d, 1H, J2,NH = 6.9 Hz, NH), 4.93 (d, 
1H, J1,2 = 7.8 Hz, H-1), 4.90 (d, 1H, Ja,b = 11.7 Hz, CH-a Bn), 4.71-4.63 (m, 3H, CH-b Bn, CH-a Troc, and 
CH-b Troc), 4.31 (dd, 1H, J5,6a = 4.9, J6a,6b = 10.5 Hz, H-6a), 3.99 (t, 1H, J2,3 = J3,4 = 8.8 Hz, H-3), 3.81 (t, 
1H, J5,6b = J6a,6b = 10.2 Hz, H-6b), 3.75 (t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4), 3.47 (td, 1H, J4,5 = J5,6b = 9.7, J5,6a 
= 5.1 Hz, H-5), 3.33 (q, 1H, J1,2 = J2,3 = J2,NH = 8.3 Hz, H-2), 0.88 (s, 9H, 3  CH3 Si
t
Bu), 0.10 (s, 3H, CH3 
SiMea), 0.08 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  154.0 (C=O Troc), 138.3 (Ci arom. Bn), 
137.5 (Ci arom. PhCH), 129.2 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 127.9 
(CH arom.), 126.2 (CH arom.), 101.4 (PhCH), 96.1 (C-1), 95.5 (CCl3 Troc), 82.8 (C-4), 76.3 (C-3),  74.7 
(CH2 Troc), 74.4 (CH2 Bn), 68.9 (C-6), 66.2 (C-5), 60.2 (C-2), 25.7 (CH3 Si
t
Bu), 18.0 (Cq Si
t
Bu), -4.1 (CH3 
SiMea), -5.2 (CH3 SiMeb); HRMS(ESI) m/z calcld. for [C29H38O7N1SiCl3+Na]
+
: 668.1381, obsd.: 668.1379. 
 
3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)-/-D-glucopyranose (55). 
Monosaccharide 54 (0.126 g, 0.194 mmol) was dissolved in THF (1.0 mL) in 
a plastic vial. After addition of HF.pyridine (0.242 mL, 70% in pyridine, 1.79 mmol, 8.8 eq.), the reaction 
mixture was left for 18 h. After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed 
complete deprotection, the reaction mixture was neutralised with sat. aq. NaHCO3, extracted with DCM 
three times, washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/2, v/v) yielded lactol 55 as a white 
amorphous solid upon concentration in vacuo (0.0932 g, 90%). Rf 0.40 and 0.34 (ethyl acetate/light 
petroleum ether, 1/1, v/v); []D
21
 = -31.1 (c 1.0, CHCl3); IR (thin film): 3598, 3309, 3065, 3034, 2922, 
2870, 1712, 1546, 1497, 1453, 1368, 1308, 1283, 1245, 1172, 1126, 1089, 1030, 1016, 984, 968, 914, 817, 
775, 745, 695 cm
-1
; (NMR data given for the α-anomer only, as only trace amounts of the β-anomer were 
detectable) 
1
H-NMR (500 MHz, CDCl3):  7.52-7.50 (m, 2H, CH arom.), 7.42-7.27 (m, 8H, CH arom.), 
5.60 (s, 1H, PhCH), 5.26 (t, 1H, JOH,1 = J1,2 = 3.4 Hz, H-1), 5.19 (d, 1H, J2,NH = 9.5 Hz, NH), 4.93 (d, 1H, 
Ja,b = 11.9 Hz, CH-a Bn), 4.79 (d, 1H, Ja,b = 11.9 Hz, CH-a Troc), 4.70 (d, 1H, Ja,b = 12.2 Hz, CH-b Bn), 
4.68 (d, 1H, Ja,b = 12.0 Hz, CH-b Troc), 4.28 (dd, 1H, J5,6a = 4.9, J6a,6b = 10.2 Hz, H-6a), 4.06 (td, 1H, J4,5 = 
J5,6b = 9.7, J5,6a = 4.9 Hz, H-5), 3.97 (td, 1H,  J1,2 = 3.4, J2,3 = J2,NH = 9.5 Hz, H-2), 3.82-3.75 (m, 3H, H-3, 
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H-4, and H-6b), 3.12 (d, 1H, JOH,1 = 2.4, OH); 
13
C-NMR (125 MHz, CDCl3):  154.6 (C=O Troc), 138.3 (Ci 
arom. Bn), 137.4 (Ci arom. PhCH), 129.2 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.1 (CH 
arom.), 127.9 (CH arom.), 126.1 (CH arom.), 101.5 (PhCH), 95.5 (CCl3 Troc), 92.8 (C-1), 83.0 (C-4), 75.6 
(C-3), 74.9 (CH2 Troc), 74.5 (CH2 Bn), 69.1 (C-6), 62.9 (C-5), 55.2 (C-2); HRMS(ESI) m/z calcld. for 
[C23H24O7N+Na]
+
: 554.0516, obsd.: .554.0516 
 
3-O-Benzyl-4,6-O-benzylidene-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranosyl 
trichloroacetimidate (56). Lactol 55 (0.0923 g, 0.173 mmol) was 
coevaporated three times with toluene and dissolved in DCM (1.4 mL) 
under a nitrogen atmosphere. The solution was stirred for 30 mins in the presence of molecular sieves (type 
4A). Trichloroacetonitrile (0.279 mL, 2.78 mmol, 16.0 equiv.) and caesium carbonate (cat.) were added and 
the reaction was stirred for 6 h. After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed 
completion of the reaction, the reaction mixture was filtered and purified directly by column 
chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/1, v/v) to yield 56 as a colourless oil (0.116 
g, 99%). The imidate was stored in the freezer until it was used.  Rf 0.61 (ethyl acetate/light petroleum 
ether, 1/1, v/v); IR (thin film): 3427, 3337, 3067, 3033, 2931, 2869, 1734, ,1675, 1515, 1453, 1379, 1279, 
1140, 1084, 1066, 1026, 967, 907, 823, 794, 731, 697, 673 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  8.68 (s, 
1H, NH Imidate), 7.53-7.51 (m, 2H, CH arom.), 7.43-7.28 (m, 8H, CH arom.), 6.35 (d, 1H, J1,2 = 3.7 Hz, 
H-1), 5.64 (s, 1H, PhCH), 5.00 (d, 1H, Ja,b = 11.7 Hz, CH-a Bn), 4.75 (d, 1H, Ja,b = 11.9 Hz, CH-a Troc), 
4.72 (d, 1H, Ja,b = 12.0 Hz, CH-b Bn), 4.71 (d, 1H, J2,NH = 8.8 Hz, NH Troc), 4.68 (d, 1H, Ja,b = 12.0Hz, 
CH-b Troc), 4.35 (dd, 1H, J5,6a = 4.9, J6a,6b = 10.3 Hz, H-6a), 4.16 (dd, 1H, J1,2 = 3.4, J2,3 = J2,NH = 9.7 Hz, 
H-2), 3.98 (td, 1H, J4,5 = J5,6b = 9.8, J5,6a = 4.9 Hz, H-5), 3.90-3.83 (m, 2H, H-3 and H-4), 3.81 (t, 1H, J5,6b = 
J6a,6b = 10.2 Hz, H-6b); 
13
C-NMR (125 MHz, CDCl3):  160.7 (C=N), 154.3 (C=O Troc), 137.8 (Ci arom. 
Bn), 137.1 (Ci arom. PhCH), 129.3 (CH arom.), 128.7 (CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 
128.3 (CH arom.), 126.1 (CH arom.), 101.5 (PhCH), 95.7 (C-1), 95.4 (CCl3 Troc), 90.9 (CCl3 Imidate), 
82.2 (C-4), 74.8 (CH2 Troc), 74.6 (CH2 Bn), 74.5 (C-3), 68.7 (C-6), 65.6 (C-5), 54.6 (C-2); HRMS(ESI) 
m/z calcld. for [C25H24O7N2Cl6+Na]
+
: 696.9612, obsd.: 696.9605 
 
2-Azido-3,6-di-O-benzyl-4-O-[3-O-benzyl-4,6-O-
benzylidene-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-
glucopyranosyl]-1-O-tert-butyldimethylsilyl-2-
deoxy--D-glucopyranose (57). Glucosazide acceptor 52 (0.042 g, 0.084 mmol) and acetimidate donor 56 
(0.105g, 0.155 mmol, 1.8 equiv.) were coevaporated three times with toluene and dissolved in DCM (0.5 
mL) under a nitrogen atmosphere. The solution was stirred for 30 mins in the presence of molecular sieves 
(type 4A). After cooling the solution to -40°C, TMSOTf (0.0015 mL or 1.5 μL, 0.010 mmol, 0.1 equiv.) 
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was added dropwise and the reaction mixture was allowed to warm slowly to -10°C over 1 h 15 mins with 
stirring. After, TLC-analysis (ethyl acetate/light petroleum ether, 1/3, v/v) showed completion of the 
reaction, the reaction mixture was quenched with triethylamine (0.1 mL), diluted with ethyl acetate, washed 
with sat. aq. NaHCO3, brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/5, v/v) yielded disaccharide 57 as a 
colourless oil (0.063 g, 74%). Rf 0.41 (ethyl acetate/light petroleum ether, 1/3, v/v); IR (thin film): 3353, 
3065, 3033, 2929, 2859, 2111, 1713, 1539, 1497, 1454, 1386, 1369, 1313, 1252, 1172, 1064, 1028, 1010, 
957, 912, 838, 783, 733, 694 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.50-7.48 (m, 2H, CH arom.), 7.41-7.28 
(m, 17H, CH arom.), 7.12 (t, 1H, Ja,b = 6.9 Hz, CH arom.), 5.48 (s, 1H, PhCH), 4.87 (d, 2H, Ja,b = 11.4 Hz, 
CH-a 3′-O-Bn and CH-a 3-O-Bn), 4.80 (d, 1H, Ja,b = 12.2 Hz, CH-a 6-O-Bn), 4.78 (d, 1H, Ja,b = 12.2 Hz, 
CH-a Troc), 4.73 (d, 1H, Ja,b = 11.0 Hz, CH-b 3-O-Bn), 4.65 (d, 2H, Ja,b = 12.0Hz, CH-b Troc and CH-b 3′-
O-Bn), 4.45 (d, 1H, J1,2 = 7.4 Hz, H-1), 4.35 (d, 1H, Ja,b = 11.9 Hz, CH-b 6-O-Bn), 4.35 (d, 1H, J1′,2′ = 8.5 
Hz, H-1′), 4.08 (dd, 1H, J5′,6a′ = 4.9, J6a′,6b′ = 10.2 Hz, H-6a′), 3.93 (t, 1H, J3,4 = J4,5 = 9.8 Hz, H-4), 3.73 (dd, 
1H, J5,6a = 2.7, J6a,6b = 11.5 Hz, H-6a), 3.60 (t, 1H, J3′,4′ = J4′,5′ = 9.3 Hz, H-4′), 3.53-3.46 (m, 2H, H-6b and 
H-2′), 3.38-3.26 (m, 5H, H-2, H-3, H-5, H-3′, and H-6b′), 3.16 (td, 1H, J4′,5′ = J5′,6b′ = 9.8, J5′,6a′ = 4.9 Hz, H-
5′), 0.94 (s, 9H, 3  CH3 Si
t
Bu), 0.16 (s, 3H, CH3 SiMea), 0.15 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, 
CDCl3):  154.2 (C=O Troc), 138.7 (Ci arom. 3-O-Bn), 138.3 (Ci arom. 3′-O-Bn), 137.8 (Ci arom. 6-O-Bn), 
137.3 (Ci arom. PhCH), 129.4 (CH arom.), 129.2 (CH arom.), 129.0 (CH arom.), 128.5 (CH arom.), 128.5 
(CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.0 (CH arom.), 128.0 (CH arom.), 127.7 (CH arom.), 
127.6 (CH arom.), 126.1 (CH arom.), 101.2 (PhCH), 101.1 (C-1′), 97.4 (C-1), 95.7 (CCl3 Troc), 82.3 (C-
4′), 81.1 (C-3), 77.7 (C-3′), 76.7 (C-4), 75.2 (CH2 3-O-Bn), 74.7 (CH2 Troc), 74.5 (C-5), 74.2 (CH2 3′-O-
Bn), 73.7 (CH2 6-O-Bn), 68.7 (C-6′), 68.4 (C-2), 67.7 (C-6), 65.7 (C-5′), 57.8 (C-2′), 25.8 (CH3 Si
t
Bu), 
18.2 (Cq Si
t
Bu), -4.1 (CH3 SiMea), -5.0 (CH3 SiMeb); HRMS(ESI) m/z calcld. for [C49H59O11N4Cl3Si+Na]
+
: 
1035.2913, obsd.: 1035.2908. 
 
2-Azido-6-O-benzyl-3-O-(2,3,4-tri-O-benzyl-α-L-
fucopyranosyl)-4-O-[3-O-benzyl-4,6-O-benzylidene-
2-deoxy-2-(2,2,2-trichloroethoxycarbonylamido)--
D-glucopyranosyl]-1-O-tert-butyldimethylsilyl-2-
deoxy--D-glucopyranose (58). Glucosazide acceptor 
26 (0.0781 g, 0.0948 mmol) and acetimidate donor 56 (0.0946 g, 0.140 mmol, 1.47 equiv.) were 
coevaporated three times with toluene and dissolved in DCM (0.50 mL) under a nitrogen atmosphere. After 
cooling the solution to -40°C, TMSOTf (0.0017 mL or 1.7 μL, 0.0095 mmol, 0.1 equiv.) was added 
dropwise and the reaction mixture was stirred for 1 h. After, TLC-analysis (ethyl acetate/light petroleum 
ether, 1/5, v/v) showed completion of the reaction, the reaction mixture was quenched with triethylamine 
(0.1 mL) at -40°C. The reaction mixture was then diluted with ethyl acetate and washed with sat. aq. 
NaHCO3 and brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
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chromatography (ethyl acetate/light petroleum ether, 1/15 → 1/5, v/v) yielded trisaccharide 58 as a 
colourless oil (0.0907 g, 72%). Rf 0.65 (ethyl acetate/light petroleum ether, 1/2, v/v); []D
20
 = -37.5 (c 1.0, 
CHCl3); IR (thin film): 3387, 3064, 3031, 2950, 2929, 2859, 2111, 1732, 1605, 1524, 1497, 1454, 1363, 
1311, 1256, 1216, 1169, 1097, 1066, 1041, 1029, 1010, 839, 750, 736, 697 cm
-1
; 
1
H-NMR (500 MHz, 
CDCl3):  7.51-7.17 (m, 30H, CH arom.), 5.55 (d, 1H, J1′,2′ = 3.7 Hz, H-1′), 5.34 (s, 1H, PhCH), 5.05 (d, 
1H, Ja,b = 11.5 Hz, CH-a 4′-O-Bn), 4.99 (d, 1H, Ja,b = 12.2 Hz, CH-a 3′-O-Bn), 4.87 (d, 1H, Ja,b = 11.9 Hz, 
CH-a 2′-O-Bn), 4.83 (d, 1H, Ja,b = 12.0 Hz, CH-a 3″-O-Bn), 4.81 (d, 1H, Ja,b = 12.7 Hz, CH-b 3′-O-Bn), 
4.79 (d, 1H, Ja,b = 12.2 Hz, CH-a 6-O-Bn), 4.78 (d, 1H, Ja,b = 12.0 Hz, CH-b 2′-O-Bn), 4.73 (d, 1H, Ja,b = 
11.9 Hz, CH-a Troc), 4.71 (d, 1H, Ja,b = 11.5 Hz, CH-b 4′-O-Bn), 4.67 (d, 1H, Ja,b = 12.0 Hz, CH-b Troc), 
4.62 (d, 1H, Ja,b = 11.7 Hz, CH-b 3″-O-Bn), 4.58 (q, 1H, J5,6 = 6.6 Hz, H-5′), 4.54 (d, 1H, J1,2 = 7.5 Hz, H-
1), 4.41 (d, 1H, J1″,2″ = 7.9 Hz, H-1″), 4.36 (d, 1H, Ja,b = 12.0 Hz, CH-b 6-O-Bn), 4.24 (dd, 1H, J5″,6a″ = 4.9, 
J6a″,6b″ = 10.2 Hz, H-6a″), 4.12 (dd, 1H, J1′,2′ = 3.9, J2′,3′ = 10.3 Hz, H-2′), 4.04 (d, 1H, J2″,NH = 6.8 Hz, NH), 
3.97 (t, 1H, J3,4 = J4,5 = 9.5 Hz, H-4), 3.92 (dd, 1H, J2′,3′ = 10.2, J3′,4′ = 2.7 Hz, H-3′), 3.73 (dd, 1H, J5,6a = 
2.2, J6a,6b = 11.0 Hz, H-6a), 3.69 (s, 1H, H-4′), 3.57 (t, 1H, J2,3 = J3,4 = 9.8 Hz, H-3), 3.50 (d, 1H, J6a,6b = 
11.3 Hz, H-6b), 3.47 (dd, 1H, J1,2 = 7.9, J2,3 = 10.3 Hz, H-2), 3.37-3.25 (m, 5H, H-5, H-2″, H-3″, H-4″, and 
H-6″b), 3.13 (td, 1H, J4″,5″ = J5″,6b″ = 9.5, J5″,6a″ = 4.9 Hz, H-5″), 1.23 (d, 3H, J5′,6′ = 6.6 Hz, CH3 H-6′), 0.95 
(s, 9H, 3  CH3 Si
t
Bu), 0.17 (s, 3H, CH3 SiMea), 0.16 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  
153.9 (C=O Troc), 139.4 (Ci arom. 3′-O-Bn), 138.9 (Ci arom. 4′-O-Bn), 138.4 (Ci arom. 2′-O-Bn), 138.2 
(Ci arom. 3″-O-Bn), 137.6 (Ci arom. 6-O-Bn), 137.2 (Ci arom. PhCH), 129.2 (CH arom.), 129.0 (CH 
arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 
128.3 (CH arom.), 128.0 (CH arom.), 127.7 (CH arom.), 127.6 (CH arom.), 127.5 (CH arom.), 126.9 (CH 
arom.), 126.1 (CH arom.), 101.2 (PhCH), 100.6 (C-1″), 97.7 (C-1), 96.8 (C-1′), 95.7 (CCl3 Troc), 82.6 (C-
4″), 79.4 (C-3′), 79.3 (C-4′), 77.8 (C-3″), 76.3 (C-2′), 75.2 (CH2 4′-O-Bn), 74.8 (C-5), 74.6 (CH2 Troc), 
74.5 (C-3), 74.3 (CH2 3″-O-Bn), 74.0 (C-4), 73.9 (CH2 6-O-Bn), 73.2 (CH2 3′-O-Bn), 73.2 (CH2 2′-O-Bn), 
68.8 (C-6″), 68.6 (C-2), 68.0 (C-6), 66.2 (C-5′), 65.6 (C-5″), 57.5 (C-2″), 25.8 (CH3 Si
t
Bu), 18.1 (Cq Si
t
Bu), 
16.9 (C-6′), -4.2 (CH3 SiMea), -4.9 (CH3 SiMeb); HRMS(ESI) m/z calcld. for [C69H81O15N4Cl3Si+Na]
+
: 
1361.4431 obsd.: 1361.4424. 
 
4,6-O-Benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranose (59). 
Glucosazide 23 (0.086 g, 0.212 mmol) was coevaporated three times 
with toluene and dissolved in THF (1.21 mL). After cooling the solution to 0°C, trimethyl phosphine (1.21 
mL, 1M in THF, 1.21 mmol, 5 equiv.) was added and the reaction mixture was stirred for 10 mins at 0°C 
and a further 1 h at room temperature. After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) 
showed complete reduction of the azide, 2,2,2-trichloroethyl chloroformate (0.058 mL, 0.424 mmol, 2 
equiv.) and sodium hydroxide 1M (aq) (reaction solution pH ≈ 8) were added and the reaction mixture was 
stirred for another 23 h. Additional 2,2,2-trichloroethyl chloroformate (0.015 mL, 0.106 mmol, 0.5 equiv.), 
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(0.015 mL, 0.106 mmol, 0.5 equiv.), (0.029 mL, 0.212 mmol, 1 equiv.) and sodium hydroxide 1M (aq) (to 
adjust reaction solution to pH ≈ 8) were added after 2 h, 5 h, and 22.5 h respectively. After TLC-analysis 
(ethyl acetate/light petroleum ether, 1/1, v/v) showed completion of the reaction, the reaction mixture was 
neutralised with sat. aq. NaHCO3 and brine, dried (MgSO4), filtered and concentrated in vacuo. Purification 
by column chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/5, v/v) yielded pure 59 as a 
colourless oil (0.072 g, 61%). Rf 0.60 (ethyl acetate/light petroleum ether, 1/1, v/v); []D
22
 = -24.3 (c 1.0, 
CHCl3); IR (thin film): 3358, 3325, 3065, 3032, 2929, 2857, 1721, 1538, 1497, 1454, 1387, 1361, 1308, 
1250, 1173, 1093, 1040, 1028, 1012, 916, 839, 783, 733, 697 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.50-
7.48 (m, 2H, CH-m arom.), 7.40-7.36 (m, 3H, CH-o and CH-p arom.), 5.54 (s, 1H, PhCH), 5.16 (d, 1H, 
J2,NH = 8.1 Hz, NH), 4.86 (d, 1H, J1,2 = 7.5 Hz, H-1), 4.73 (d, 1H, Ja,b = 12.0 Hz, CH-a Troc), 4.67 (d, 1H, 
Ja,b = 11.9 Hz, CH-b Troc), 4.30 (dd, 1H, J5,6a = 5.2, J6a,6b = 10.5 Hz, H-6a), 3.78 (t, 1H, J5,6b = J6a,6b = 
10.3Hz, H-6b), 4.05 (t, 1H, J2,3 = J3,4 = 9.3 Hz, H-3), 3.57 (t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4), 3.47 (td, 1H, J4,5 
= J5,6b = 9.8, J5,6a = 4.9 Hz, H-5), 3.37 (q, 1H, J1,2 = J2,3 = J2,NH = 8.0 Hz, H-2), 0.89 (s, 9H, 3  CH3 Si
t
Bu), 
0.12 (s, 3H, CH3 SiMea), 0.11 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  154.6 (C=O Troc), 
137.2 (Ci arom.), 129.5 (CH-p arom.), 128.5 (CH-o arom.), 126.6 (CH-m arom.), 102.0 (PhCH), 96.3 (C-1), 
95.3 (CCl3 Troc), 81.6 (C-4), 74.9 (CH2 Troc), 70.8 (C-3), 68.8 (C-6), 66.3 (C-5), 60.8 (C-2), 25.7 (CH3 
Si
t
Bu), 18.0 (Cq Si
t
Bu), -4.0 (CH3 SiMea), -5.1 (CH3 SiMeb); HRMS(ESI) m/z calcld. for 
[C22H32O7NCl3Si+Na]
+
: 578.0911, obsd.: 578.0918. 
 
2-Amino-4,6-O-benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy--
D-glucopyranose (60). Glucosazide 23 (0.099 g, 0.242 mmol) was 
coevaporated three times with toluene and dissolved in THF (1.21 
mL). After cooling the solution to 0°C, trimethyl phosphine (1.21 mL, 1M in THF, 1.21 mmol, 5 equiv.) 
was added and the reaction mixture was stirred for 10 mins at 0°C and a further 2 h at room temperature. 
After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed completion of the reaction, 
sodium hydroxide (1.21 mL, 1M (aq), 1.21 mmol, 5 equiv.) was added and the reaction mixture was stirred 
for 5 mins and was then washed with sat. aq. NaHCO3, then water and brine, dried (MgSO4), filtered and 
concentrated in vacuo to yield crude amine 60 (0.0924 g) which was then used without further purification. 
 
4,6-O-Benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranose (59). Crude 
glucosamine 60 (0.0427 g, 0.112 mmol) was dissolved in pyridine (1.0 
mL) and 2,2,2-trichloroethyl chloroformate (0.042 mL, 0.303 mmol, 2.5 equiv.) was added and the reaction 
mixture was stirred for 1 h 40 mins. After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) 
showed completion of the reaction, MeOH was added and the reaction mixture was concentrated in vacuo. 
Purification by column chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/5, v/v) yielded pure 
59 as a colourless oil (0.031 g, 46% over 2 steps). (4,6-O-benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy-
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3-O-(2,2,2-trichloroethoxycarbonyl)-2-(2,2,2-trichloroethoxycarbonylamido)--D-glucopyranose (61), was 
also isolated, 0.022g, 25% over 2 steps). Characterisation is as above. 
 
4,6-O-Benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranose (59). Crude 
glucosamine 60 (0.0497 g, 0.130 mmol) was dissolved in DCM (1.0 
mL). Diisopropylethylamine (0.045 mL, 0.260 mmol, 2 equiv.) and 2,2,2-trichloroethyl chloroformate 
(0.027 mL, 0.195 mmol, 1.5 equiv.) were added and the reaction mixture was stirred for 1 h 15 mins. After 
TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed completion of the reaction, MeOH was 
added and the reaction mixture was concentrated in vacuo. Purification by column chromatography (ethyl 
acetate/light petroleum ether, 1/20 → 1/5, v/v) yielded pure 59 as a colourless oil (0.053 g, 73% over 2 
steps). Characterisation is as above. 
 
3-O-(2,3,4-Tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-benzylidene-
1-O-tert-butyldimethylsilyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranose (62). N-Troc 
protected acceptor 59 (0.0240 g, 0.0431 mmol) and thiofucoside 
donor 22 (0.0371 g, 0.0776 mmol, 1.8 equiv.) were coevaporated 
three times with DMF, on the final time the solution was coevaporated to half volume leaving 0.35 mL of 
DMF. DCM (0.35 mL) was added and the solution stirred for 45 mins in the presence of molecular sieves 
(type 4A) under a nitrogen atmosphere. Tetrapropylammonium bromide (0.0367 g, 0.138 mmol, 3.2 equiv.) 
was added and to solution stirred for 1 h before copper(II) bromide (0.0308 g, 0.138 mmol, 3.2 equiv.) was 
added and stirring was continued for another 70 h. After TLC-analysis (ethyl acetate/light petroleum ether, 
1/4, v/v) showed completion of the reaction, the reaction mixture was neutralised with sat. aq. NaHCO3 and 
the aqueous layer extracted twice with ethyl acetate. The organic layers were combined, washed with sat 
aq. NH4Cl, and brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/20 → 1/5, v/v) yielded disaccharide 62 as a 
colourless oil (0.0242 g, 58%, α:β, 16.8:1). The α and β anomers were separated by column 
chromatography (DCM). Rf 0.30 (ethyl acetate/light petroleum ether, 1/4, v/v); []D
24
 = -51 (c 0.1, 
CHCl3); IR (thin film): 3361, 3064, 3032, 2928, 2857, 1739, 1533, 1498, 1455, 1389, 1363, 1341, 1312, 
1250, 1160, 1101, 1046, 1029, 914, 840, 783, 737, 698 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.45-7.24 (m, 
20H, CH arom.), 5.48 (s, 1H, PhCH), 5.24 (d, 1H, J2, NH = 7.4 Hz, NH), 5.15 (d, 1H, J1′,2′ = 3.4 Hz, H-1′), 
4.98 (d, 1H, J1,2 = 7.8 Hz, H-1), 4.91 (d, 1H, Ja,b = 11.4 Hz, CH-a 4′-O-Bn), 4.85 (d, 1H, Ja,b = 11.2 Hz, CH-
a 2′-O-Bn), 4.84 (d, 1H, Ja,b = 11.5 Hz, CH-a 3′-O-Bn), 4.73 (d, 1H, Ja,b = 11.7 Hz, CH-b 3′-O-Bn), 4.71 (d, 
1H, Ja,b = 11.3 Hz, CH-a Troc), 4.67 (d, 1H, Ja,b = 11.2 Hz, CH-b 2′-O-Bn), 4.58 (d, 1H, Ja,b = 11.5 Hz, CH-
b 4′-O-Bn), 4.52 (d, 1H, Ja,b = 12.0 Hz, CH-b Troc), 4.28 (dd, 1H, J5,6a = 4.8, J6a,6b = 10.4 Hz, H-6a), 4.22 
(t, 1H, J2,3 = J3,4 = 9.8 Hz, H-3), 4.07 (q, 1H, J5′,6′ = 6.3 Hz, H-5′), 4.05 (dd,  1H, J1′,2′ = 3.6, J2′,3′ = 10.0 Hz, 
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H-2′), 3.92 (dd, 1H, J2′,3′ = 10.2, J3′,4′ = 2.6 Hz, H-3′), 3.75 (t, 1H, J5,6b = J6a,6b = 10.3 Hz, H-6b), 3.60 (t, 1H, 
J3,4 = J4,5 = 9.3 Hz, H-4), 3.56 (d, 1H, J3′,4′ = 1.7 Hz, H-4′), 3.47-3.43 (m, 1H, H-5), 3.20 (q, 1H, J1,2 = J2,3 = 
J2, NH = 8.0 Hz, H-2), 0.85 (s, 9H, 3  CH3 Si
t
Bu), 0.80 (d, 3H, J5′,6′ = 6.4 Hz, CH3 H-6′), 0.06 (s, 3H, CH3 
SiMea), 0.04 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  153.9 (C=O Troc), 139.0 (Ci arom. 3′-O-
Bn), 138.7 (Ci arom. 4′-O-Bn), 138.6 (Ci arom. 2′-O-Bn), 137.4 (Ci arom. PhCH), 129.2 (CH arom.), 128.7 
(CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.3 (CH arom.), 
128.2 (CH arom.), 128.0 (CH arom.), 127.7 (CH arom.), 127.6 (CH arom.), 127.6 (CH arom.), 127.5 (CH 
arom.), 126.3 (CH arom.), 101.8 (PhCH), 98.0 (C-1′), 95.7 (C-1), 95.3 (CCl3 Troc), 80.7(C-4), 79.6 (C-3′), 
77.9 (C-4′), 77.3 (C-2′), 75.0 (CH2 4′-O-Bn), 74.8 (CH2 Troc), 74.4 (C-3), 73.8 (CH2 2′-O-Bn), 73.1 (CH2 
3′-O-Bn), 68.9 (C-6), 66.9 (C-5′), 66.3 (C-5), 61.4 (C-2), 25.7 (CH3 Si
t
Bu), 18.0 (Cq Si
t
Bu), 16.4 (C-6′), -
4.1 (CH3 SiMea), -5.2 (CH3 SiMeb); HRMS(ESI) m/z calcld. for [C49H60O11NCl3Si+Na]
+
: 994.2899, obsd.: 
994.2901.  
 
6-O-Benzyl-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-1-O-
tert-butyldimethylsilyl-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-glucopyranose (63). 
Disaccharide 62 (0.028 g, 0.029 mmol) was coevaporated three 
times with toluene and dissolved in DCM (0.50 mL) under a 
nitrogen atmosphere. After cooling the solution to 0°C, triethylsilane (0.028 mL, 0.173 mmol, 6.0 equiv.) 
was added and the reaction mixture was stirred for 10 mins. TFAA (0.004 mL, 0.029 mmol, 1.0 equiv.) was 
added and the reaction mixture was stirred for another 10 mins. TFA (0.011 mL, 0.144 mmol, 5.0 equiv.) 
was then added and the reaction mixture was stirred for a further 3.5 h. The reaction mixture was allowed 
to warm to room temperature and stirred for a further 2 h. After TLC-analysis (ethyl acetate/light petroleum 
ether, 1/4, v/v) showed completion of the reaction, the reaction mixture was neutralised with sat. aq. 
NaHCO3 and the aqueous layer extracted twice with DCM. The organic layers were combined, washed 
with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column chromatography 
(ethyl acetate/light petroleum ether, 1/15 → 1/7, v/v) yielded 63 as a colourless oil (0.017 g, 60%). Rf 0.25 
(ethyl acetate/light petroleum ether, 1/4, v/v); []D
24
 = -24.2 (c 1.0, CHCl3); IR (thin film): 3394, 3089, 
3064, 3031, 2927, 2856, 1733, 1524, 1497, 1454, 1362, 1306, 1252, 1134, 1082, 1028, 945, 912, 839, 783, 
735, 697 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.40-7.28 (m, 20H, CH arom.), 5.20 (d, 1H, J2,NH = 6.1 Hz, 
NH), 4.95 (d, 1H, Ja,b = 11.7 Hz, CH-a 4′-O-Bn), 4.94 (d, 1H, J1′,2′ = 3.7 Hz, H-1′), 4.86 (d, 1H, J1,2 = 5.8 
Hz, H-1), 4.82 (d, 1H, Ja,b = 11.7 Hz, CH-a 3′-O-Bn), 4.80 (d, 1H, Ja,b = 11.7 Hz, CH-a 2′-O-Bn), 4.73 (d, 
1H, Ja,b = 11.8 Hz, CH-b 3′-O-Bn), 4.68 (d, 1H, Ja,b = 11.9 Hz, CH-b 2′-O-Bn), 4.63-4.58 (m, 4H, CH-b 4′-
O-Bn, CH-a 6-O-Bn, CH-b 6-O-Bn, and CH-a Troc), 4.47 (d, 1H, Ja,b = 7.5 Hz, CH-b Troc), 4.10 (q, 1H, 
J5′,6′ = 6.1 Hz, H-5′), 4.06 (dd, 1H, J1′,2′ = 3.6, J2′,3′ = 10.2 Hz, H-2′), 3.94 (dd, 1H, J2′,3′ = 10.3, J3′,4′ = 2.4 Hz, 
H-3′), 3.78 (dd, 1H, J5,6a = 1.5, J6a,6b = 10.7 Hz, H-6a), 3.69-3.66 (m, 3H, H-3, H-6b, and H-4′), 3.50-3.44 
(m, 2H, H-4 and H-5), 3.27 (q, 1H, J1,2 =  J2,3 = J2,NH = 7.6 Hz, H-2), 1.14 (d, 3H, J5′,6′ = 6.6 Hz, CH3 H-6′), 
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0.88 (s, 9H, 3  CH3 Si
t
Bu), 0.13 (s, 3H, CH3 SiMea), 0.09 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, 
CDCl3):  154.1 (C=O Troc), 138.7 (Ci arom. 3′-O-Bn), 138.5 (Ci arom. 6-O-Bn), 138.4 (Ci arom. 4′-O-
Bn), 138.4 (Ci arom. 2′-O-Bn), 128.7 (CH arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 
128.4 (CH arom.), 128.3 (CH arom.), 128.1 (CH arom.), 127.9 (CH arom.), 127.8 (CH arom.), 127.6 (CH 
arom.), 127.6 (CH arom.), 127.6 (CH arom.), 98.3 (C-1′), 95.7 (C-1), 95.5 (CCl3 Troc), 88.1 (C-3), 73.3 (C-
3′), 77.5 (C-4′), 76.1 (C-2′), 75.1 (CH2 4′-O-Bn), 74.9 (C-5), 74.6 (CH2 Troc), 74.0 (2′-O-Bn), 73.6 (CH2 6-
O-Bn), 73.3 (3′-O-Bn), 70.1 (C-4), 69.8 (C-6), 68.1 (C-5′), 58.6 (C-2), 25.8 (CH3 Si
t
Bu), 18.1 (Cq Si
t
Bu), 
16.8 (C-6′), -4.0 (CH3 SiMea), -5.2 (CH3 SiMeb); HRMS(ESI) m/z calcld. for [C49H62O11NCl3Si+Na]
+
: 
996.3055, obsd.: 996.3055. 
 
3-O-(2-O-Acetyl-4,6-O-benzylidene-3-O-para-
methoxybenzyl--D-glucopyranosyl)-3,6-di-O-benzyl-2-
deoxy-2-(2,2,2-trichloroethoxycarbonylamido)-/-D-
glucopyranose (68). Disaccharide 64 (0.107 g, 0.101 mmol) 
was dissolved in THF (1.0 mL) in a plastic container. After addition of HF.pyridine (0.126 mL, 70% in 
pyridine, 0.889 mmol, 8.8 eq.), the reaction mixture was left for 26 h. After TLC-analysis (ethyl 
acetate/light petroleum ether, 1/2, v/v) showed complete deprotection, the reaction mixture was neutralised 
with sat. aq. NaHCO3, extracted with ethyl acetate three times, the combined organic layers were then 
washed with brine, dried (MgSO4), filtered and concentrated in vacuo. Purification by column 
chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/2, v/v) yielded lactol 68 as a white 
amorphous solid upon concentration in vacuo (0.0880 g, 92%). Rf 0.09 and 0.06 (ethyl acetate/light 
petroleum ether, 1/2, v/v); []D
21
 = +10.3 (c 1.0, CHCl3); IR (thin film): 3421, 3322, 3065, 3033, 2934, 
2873, 1743, 1612, 1513, 1454, 1368, 1313, 1231, 1172, 1090, 1059, 1029, 967, 909, 817, 731, 697, 669 cm
-
1
; (NMR data given for the α-anomer only, as only trace amounts of the β-anomer were detectable) 1H-
NMR (500 MHz, CDCl3): δ 7.49-7.47 (m, 2H, CH arom.), 7.42-7.25 (m, 13H, CH arom.), 7.19 (d, 2H, Ja,b 
= 8.6 Hz, CH arom. PMB), 6.86 (d, 2H, Ja,b = 8.8 Hz, CH arom. PMB), 5.46 (s, 1H, CHPh), 5.25 (d, 1H, 
J1,2 = 3.1 Hz, H-1), 5.07 (d, 1H, J2′,NH = 9.5 Hz, NH), 4.93 (t, 1H, J1′,2′ = J2′,3′ = 8.7 Hz, H-2′), 4.88 (d, 1H, 
Ja,b = 11.5 Hz, CH-a 3-O-Bn), 4.77 (d, 1H, Ja,b = 11.7 Hz, CH-a 3′-OPMB), 4.73 (d, 1H, Ja,b = 12.0 Hz, CH-
a Troc), 4.72 (d, 1H, Ja,b = 12.2 Hz, CH-a 6-O-Bn), 4.61 (d, 2H, Ja,b = 11.7 Hz, CH-b 3-O-Bn and CH-b 
Troc), 4.57 (d, 1H, Ja,b = 11.8 Hz, CH-b 3′-O-PMB), 4.44 (d, 1H, J1′,2′ = 8.5 Hz, H-1′), 4.42 (d, 1H, Ja,b = 
12.2 Hz, CH-b 6-O-Bn), 4.15 (dd, 1H, J6a′ ,6b′ = 10.5 Hz, J5′,6a′ = 4.9 Hz, H-6a′), 3.95-3.86 (m, 3H, H-2, H-4, 
and H-5), 3.80 (s, 3H, OMe PMB), 3.72 (dd, 1H, J6a,6b = 10.4 Hz, J5,6a = 3.1 Hz, H-6a), 3.64-3.58 (m, 3H, 
H-3, H-6b, and H-4′), 3.51 (t, 1H, J2′,3′ = J3′,4′ = 9.0 Hz, H-3′), 3.38 (t, 1H, J5′,6b′ = J6a′,6b′ = 10.2 Hz, H-6b′), 
3.20 (bs, 1H, OH), 3.16 (td, 1H, J4′,5′ = J5′,6b′ = 9.6 Hz, J5′,6a′ = 4.9 Hz, H-5′), 1.94 (s, 3H, OMe Ac); 
13
C-
NMR (125MHz, CDCl3): δ 169.4 (C=O Ac), 159.4 (C-p arom. PMB), 154.5 (C=O Troc), 138.7 (Ci arom. 
3-O-Bn), 137.7 (Ci arom. 6-O-Bn), 137.4 (Ci arom. PhCH), 130.5 (CH arom.), 129.6 (CH arom.), 129.2 
(CH arom.), 128.7 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 128.2 (CH arom.), 127.8 (CH arom.), 
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127.6 (CH arom.), 126.1 (CH arom.), 113.8 (C arom. PMB), 101.3 (PhCH), 100.9 (C-1′), 95.5 (CCl3 Troc), 
91.9 (C-1), 81.8 (C-4′), 78.0 (C-3′), 77.4 (C-4), 77.0 (C-3), 74.7 (CH2 3-O-Bn and CH2 Troc), 73.8 (CH2 6-
O-Bn), 73.8 (CH2 3′-O-PMB), 73.5 (C-2′), 70.8 (C-5), 68.6 (C-6′), 67.8 (C-6), 66.1 (C-5′), 55.4 (OMe 
PMB), 54.9 (C-2), 21.0 (CH3 2′-O-Ac); HRMS(ESI) m/z calcld. for [C46H50O14NCl3+Na]
+
: 968.2195, 
obsd.: 968.2195. 
 
 3-O-(2-O-Acetyl-4,6-O-benzylidene-3-O-para-
methoxybenzyl--D-glucopyranosyl)-3,6-di-O-benzyl-
2-deoxy-2-(2,2,2-trichloroethoxycarbonylamido)--D-
glucopyranosyl trichloroacetimidate (67). Lactol 68 
(0.070 g, 0.074 mmol) was coevaporated three times with 
toluene and dissolved in DCM (1.0 mL) under a nitrogen atmosphere. Trichloroacetonitrile (0.074 mL, 
0.735 mmol, 10.0 equiv.) and caesium carbonate (cat.) were added and the reaction was stirred for 15 h. 
After TLC-analysis (ethyl acetate/light petroleum ether, 1/1, v/v) showed completion of the reaction, the 
reaction mixture was filtered and purified directly by column chromatography (ethyl acetate/light 
petroleum ether, 1/10 → 1/2, v/v) to yield 67 as a colourless oil upon concentration in vacuo (0.040 g, 
50%). The imidate was stored in the freezer until it was used. Rf 0.56 (ethyl acetate/light petroleum ether, 
1/1, v/v); IR (thin film): 3420, 3340, 3088, 3064, 3033, 2955, 2925, 2871, 1729, 1673, 1612, 1587, 1513, 
1455, 1368, 1302, 1277, 1230, 1173, 1091, 1061, 1029, 1010,  969, 916, 822, 797, 737, 698 cm
-1
; 
1
H-NMR 
(500 MHz, CDCl3): δ 8.63 (s, 1H, NH), 7.50-7.48 (m, 2H, CH arom.), 7.43-7.27 (m, 13H, CH arom.), 7.19 
(d, 2H, Ja,b = 8.8 Hz, CH arom. PMB), 6.86 (d, 2H, Ja,b = 8.8 Hz, CH arom. PMB), 6.34 (d, 1H, J1,2 = 3.5 
Hz, H-1), 5.50 (d, 1H, J2′,NH = 8.8 Hz, NH), 5.49 (s, 1H, CHPh), 4.95 (dd, 1H, J1′,2′ = 8.3, J2′,3′ = 9.3 Hz, H-
2′), 4.89 (d, 1H, Ja,b = 11.7 Hz, CH-a 3-O-Bn), 4.78 (d, 1H, Ja,b = 11.7 Hz, CH-a 3′-OPMB), 4.74 (d, 1H, 
Ja,b = 11.9 Hz, CH-a 6-O-Bn), 4.70 (d, 1H, Ja,b = 12.0 Hz, CH-a Troc), 4.66 (d, 1H, Ja,b = 12.0 Hz, CH-b 3-
O-Bn), 4.63 (d, 1H, Ja,b = 12.0 Hz, CH-b Troc), 4.58 (d, 1H, Ja,b = 11.5 Hz, CH-b 3′-O-PMB), 4.51 (d, 1H, 
J1′,2′ = 8.0 Hz, H-1′), 4.41 (d, 1H, Ja,b = 11.9 Hz, CH-b 6-O-Bn), 4.23 (dd, 1H, J6a′,6b′ = 10.7 Hz, J5′,6a′ = 5.1 
Hz, H-6a′), 4.14 (t, 1H, J3,4 = J4,5 = 9.5 Hz, H-4), 4.05 (dd, 1H, J1,2 = 3.7, J2,3 = 8.5 Hz, H-2), 3.80 (s, 3H, 
OMe PMB), 3.79-3.71 (m, 2H, H-5 and H-6a), 3.68-3.61 (m, 3H, H-3, H-6b, and H-4′), 3.51 (t, 1H, J2′,3′ = 
J3′,4′ = 9.3 Hz, H-3′), 3.48 (t, 1H, J5′,6b′ = J6a′,6b′ = 9.3 Hz, H-6b′), 3.20 (td, 1H, J4′,5′ = J5′,6b′ = 9.8 Hz, J5′,6a = 
4.9 Hz, H-5′), 1.91 (s, 3H, OMe Ac); 13C-NMR (125MHz, CDCl3): δ 169.2 (C=O Ac), 160.7 (C=N), 159.4 
(C-p arom. PMB), 154.2 (C=O Troc), 138.2 (Ci arom. 3-O-Bn), 137.7 (Ci arom. 6-O-Bn), 137.3 (Ci arom. 
PhCH), 130.4 (CH arom.), 129.6 (CH arom.), 129.6 (CH arom.), 129.2 (CH arom.), 128.7 (CH arom.), 
128.7 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 128.0 (CH arom.), 127.8 (CH 
arom.), 126.1 (CH arom.), 113.9 (C arom. PMB), 101.3 (PhCH), 100.9 (C-1′), 95.6 (C-1), 95.5 (CCl3 Troc), 
91.9 (CCl3 imidate), 81.8 (C-4′), 78.1 (C-3′), 76.5 (C-4), 75.4 (C-3), 74.7 (CH2 Troc), 74.6 (CH2 3-O-Bn), 
73.8 (CH2 6-O-Bn and CH2 3′-O-PMB), 73.6 (C-5), 73.4 (C-2′), 68.7 (C-6′), 67.0 (C-6), 66.1 (C-5′), 55.4 
(OMe PMB), 54.3 (C-2), 21.0 (CH3 2′-O-Ac). 
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2-Amino-1-O-tert-butyldimethylsilyl-2-deoxy-3-O-(α-L-
fucopyranosyl)--D-glucopyranose (77). Disaccharide 21 (0.0205 
g, 0.0249 mmol) was dissolved in chloroform/ethanol/acetic 
anhydride (1.2 mL, 1/1/0.1, v/v/v) in a Fisher-Porter Bottle. 
Pd(OH)2/C (0.0166 g) was added and the reaction mixture was 
purged with H2 gas  twice and placed under a H2 atmosphere (4 bar) and stirred for 2.5 h. After TLC-
analysis (DCM/methanol/ethanol/NH3 (30% aq.), 55/2/2/1, v/v/v/v) showed completion of the reaction, the 
reaction mixture was diluted with ethanol, filtered over celite and concentrated in vacuo. Crude 
disaccharide 77 was used without further purification. Rf 0.03 (DCM/methanol/ethanol/NH3 (30% aq.), 
55/2/2/1, v/v/v/v). 
 
2-Acetamido-1-O-tert-butyldimethylsilyl-2-deoxy-3-O-(α-L-
fucopyranosyl)--D-glucopyranose (75). To a solution of crude 
disaccharide 77 (0.0123 g) in methanol (1 mL) was added acetic 
anhydride (0.060 mL, 0.63 mmol, 36 equiv.) and K2CO3 (0.017 g, 
0.12 mmol, 6.9 equiv.). The reaction mixture was stirred for 4 days, 
with extra acetic anhydride (0.10 mL, 1.1 mmol, 60 equiv.) and K2CO3 (0.019 g,, 0.14 mmol, 67.8 equiv.) 
added after 24 h. After TLC-analysis (DCM/methanol/ethanol/NH3 (30% aq.), 15/2/2/1, v/v/v/v) showed 
completion of the reaction, the reaction mixture was concentrated in vacuo. Purification by column 
chromatography (DCM/methanol/ethanol/NH3 (30% aq.), 55/2/2/1 → 5/2/2/1, v/v/v/v) yielded disaccharide 
75 as a colourless oil (0.0073 g, 61% 2 steps). Rf 0.17 (DCM/methanol/ethanol/NH3 (30% aq.), 15/2/2/1, 
v/v/v/v); 
1
H-NMR (500 MHz, CDOD3):  4.95 (d, 1H, J1′,2′ = 4.2 Hz, H-1′), 4.71 (d, 1H, J1,2 = 8.0 Hz, H-1), 
4.31 (q, 1H, J5′,6′ = 6.6 Hz, H-5′), 3.89 (dd, 1H, J5,6a = 1.9, J6a,6b = 12.4 Hz, H-6a), 3.81 (dd, 1H, J2′,3′ = 10.2, 
J3′,4′ = 3.1 Hz, H-3′), 3.78 – 3.74 (m, 2H, H-2 and H-4′), 3.71 (dd, 1H, J5,6b = 5.6, J6a,6b = 12.4 Hz, H-6b), 
3.66 (dd, 1H, J1′,2′ = 4.2, J2′,3′ = 10.2 Hz, H-2′), 3.59 (t, 1H, J2,3 = J3,4 = 10.3 Hz, H-3), 3.49 (t, 1H, J3,4 = J4,5 
= 10.0 Hz, H-4), 3.44 (ddd, 1H, J5,6a = 10.1, J5,6a = 1.8, J5,6b = 5.3 Hz, H-5), 2.00 (s, 3H, CH3 N-Ac), 1.13 
(d, 3H, J5′,6′ = 6.6 Hz, H-6′), 0.86 (s, 9H, 3  CH3 Si
t
Bu), 0.12 (s, 3H, CH3 SiMea), 0.11 (s, 3H, CH3 SiMeb); 
HRMS(ESI) m/z calcld. for [C20H39O10NSi+Na]
+
: 504.2241, obsd.: 504.2236. 
 
 2-Acetamido-2-deoxy-3-O-(α-L-fucopyranosyl)-α/-D-glucopyranose 
(76). Disaccharide 75 (0.007 g, 0.015 mmol) was dissolved in 
AcOH/H2O/THF (0.50 mL, 3:1:1) and stirred at room temperature for 72 h 
and then at 65°C for a further 6 hours. TLC-analysis 
(DCM/methanol/ethanol/NH3 (30% aq.), 15/2/2/1, v/v/v/v) showed 
formation of product (reaction was incomplete). The reaction mixture was concentrated in vacuo. 
1
H NMR 
analysis of the crude reaction mixture showed the presence of product as well as L-fucose and starting 
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material. HRMS(ESI) confirmed that product was present in the crude reaction mixture. Rf 0.01 
(DCM/methanol/ethanol/NH3 (30% aq.), 15/2/2/1, v/v/v/v); HRMS(ESI) m/z calcld. for [C14H25O10N+Na]
+
: 
390.1376, obsd.: 390.1378. 
 
2-Acetamido-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-
benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy--D-
glucopyranose (78). Azide 21 (0.0334 g, 0.0715 mmol) was 
coevaporated three times with toluene and dissolved in dissolved in 
THF (0.20 mL) under a nitrogen atmosphere. After cooling the 
solution to 0°C, trimethyl phosphine (0.203 mL, 1M in THF, 0.203 mmol, 5 equiv.) was added and the 
reaction mixture was stirred for 15 mins at 0°C and a further 3 h at room temperature. After TLC-analysis 
(ethyl acetate/light petroleum ether, 1/2, v/v) showed complete reduction of the azide, sodium hydroxide 
(0.30 mL, 1M (aq)) was added and the reaction mixture was stirred for another 20 mins. The reaction 
mixture was diluted with ethyl acetate and washed with sat. aq. NaHCO3, dried (MgSO4), filtered and 
concentrated in vacuo.  The resulting crude amine was then dissolved in acetic acid anhydride/pyridine 
(0.75 mL, 1/2, v/v) and stirred for 72 h. After TLC-analysis (ethyl acetate/light petroleum ether, 1/2, v/v) 
showed complete acetylation of the amine the reaction mixture was concentrated in vacuo, dissolved in 
ethyl acetate washed with sat. aq. NaHCO3, H2O, and brine, dried (MgSO4), filtered and concentrated in 
vacuo.  Purification by column chromatography (ethyl acetate/light petroleum ether, 1/17 → 1/3, v/v) 
yielded acetamide 78 as a colourless oil (0.0267 g, 79%). Rf 0.33 (ethyl acetate/light petroleum ether, 1/2, 
v/v); []D
20
 = -86.2 (c 1.0, CHCl3); IR (thin film): 3281, 3088, 3064, 3032, 2930, 2858, 1660, 1543, 1497, 
1455, 1389, 1371, 1311, 1253, 1208, 1182, 1097, 1028, 1004, 913, 840, 783, 736, 698 cm
-1
; 
1
H-NMR (500 
MHz, CDCl3):  7.48-7.24 (m, 20H, CH arom.), 5.51 (d, 1H, J2,NH = 8.5 Hz, NH), 5.50 (s, 1H, PhCH), 5.08 
(d, 1H, J1′,2′ = 3.7 Hz, H-1′), 5.01 (d, 1H, J1,2 = 7.8 Hz, H-1), 4.93 (d, 1H, Ja,b = 11.5 Hz, CH-a 2′-O-Bn), 
4.92 (d, 1H, Ja,b = 11.4 Hz, CH-a 4′-O-Bn), 4.75 (s, 2H, CH-a 3′-O-Bn and CH-b 3′-O-Bn), 4.64 (d, 1H, Ja,b 
= 11.7 Hz, CH-b 2′-O-Bn), 4.59 (d, 1H, Ja,b = 11.7 Hz, CH-b 4′-O-Bn), 4.28 (dd, 1H, J5,6a = 4.9, J6a,6b = 
10.5 Hz, H-6a), 4.26 (t, 1H, J2,3 = J3,4 = 9.6 Hz, H-3), 4.09-4.05 (m, 2H, H-2′ and H-5′), 3.94 (dd, 1H, J2′,3′ = 
10.0, J3′,4′ = 2.4 Hz, H-3′), 3.76 (t, 1H, J5,6b = J6a,6b = 10.3 Hz, H-6b), 3.61 (s, 1H, H-4′), 3.59 (t, 1H, J3,4 = 
J4,5 = 9.0 Hz, H-4), 3.49 (td, 1H, J4,5 = J5,6b = 9.5, J5,6a = 4.8 Hz, H-5), 3.35 (q, 1H, J1,2 = J2,3 = J2,NH = 7.8 
Hz, H-2), 1.60 (s, 3H, CH3 N-Ac), 0.86 (s, 9H, 3  CH3 Si
t
Bu), 0.85 (d, 3H, J5′,6′ = 6.1 Hz, CH3 H-6′), 0.07 
(s, 3H, CH3 SiMea), 0.03 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  170.3 (C=O N-Ac), 139.1 
(Ci arom. 2′-O-Bn), 138.9 (Ci arom. 3′-O-Bn), 138.8 (Ci arom. 4′-O-Bn), 137.6 (Ci arom. PhCH), 129.1 
(CH arom.), 128.8 (CH arom.), 128.6 (CH arom.), 128.6 (CH arom.), 128.4 (CH arom.), 128.3 (CH arom.), 
128.1 (CH arom.), 127.9 (CH arom.), 127.7 (CH arom.), 127.5 (CH arom.), 126.4 (CH arom.), 101.7 
(PhCH), 98.4 (C-1′), 95.9 (C-1), 81.2 (C-4), 79.9 (C-3′), 77.9 (C-4′), 77.5 (C-2′), 75.3 (C-3), 75.1 (CH2 4′-
O-Bn), 74.1 (CH2 2′-O-Bn), 72.8 (CH2 3′-O-Bn), 69.1 (C-6), 67.1 (C-5′), 66.4 (C-5), 60.5 (C-2), 25.7 (CH3 
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Si
t
Bu), 23.4 (CH3 N-Ac), 18.0 (Cq Si
t
Bu), 16.5 (C-6′), -4.1 (CH3 SiMea), -5.2 (CH3 SiMeb); HRMS(ESI) 
m/z calcld. for [C48H61O10NSi+Na]
+
: 862.3962, obsd.: 862.3967. 
 
2-Acetamido-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-
benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy--D-
glucopyranose (78). Azide 21 (0.0287 g, 0.0348 mmol) was 
coevaporated three times with toluene and dissolved in 
AcOH:Ac2O:THF (0.70 mL, 3:2:1) under a nitrogen atmosphere. 
After cooling the solution to 0°C, activated Zn (0.0068 g, 0.105 mmol, 3.0 equiv.) was added and the 
reaction mixture was stirred for 24 h, with additional activated Zn (0.0070 g, 0.107 mmol, 3.0 equiv.) 
added after 7 h. After, TLC-analysis (ethyl acetate/light petroleum ether, 1/2, v/v) showed completion of 
the reaction, the reaction mixture was filtered through celite and washed with ethyl actate and concentrated 
in vacuo.  Purification by column chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/3, v/v) 
yielded acetamide 21 (0.0076 g, 26%) as colourless oil. Characterisation is as above. 
 
2-Acetamido-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-
benzylidene-1-O-tert-butyldimethylsilyl-2-deoxy--D-
glucopyranose (78). Azide 21 (0.0260 g, 0.0316 mmol) was 
coevaporated three times with toluene and dissolved in dissolved in 
pyridine (0.17 mL) under a nitrogen atmosphere. After cooling the 
solution to 0°C, thioacetic acid (0.17 mL) was slowly added and the reaction mixture was stirred for 30 
mins at 0°C and a further 24 h at room temperature. After TLC-analysis (ethyl acetate/light petroleum 
ether, 1/2, v/v) showed completion of the reaction, the reaction mixture was concentrated in vacuo. 
Purification by column chromatography (ethyl acetate/light petroleum ether, 1/10 → 1/3, v/v) yielded 
amino acetate 78 as a colourless oil (0.0164 g, 62%). Characterisation is as above. 
  
2-Acetamido-3-O-(2,3,4-tri-O-benzyl-α-L-fucopyranosyl)-4,6-O-
benzylidene-2-deoxy-α/-D-glucopyranose (86). Disaccharide 78 (0.148 
g, 0.176 mmol) was dissolved in THF (2.2 mL) in a plastic container. 
After addition of HF.pyridine (0.220 mL, 70% in pyridine, 1.552 mmol, 
8.8 eq.), the reaction mixture was left for 18 h. After TLC-analysis (ethyl 
acetate/light petroleum ether, 1/1, v/v) showed complete deprotection, the reaction mixture was neutralised 
with sat. aq. NaHCO3, extracted with ethyl acetate, washed with brine, dried (MgSO4), filtered and 
concentrated in vacuo. Purification by column chromatography (ethyl acetate/light petroleum ether, 1/2 → 
2/1, v/v) yielded lactol 86 as a white amorphous solid upon concentration in vacuo (0.125 g, 98%). Rf 0.08 
(ethyl acetate/light petroleum ether, 1/1, v/v); []D
20
 = -110.4 (c 1.0, CHCl3); IR (thin film): 3310, 3089, 
3064, 3032, 2978, 2933, 2870, 1653, 1542, 1497, 1454, 1372, 1313, 1276, 1210, 1173, 1088, 1048, 1027, 
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998, 909, 813, 729, 696 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.56-7.53 (m, 2H-α and 2H-β, CH arom.), 
7.45 (d, 1H, J2,NH = 3.4 Hz, NH-β), 7.43-7.27 (m, 18H-α and 18H-β, CH arom.), 6.78 (d, 1H, J2,NH = 5.9 
Hz, NH-α), 5.60 (s, 1H, PhCH-β), 5.59 (s, 1H, PhCH-α), 5.51 (d, 1H, J1,2 = 3.4 Hz, H-1-α), 5.23 (d, 1H, 
J1′,2′ = 3.4 Hz, H-1′-α), 5.19 (d, 1H, J1′,2′ = 3.5 Hz, H-1′-β), 4.98 (d, 1H, Ja,b = 11.5 Hz, CH-a 4′-β-O-Bn), 
4.92 (d, 1H, Ja,b = 11.5 Hz, CH-a 4′-α-O-Bn), 4.89 (d, 1H, Ja,b = 10.0 Hz, CH-a 2′-β-O-Bn), 4.79 (d, 1H, Ja,b 
= 11.7 Hz, CH-a 3′-β-O-Bn), 4.78 (d, 1H, Ja,b = 10.3 Hz, CH-a 2′-α-O-Bn), 4.74 (d, 1H, Ja,b = 12.0 Hz, CH-
a 3′-α-O-Bn), 4.73 (d, 1H, Ja,b = 10.2 Hz, CH-b 2′-α-O-Bn), 4.71 (d, 2H, Ja,b = 10.8 Hz, CH-b 3′-α-O-Bn 
and CH-b 2′-β-O-Bn), 4.68 (d, 1H, Ja,b = 11.7 Hz, CH-b 4′-β-O-Bn), 4.66 (d, 1H, Ja,b = 11.5 Hz, CH-b 4′-α-
O-Bn), 4.65 (d, 2H, Ja,b = 11.5 Hz, CH-b 3′-β-O-Bn), 4.51 (d, 1H, J1,2 = 8.0 Hz, H-1-β), 4.40 (dd, 1H, J5,6a = 
4.8, J6a,6b = 10.5 Hz, H-6a-β), 4.28 (dd, 1H, J5,6a = 4.9, J6a,6b = 10.3 Hz, H-6a-α), 4.16 (t, 1H, J2,3 = J3,4 = 9.7 
Hz, H-3-α), 4.16 (dd, 1H, J1′,2′ = 3.6, J2′,3′ = 10.0 Hz, H-2′-β), 4.11-4.03 (m, 4H, H-5-α, H-2′-α, H-5′-α and 
H-5′-β), 3.96 (ddd, 1H, J1,2 = 3.7, J2,3 = 9.8, J2,NH = 5.9 Hz, H-2-α), 3.92 (dd, 1H, J2′,3′ = 10.0, J3′,4′ = 2.4 Hz, 
H-3′-α), 3.89 (dd, 1H, J2′,3′ = 10.0, J3′,4′ = 2.4 Hz, H-3′-β), 3.84 (t, 1H, J5,6b = J6a,6b = 10.2 Hz, H-6b-β), 3.77-
3.73 (m, 3H, H-6b-α, H-3-β,and H-4′-β), 3.70 (td, 1H, J1,2 = J2,3 = 7.8, J2,NH = 3.6 Hz, H-2-β), 3.67 (s, 1H, 
H-4′-α), 3.64 (t, 1H, J3,4 = J4,5 = 9.3 Hz, H-4-α), 3.63 (t, 1H, J3,4 = J4,5 = 9.8 Hz, H-4-β), 3.42 (td, 1H, J4,5 = 
J5,6b = 9.7, J5,6a = 4.8 Hz, H-5-β), 1.55 (s, 3H, CH3 N-Ac-β), 1.51 (s, 3H, CH3 N-Ac-α), 1.15 (d, 3H, J5′,6′ = 
6.3 Hz, CH3 H-6′-β), 1.06 (d, 3H, J5′,6′ = 6.4 Hz, CH3 H-6′-α); 
13
C-NMR (125 MHz, CDCl3):  175.4 (C=O 
N-Ac-α), 170.9 (C=O N-Ac-β), 138.5 (Ci arom. 3′-α-O-Bn), 138.4 (Ci arom. 4′-α-O-Bn), 138.2 (Ci arom. 4′-
β-O-Bn), 138.1 (Ci arom. 3′-β-O-Bn), 137.5 (Ci arom. 2′-α-O-Bn), 137.3 (Ci arom. PhCH-α), 137.1 (Ci 
arom. PhCH-β), 136.9 (Ci arom. 2′-β-O-Bn), 129.0 (CH arom.), 129.0 (CH arom.), 128.9 (CH arom.), 128.9 
(CH arom.), 128.7 (CH arom.), 128.7 (CH arom.), 128.5 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 
128.3 (CH arom.), 128.3 (CH arom.), 128.2 (CH arom.), 128.2 (CH arom.), 128.0 (CH arom.), 127.9 (CH 
arom.), 127.7 (CH arom.), 127.7 (CH arom.), 127.3 (CH arom.), 127.3 (CH arom.), 125.9 (CH arom.), 
125.8 (CH arom.), 100.9 (PhCH-α), 100.7 (PhCH-β), 100.2 (C-1′-β), 99.4 (C-1′-α), 99.2 (C-1-β), 91.8 (C-1-
α), 82.0 (C-4-α), 81.4 (C-4-β), 80.2 (C-3′-β), 79.9 (C-3′-α), 78.5 (C-3-β), 78.5 (C-2′-β), 78.0 (C-2′-α), 77.4 
(C-4′-α), 76.9 (C-4′-β), 75.6 (CH2 2′-β-O-Bn), 75.1 (CH2 4′-β-O-Bn and C-3-α), 75.0 (CH2 4′-α-O-Bn), 
74.6 (CH2 2′-α-O-Bn), 73.1 (CH2 3′-α-O-Bn), 72.8 (CH2 3′-β-O-Bn), 70.0 (C-6-α), 68.5 (C-6-β), 68.2 (C-5′-
β), 67.7 (C-5′-α), 66.5 (C-5-β), 63.0 (C-5-α), 58.4 (C-2-β), 54.9 (C-2-α), 22.5 (CH3 N-Ac-α), 22.0 (CH3 N-
Ac-β), 16.9 (C-6′-β), 16.7 (C-6′-α); HRMS(ESI) m/z calcld. for [C42H47O10N+Na]
+
: 748.3098, obsd.: 
748.3099.  
 
 2-Acetamido-2-deoxy-3-O-(α-L-fucopyranosyl)-α/-D-glucopyranose 
(76). To a solution of disaccharide 78 (0.0264 g, 0.0364 mmol) in 
EtOH/ethyl acetate (1.2 mL, 1/1, v/v) was added Pd(OH)2/C (0.0100 g, 
20% catalyst, 0.0138 mmol, 0.4 equiv.). The reaction mixture was placed 
under a H2 atmosphere and stirred for 7.5 h. After TLC-analysis (30% 
MeOH in ethyl acetate) showed completion of the reaction, the reaction mixture was filtered over celite, 
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washed though with MeOH and H2O, and concentrated in vacuo. Purification by C18 reverse phase column 
chromatography (MeOH in H2O, 0% → 2%, v/v) yielded fully deprotected disaccharide 76 as a white 
amorphous solid after lyophilisation (0.0123 g, 92%). Rf 0.24 (30% MeOH in ethyl acetate, v/v); []D
18
 = -
91.5 (c 1.0, H2O); IR (thin film): 3286, 2980, 2922, 1635, 1555, 1429, 1377, 1315, 1257, 1165, 1123, 
1071, 1018, 996, 916, 813, 788, 732, 695 cm
-1
; 
1
H-NMR (600 MHz, D2O):  5.09 (d, 1H, J1,2 = 3.5 Hz, H-
1-α), 4.97 (d, 1H, J1′,2′ = 4.1 Hz, H-1′-α), 4.93 (d, 1H, J1′,2′ = 4.2 Hz, H-1′-β), 4.67 (d, 1H, J1,2 = 8.4 Hz, H-1-
β), 4.30 (q, 1H, J5′,6′ = 6.5 Hz, H-5′-α), 4.28 (q, 1H, J5′,6′ = 6.4 Hz, H-5′-β), 4.00 (dd, 1H, J1,2 = 3.5, J2,3 = 
10.5, H-2-α), 3.87 (dd, 1H, J5,6a = 2.0, J6a,6b = 12.1 Hz, H-6a-β), 3.85 (ddd, 1H, J4,5 = 9.5, J5,6a = 2.2, J5,6b = 
5.2 Hz, H-5-α), 3.81 (dd, 1H, J5,6a = 2.2, J6a,6b = 12.4 Hz, H-6a-α), 3.79-3.73 (m, 7H, H-3-α, H-6b-α, H-3′-
α, H-4′-α, H-2-β, H-3′-β, and H-4′-β), 3.70 (dd, 1H, J5,6b = 5.7, J6a,6b = 12.3 Hz, H-6b-β), 3.66-3.63 (m, 2H, 
H-2′-α and H-2′-β), 3.58 (dd, 1H, J2,3 = 8.7, J3,4 = 10.0 Hz, H-3-β), 3.52 (t, 1H, J3,4 = J4,5 = 9.4 Hz, H-4-α), 
3.48 (t, 1H, J3,4 = J4,5 = 8.6 Hz, H-4-β), 3.43 (ddd, 1H, J4,5 = 9.8, J5,6a = 2.0 J5,6b = 5.6 Hz, H-5-β), 1.98 (s, 
6H, CH3 N-Ac-α and CH3 N-Ac-β), 1.12 (d, 3H, J5′,6′ = 6.6 Hz, CH3 H-6′-α), 1.11 (d, 3H, J5′,6′ = 6.4 Hz, 
CH3 H-6′-β); 
13
C-NMR (150 MHz, D2O):  174.6 (C=O N-Ac-β), 174.4 (C=O N-Ac-α), 99.9 (C-1′-β), 99.6 
(C-1′-α), 94.6 (C-1-β), 90.9 (C-1-α), 80.4 (C-3-β), 77.8 (C-3-α), 75.8 (C-5-β), 71.7 (C-4′-α), 71.7 (C-4′-β), 
71.6 (C-5-α), 69.4 (C-3′-α), 69.4 (C-3′-β), 68.4 (C-4-β), 68.4 (C-4-α), 67.9 (C-2′-α), 67.8 (C-2′-β), 66.8 (C-
5′-β), 66.7 (C-5′-α), 60.6 (C-6-β), 60.4 (C-6-α), 56.2 (C-2-β), 53.5 (C-2-α), 22.1 (CH3 N-Ac-β), 21.8 (CH3 
N-Ac-α), 15.1 (C-6′-α), 15.0 (C-6′-β); HRMS(ESI) m/z calcld. for [C14H25O10N+Na]
+
: 390.1376, obsd.: 
390.1376.  
 
2-Acetamido-6-O-benzyl-3-O-(2,3,4-tri-O-benzyl-α-
L-fucopyranosyl)-4-O-[3-O-benzyl-4,6-O-
benzylidene-2-deoxy-2-(2,2,2-
trichloroethoxycarbonylamido)--D-
glucopyranosyl]-1-O-tert-butyldimethylsilyl-2-
deoxy--D-glucopyranose (87). Azide 58 (0.0876 g, 
0.0646 mmol) was coevaporated three times with toluene and dissolved in dissolved in pyridine (0.35 mL) 
under a nitrogen atmosphere. After cooling the solution to 0°C, thioacetic acid (0.35 mL) was slowly added 
and the reaction mixture was stirred for 10 mins at 0°C and a further 25 h at room temperature. After TLC-
analysis (ethyl acetate/light petroleum ether, 1/2, v/v) showed completion of the reaction, the reaction 
mixture was concentrated in vacuo. Purification by column chromatography (ethyl acetate/light petroleum 
ether, 1/10 → 1/2, v/v) yielded acetamide 87 as a colourless oil (0.0628 g, 71%). Rf 0.31 (ethyl acetate/light 
petroleum ether, 1/2, v/v); IR (thin film): 3327, 3223, 3063, 3031, 2929, 2859, 1720, 1650, 1544, 1497, 
1454, 1376, 1311, 1290, 1258, 1219, 1173, 1097, 1066, 1034, 1028, 1005, 949, 922, 902, 837, 821, 772, 
734, 696 cm
-1
; 
1
H-NMR (500 MHz, CDCl3):  7.51-7.50 (m, 2H, CH arom.), 7.45-7.27 (m, 27H, CH 
arom.), 7.22-7.18 (m, 1H, CH arom.), 5.92 (bs, 1H, NH N-Ac), 5.46 (s, 1H, PhCH), 5.11 (d, 1H, J1′,2′ = 3.4 
Hz, H-1′), 4.99 (d, 1H, Ja,b = 11.7 Hz, CH-a 4′-O-Bn), 4.89 (d, 1H, Ja,b = 11.2 Hz, CH-a 2′-O-Bn), 4.86 (d, 
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1H, Ja,b = 12.0 Hz, CH-a 3″-O-Bn), 4.81 (d, 1H, Ja,b = 12.2 Hz, CH-a 3′-O-Bn), 4.81 (d, 1H, J1,2 = 7.1 Hz, 
H-1), 4.76 (d, 1H, Ja,b = 12.2 Hz, CH-b 3′-O-Bn), 4.73 (d, 1H, Ja,b = 12.0 Hz, CH-a Troc), 4.68 (d, 1H, Ja,b 
= 12.2 Hz, CH-b Troc), 4.67 (d, 2H, Ja,b = 11.7 Hz, CH-b 2′-O-Bn and CH-b 4′-O-Bn), 4.65 (d, 1H, Ja,b = 
12.0 Hz, CH-b 3″-O-Bn), 4.62 (d, 1H, Ja,b = 12.0 Hz, CH-a 6-O-Bn), 4.54 (bs, 1H, NH N-Troc), 4.52 (d, 
1H, J1″,2″ = 8.1 Hz, H-1″), 4.42 (d, 1H, Ja,b = 11.9 Hz, CH-b 6-O-Bn), 4.23-4.20 (m, 2H, H-5′ and H-6a″), 
4.07 (dd, 1H, J1′,2′ = 3.6, J2′,3′ = 10.0 Hz, H-2′), 4.00 (t, 1H, J2,3 = J3,4 = 7.3 Hz, H-3), 3.93 (t, 1H, J3,4 = J4,5 = 
7.3 Hz, H-4), 3.87 (d, 1H, J2′,3′ = 9.8, H-3′), 3.69-3.64 (m, 3H, H-6a, H-6b, and H-4′), 3.58-3.49 (m, 4H, H-
2, H-3″, H-4″, and H-6″b), 3.45-3.39 (m, 2H, H-5 and H-2″), 3.23 (td, 1H, J4′,5′ = J5′,6b′ = 9.5, J5′,6a′ = 4.2 Hz, 
H-5″), 1.72 (s, 3H, CH3 N-Ac), 1.14 (d, 3H, J5′,6′ = 6.1 Hz, CH3 H-6′), 0.85 (s, 9H, 3  CH3 Si
t
Bu), 0.06 (s, 
3H, CH3 SiMea), 0.02 (s, 3H, CH3 SiMeb); 
13
C-NMR (125 MHz, CDCl3):  170.0 (C=O N-Ac), 154.3 (C=O 
Troc), 139.0 (Ci arom. 3′-O-Bn), 138.8 (Ci arom. 2′-O-Bn), 138.8 (Ci arom. 4′-O-Bn), 138.2 (Ci arom. 3″-
O-Bn), 138.0 (Ci arom. 6-O-Bn), 137.3 (Ci arom. PhCH), 129.2 (CH arom.), 128.8 (CH arom.), 128.7 (CH 
arom.), 128.6 (CH arom.), 128.6 (CH arom.), 128.5 (CH arom.), 128.4 (CH arom.), 128.4 (CH arom.), 
128.2 (CH arom.), 128.2 (CH arom.), 128.1 (CH arom.), 128.0 (CH arom.), 127.7 (CH arom.), 127.7 (CH 
arom.), 127.3 (CH arom.), 126.1 (CH arom.), 101.3 (PhCH), 99.9 (C-1″), 98.0 (C-1′), 95.2 (CCl3 Troc), 
92.3 (C-1), 82.6 (C-4″), 79.6 (C-3′), 78.1 (C-4′), 77.4 (C-2′), 76.9 (C-3″), 76.0 (C-3), 75.0 (CH2 4′-O-Bn), 
74.7 (CH2 Troc), 74.3 (CH2 3″-O-Bn), 74.2 (C-4 and C-5), 73.9 (CH2 2′-O-Bn), 73.7 (CH2 6-O-Bn), 72.8 
(CH2 3′-O-Bn), 69.2 (C-6), 68.8 (C-6″), 66.7 (C-5′), 65.8 (C-5″), 57.8 (C-2 and C-2″), 25.8 (CH3 Si
t
Bu), 
18.0 (Cq Si
t
Bu), 17.1 (C-6′), -4.2 (CH3 SiMea), -5.2 (CH3 SiMeb); HRMS(ESI) m/z calcld. for 
[C71H85O16N2Cl3Si+Na]
+
: 1377.4632 obsd.: 1377.4646. 
 
2-Acetamido-2-deoxy--D-glucopyranosylamine (92). N-Acetylglucosamine 
(91) (0.109 g, 0.493 mmol) was dissolved in water (5.0 mL) and NH4HCO3 (6.0 
g) was added. The reaction was stirred at 40°C in a sealed vessel for 6 days. The 
vessel was opened periodically to remove the liberated CO2. After completion, the excess ammonium 
bicarbonate and water were removed via repetitive lyophilisation (10 times, 5 mL of water added each 
time) until the mass of the product became constant (0.204 g). The crude amine was further purified by 
Dowex H
+
 exchange resin column chromatography (NH3 in water, 0% → 5%, v/v) which yielded 92, in the 
NH3 fractions, as a white amorphous solid after lyophilisation (0.074 g, 68%). Starting material was eluted 
in the water fractions (0.034 g, 31%). Rf 0.57 (isopropanol/water/NH3, 7/2/1, v/v); 
1
H-NMR (500 MHz, 
D2O):  4.13 (d, 1H, J1,2 = 9.3 Hz, H-1), 3.87 (dd, 1H, J5,6a = 1.2, J6a,6b = 12.2 Hz, H-6a), 3.71-3.67 (m, 1H, 
H-6b), 3.59 (t, 1H, J1,2 = J2,3 = 9.8 Hz, H-2), 3.53-3.46 (m, 1H, H-3), 3.42-3.37 (m, 2H, H-4 and H-5), 2.02 
(s, 3H, CH3 N-Ac); 
13
C-NMR (125 MHz, D2O):  175.9 (C=O N-Ac), 85.4 (C-1), 78.0 (C-5), 75.8 (C-3), 
71.3 (C-4), 62.1 (C-6), 57.5 (C-2), 23.5 (CH3 N-Ac). HRMS(ESI) m/z calcld. for [C8H16O5N2+Na]
+
: 
243.0957, obsd.: 243.0951.  
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3,6-di-O-(-D-mannopyranosyl)-/β-D-mannopyranosylamine (95). 
Trisaccharide 42 (0.0047 g, 0.0093 mmol) was dissolved in water (5.0 
mL) and NH4HCO3 (6.0 g) was added. The reaction was stirred at 
40°C in a sealed vessel for 6 days. The vessel was opened periodically 
to remove the liberated CO2. After completion, the excess ammonium 
bicarbonate and water were removed via repetitive lyophilisation  to 
yield 95. HRMS(ESI) m/z calcld. for [C18H33O15N+H]
+
: 504.1928, 
obsd.: 504.1930.  
 
2-Acetamido-2-deoxy-3-O-(α-L-fucopyranosyl)-α/-D-
glucopyranosylamine (96). Disaccharide 76 (0.0122 g, 0.0332 mmol) was 
dissolved in water (5.0 mL) and NH4HCO3 (6.0 g) was added. The reaction 
was stirred at 40°C in a sealed vessel for 6 days. The vessel was opened 
periodically to remove the liberated CO2. After completion, the excess 
ammonium bicarbonate and water were removed via repetitive lyophilisation to yield 96. HRMS(ESI) m/z 
calcld. for [C14H26O9N2+H]
+
: 367.1717, obsd.: 367.1723.  
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